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EPIGRAPH
A scientist in his laboratory is not a mere technician: he is also a child confronting
natural phenomena that impress him as though they were fairy tales.
– Marie Curie
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ABSTRACT OF THE DISSERTATION
Biointerfacing via Cell Membrane-Coated Nanoparticles for Novel
Antibacterial Nanotherapeutics
by
Pavimol Angsantikul
Doctor of Philosophy in NanoEngineering
University of California San Diego, 2018
Professor Liangfang Zhang, Chair
Antibiotic resistance has become an undeniable burden on global health as we
move further into the twenty-first century. It is predicted that drug-resistant infections
could lead to an annual mortality rate of 10 million people by 2050 and a cumulative
cost of up to 100 trillion USD on the world’s economy. These unsettling projections
have necessitated the exploration of new and more eﬀective ways to manage bacterial
xx
infection. This dissertation focuses on novel strategies for addressing this pressing
challenge via nanomedicine, particularly the use of natural cell-derived membrane
to enhance the biointerfacing of synthetic nanomaterials. The resulting membrane-
cloaked platforms exhibit unique, cell-specific properties that can be leveraged for
antibacterial therapy. Additionally, novel nano/micromotors are further exploited to
design new biomimetic therapeutic modalities capable of active movement.
The first part of this thesis will focus on novel antibiotic delivery systems,
including targeted delivery and active delivery platforms. For targeted antibiotic
delivery, the native function of the source cells, particularly their natural adhesion
property was exploit by the natural cell membranes-coated nanoparticles. Meanwhile,
the second delivery platform involves mobile micromotor which are acid-powered and
enable active delivery. Not only can the propulsion of antibiotic-loaded motors in
gastric media eﬀectively deliver the drug payload, but the motor-based therapy can
also rapidly neutralize gastric acid without the need of proton pump inhibitor.
the second portion of this dissertation will focus on the exploitation of biomim-
icking nanoplatforms as countermeasures against pathologic moieties for the abroga-
tion of bacterial infection. This is demonstrated through a range of bacterial virulence
including diarrhea-causing cholera toxin, Shiga toxin, and systemic endotoxin. Ul-
timately, cell membrane-coated technology has the potential to greatly impact the
landscape of nanomedicine and contribute to the management of bacterial infections
in the future.
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Chapter 1
Nanoparticle approaches against
bacterial infections
1
1.1 Introduction
Despite the profound success achieved by the use of antibiotics against in-
fectious diseases, bacterial infections continue to impose significant challenges on
global healthcare. [1,2] Eradication of certain bacterial infections such as tuberculosis
remains diﬃcult due to the complex mechanisms of the pathogen in subverting its
host’s immune system as well as the delivery barriers that prevent antibiotics from
reaching sites of infection. [3, 4] Highly potent antibiotics, including certain aminogly-
cosides and fluoroquinolones, generate severe adverse eﬀects and are reserved only for
serious infections. [5, 6] More significantly, the emergence of antibiotic resistance has
generated alarming impact, threatening to set back the progress against a range of
infectious diseases to the pre-antibiotic era. [7, 8] The widespread drug resistance is
further exacerbated by the retreat of the pharmaceutical sector from new antibiotic
development. [9, 10] These challenges, together, highlight the demand for alternative
and eﬀective antimicrobial strategies.
Over the last few decades, the application of nanotechnology, particularly
the use of nanoparticles for drug delivery, has generated significant impact in
medicine. [10,11] Various nanoparticle delivery platforms, especially liposomes, poly-
meric nanoparticles, dendrimers, and inorganic nanoparticles, have received significant
attention (Figure 1.1). Drug molecules loaded into nanocarriers through physical en-
capsulation, adsorption, or chemical conjugation exhibit an improved pharmacokinetic
profile and therapeutic index when compared to their free drug counterparts. [12]
Other advantages of nanoparticle delivery systems, including improved drug solubility,
prolonged systemic circulation, sustained and controlled release, precise drug target-
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Figure 1.1: Schematic illustration of major nanoparticle-based delivery plat-
forms for treating bacterial infections: (a) liposome, (b) polymeric nanoparticle,
(c) dendrimer, and (d) inorganic nanoparticle.
ing, and concurrent delivery of multiple drugs, have also been validated in various
studies. [13] As a result, a number of nanoparticle-based drug delivery systems have
been approved for clinical use to treat a variety of infectious diseases, and many
other antimicrobial nanoparticle formulations are currently under various stages of
pre-clinical and clinical tests. [14]
As the ability to engineer multifunctional nanoparticles continually advances,
numerous innovative approaches have emerged, further improving on nanoparticle
therapeutic eﬃcacy against bacterial infections. In this review article, we select five
areas where nanoparticle approaches hold significant potential to improve upon current
treatments. These areas include: (1) targeted antibiotic delivery, (2) environmentally
responsive antibiotic delivery, (3) combinatorial antibiotic delivery, (4) nanoparticle-
enabled antibacterial vaccination, and (5) nanoparticle-based bacterial detection.
Progresses made in these areas oﬀer tremendous opportunities for alternative and
more eﬀective antimicrobial strategies that alter the pharmacokinetics of existing
antibiotics, produce new antibiotics with novel microbial inhibition mechanisms, or
allow for more rapid and sensitive microbial detection. Collectively, they address
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the aforementioned challenges including overcoming antibiotic resistance. Herein,
we review each area with highlights of the current and forthcoming nanoparticle
platforms against bacterial infections.
1.2 Targeted Antibiotic Delivery
Bacterial infection increases vascular permeability, which makes passive tar-
geting possible. At the infection sites, the release and accumulation of bacterial
components such as bacterial protease and lipopolysaccharide from Gram-negative
bacteria or lipoteichoic acid from Gram-positive bacteria are known to trigger various
inflammatory mediators that directly stimulate vascular permeability. [15,16] These
bacterial components also activate immune cells, which in turn interact with vascular
endothelium through multiple inflammatory and vascular media- tors, leading to gap
widening, barrier dysfunction, and eventually increased permeability. [17] Moreover,
dysfunctional lymphatic drainage has also been reported in bacterial infection, which
potentially promotes nanoparticle accumulation at the sites of infection. [18] These
features of bacterial infection suggest that the enhanced permeation and retention
(EPR) eﬀect can be harnessed by nanoparticles for targeted antibiotic delivery. [19]
In fact, both uncoated liposomes and PEGylated liposomes have been shown to
accumulate selectively at soft tissues infected by Staphylococcus aureus (S. aureus),
and their retention times correlated closely with size. [20–23] Similar results were
observed for superparamagnetic iron oxide nanoparticles (SPIONs) at the soft tissue
of rats and in the lungs of mice infected by S. aureus. [24]
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Pathogenic bacteria maintain a negative surface charge under physiological
conditions. Therefore, cationic nanoparticles capable of binding with bacteria via
electrostatic interactions have been explored for eﬀective bacterial targeting. [25,
26] This strategy is attractive for its multivalent eﬀect and the ability to target
polymicrobial infections. As a result, a diverse range of bactericidal polymers and
peptides has been incorporated into various nanoparticle designs for antibacterial
applications. [27] More importantly, nanoparticle formulation can increase the local
charge and mass densities of the bactericidal components, resulting in enhanced
therapeutic index. For example, a self-assembled cationic peptide nanoparticle has
shown strong antimicrobial properties while inducing minimal systemic toxicity. [28]
Furthermore, improving the biodegradability of the nanoparticles can further reduce
cationic charge related toxicity. In this perspective, cationic nanoparticles self-
assembled from polycarbonate-based block copolymers with high biodegradability
have been shown to kill bacteria without inducing obvious hemolytic activity and
systemic toxicity. [29]
Active targeting with pathogen-binding ligands directly conjugated to the
surface of nanoparticles is another strategy to target bacteria. For example, small
molecules such as vancomycin have been conjugated to the surfaces of dendrimers, [30]
iron oxide nanoparticles, [31] gold nanoparticles, [32] and porous silica nanoparti-
cles, [33] resulting in preferential binding of nanoparticles to Gram-positive bacteria.
The targeting eﬃciency of small molecules was also found to be strongly dependent
on molecular orientation, surface density, and length of the spacer used in conjuga-
tion. [34] In addition to small molecules, lectins, particularly those with selective
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agglutination activities, have also been used as ligands to target bacteria. [35] Poly-
meric nanoparticles conjugated with mannose-specific or fucose-specific lectins showed
enhanced binding aﬃnity to the carbohydrate receptors on Helicobacter pylori (H.
pylori) surfaces, suggesting a promising approach for site-specific and gastroretentive
drug delivery to treat H. pylori infection. [36] Besides lectins, other protein ligands
such as single-domain antibodies [37] and bacteriophage tailspike proteins [38] are
highly specific targeting ligands and their conjugation to nanoparticles has resulted in
targeted delivery platforms eﬀective against a variety of bacterial infections. Further-
more, aptamers have also become a class of attractive targeting moieties owing largely
to the advancement in bacterium-based aptamer selection techniques, which contin-
ually improve aptamer binding aﬃnity and specificity. These targeting molecules
have been extensively explored to target nanoparticles to pathogenic bacteria such as
Salmonella typhimurium and Mycobacterium tuberculosis (M. tuberculosis). [39, 40]
Moreover, bacteria can survive ingestion by phagocytic cells such as macrophages,
hence evading the immune system and the bactericidal action of antibiotics. [3] How-
ever, macrophages are able to transport drugs to the site of infection by a chemotactic
mechanism. [41,42] Therefore, targeting antimicrobial nanoparticles to macrophages
as opposed to bacteria has become an attractive strategy for improving antibiotic
therapy, particularly to treat intracellular bacterial infection. [43] It has been observed
that following passive targeting to the infection sites, nanoparticles could preferen-
tially be taken up by macrophages due to the spontaneous scavenging feature of
macrophages. [23, 24] Such macrophage uptake could be further enhanced by attach-
ing targeting ligands onto the nanoparticles. [44,45] In this regard, various ligands,
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including mannose, maleylated bovine serum albumin, and O-steroyl amylopectin,
have been applied to successfully enhance macrophage uptake of nanoparticles for
the treatment of intracellular infection. [46,47]
1.3 Environmentally Responsive Antibiotic Delivery
To further improve upon the therapeutic eﬃcacy of antimicrobial nanoparticles,
researchers have explored environmentally responsive nanoparticles that remain
inactive until they are triggered by cues found in the microenvironment of infection
sites. These external stimuli can be physical signals such as temperature, electric
field, magnetic field, and ultrasound; they can also be chemical signals such as pH,
ionic strength, redox potential, and enzymatic activities. [48]
Among these environmental stimuli, pH gradient has been widely used to design
novel, responsive nanoparticles for antibiotic delivery. At the organ level, nanoparticles
have been designed to respond to the pH gradient along the gastrointestinal (GI)
tract [49] and the acidic environment of human skin [50] for site-specific antibiotic
delivery. At the intracellular level, nanoparticles have been formulated to respond
to the acidic pH inside the endolysosomal compart-ments for triggered drug release.
[51–53] In addition to pH gradient, bacterial enzymatic activities, including those of
secreted toxins, have also been used to trigger the release of antimicrobial agents to
inhibit the growth of the target bacteria.
Charged polymers have been adsorbed onto liposome surfaces with opposite
charge to stabilize the liposomes. [54,55] Such stabilization is pH sensitive and has
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been extensively used to treat various intracellular bacterial infections including
Salmonella enterica [56,57] as well as cases of septic shock. [58,59] On the basis of
a similar mechanism, ionic liposomes can be employed to carry oppositely charged
drug molecules for pH-sensitive drug release. In addition, loading liposomes with
membrane disrupting toxins such as hemolysin and listeriolysin that are responsive
to endosomal acidification has also shown potential for the treatment of intracellular
infections. [60, 61]
Recently, a new environment-responsive delivery strategy has emerged that
involves the attachment of small charged nanoparticles onto liposome surfaces for
liposome stabilization and triggered antimicrobial delivery (Figure 1.2). The nonspe-
cific adsorption of charged nanoparticles onto phospholipid bilayers pro- vided steric
repulsion that inhibited liposome fusion. It also reduced liposome surface tension and
thus further enhanced liposome stability. [62, 63] Intriguingly, the charge and charge
density of both the nanoparticle stabilizers and the liposomes could be precisely
tailored to enable stimulus-responsive binding and detachment of the nanoparticles,
thereby allowing for an on-demand control over liposome fusion activity for smart
drug delivery. For instance, cationic liposomes bound with negatively charged gold
nanoparticles only fused with bacteria at acidic pH, which made them suitable for
treating various skin pathogens that thrive in acidic infection sites such as the case
with Propionibacterium acnes. [64] Conversely, anionic liposomes stabilized by pos-
itively charged gold nanoparticles were highly stable in gastric acid, but capable
of fusing with bacteria at physiological pH, making them suitable to treat gastric
pathogens such as H. pylori. [65] Even in the absence of such stimulus-induced
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Figure 1.2: Schematic illustration of a phospholipid liposome stabilized by
charged gold nanoparticles and its drug release in response to pH change or the
presence of bacterial toxin.
detachment of the nanoparticle stabilizers, these liposomes still had a substantial
fraction of their surface areas exposed and highly accessible to bacterial toxins. This
feature allowed the liposomes to respond to various bacteria such as S. aureus that
secret pore-forming toxins to trigger drug release from the liposomes. [66] Aimed at
improving the topical applications of nanoparticle-stabilized liposomes, a hydrogel
form of the delivery system was recently developed, which not only preserved the
structural integrity of the nanoparticle-stabilized liposomes, but also allowed for
controllable viscoelasticity and tunable liposome release rate. [67]
Meanwhile, polymeric nanoparticles have been extensively studied for respon-
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sive antibiotic delivery. For example, tri-block copolymer nanoparticles composed
of poly(lactic-co-glycolic acid) (PLGA), poly(l-histidine), and poly(ethylene glycol)
(PEG) have been reported for acid-responsive antibiotic delivery. [68] These nanopar-
ticles maintained a negative charge at neutral pH; however, when exposed to an
acidic pH, the protonation of the imidazole groups switched the surface charge to
a positive one, resulting in enhanced bacterial binding and improved antibacterial
eﬃcacy. As another example, heparin and chitosan have been applied to form base-
sensitive nanoparticles for treating gastric pathogens such as H. pylori. The polymers
self-assembled to form nanoparticles at pH 1.2-2.5; however, upon contact with H.
pylori at the gastric epithelium with physiological pH, the chitosan deprotonated,
causing nanoparticle disassembly and release of drugs for bacteria killing. [69] More-
over, by tailoring the pKa of amphiphilic copolymers, a wide range of polymeric
nanoparticles has been engineered, which precisely respond to the subtle changes of
pH along the GI tract for site-specific antibiotic delivery. Enzyme-sensitive polymeric
nanoparticles have also been developed for intracellular delivery in macrophages. For
example, a triple-layered nanogel formulation has been reported, which contained
a bacterial lipase-sensitive poly(✏-caprolactone) interlayer between the crosslinked
polyphosphoester core and the PEG shell. [70] Following macrophage uptake, the
presence of bacterial phosphatase or phospholipase triggered rapid drug release, which
subsequently inhibited the growth of S. aureus. [47]
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1.4 Combinatorial Antibiotic Delivery
Combining two or more distinct antibiotics represents a common strategy in
treating bacterial infections with the aim to broaden the antimicrobial spectrum,
generate synergistic eﬀects, and counteract antibiotic resistance. However, varying
pharmacokinetics, biodistributions, toxicity profiles, and membrane transport proper-
ties among diﬀerent drug compounds complicate dosing and scheduling optimization,
which in turn compromise drug synergy in vivo. [71] In this regard, nanoparticles
oﬀer unique properties to enhance combinatorial antibiotic delivery and numerous
applications have been investigated to address a variety of bacterial infections (Table
1).
Liposomes are a highly versatile platform for combinatorial delivery. Hy-
drophilic drugs can be directly encapsulated in the aqueous compartments of liposomes,
while hydrophobic drugs can be incorporated into the lipid bilayer membranes. [14] For
example, isoniazid and rifampicin, first line antitubercular drugs, have been loaded in
the aqueous compartment and the lipid bilayer, respectively. The resulting liposomal
formulation has shown increased eﬃcacy compared to free drug counterparts at the
same dosages. [72–74] Liposomal formulation can also reduce drug toxicity to the host
cells, thereby allowing for co-delivery of combinatorial antibiotics that are otherwise
too toxic in their free forms. For example, drug compounds such as gallium (Ga)
and bismuth derivatives are antibiotics that inhibit bacterial growth by interrupting
their iron uptake. Although they have shown synergetic eﬀects in combination with
other antibiotics, their usage has been limited by severe toxicity. [75] To address
this challenge, Ga3+ was combined with gentamicin and loaded into liposomes. The
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Table 1.1: Combinatorial Nanoparticles for Antibacterial Drug Delivery
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TABLE 1 Combinatorial Nanoparticles for Antibacterial Drug Delivery
Platform Formulation Drug Combination Targeted Bacteria References
Liposomes DPPC, DMPG and cholesterol Gallium and gentamicin Pseudomonas aeruginosa 77
DSPC and cholesterol Bismuth-ethanedithiol (BiEDT)
and tobramycin
Pseudomonas aeruginosa and
Burkholderia cenocepacia
78
PEGylated liposome Daptomycin and clarithromycin MRSA 85
PG, PC and cholesterol Clarithromycin and ofloxacin Mycobacterium avium 86
PC, SA, and cholesterol Ciprofloxacin and vancomycin MRSA 84
PC, PEG-DSPE, and cholesterol Gentamicin and ceftazidime Klebsiella pneumoniae 83
DPPC and cholesterol Isoniazid and rifampicin Mycobacterium tuberculosis 75
PG, PC and cholesterol Streptomycinand and
ciprofloxacin
Mycobacterium avium 87
PC, PE, SA and cholesterol Amoxicillin trihydrate and
ranitidine bismuth citrate
Helicobacter pylori 88
PAA, PAH, PC, and cholesterol Amoxicillin and metronidazole Helicobacter pylori 89
Polymeric
nanoparticles
PLGA Rifampin and azithromycin Chlamydia trachomatis and
Chlamydia pneumoniae
95
PLGA Rifampicin, isoniazid,
pyrazinamide, and
ethambutol.
Mycobacterium tuberculosis 99
Sodium alginate and chitosan Rifampicin, isoniazid,
pyrazinamide, and
ethambutol.
Mycobacterium tuberculosis 100
Chitosan and glutamic acid Amoxicillin, clarithromycin, and
omeprazole
Helicobacter pylori 97
Gliadin and Pluronic F-68 Clarithromycin and omeprazole Helicobacter pylori 98
Gliadin, lectin and Pluronic F-68 Amoxicillin, clarithromycin and
omeprazole
Helicobacter pylori 96
DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DMPG, 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol; DSPC, 1,2-distearoyl-sn-glycero-3-phospho-
choline; DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; DPPC, dipalmitoylphosphatidylcholine; PG, egg yolk phosphatidylglycerol; PE, phos-
phatidylethanolamine; PC, phosphatidylcholine; PLGA, poly(lactic-co-glycolic acid); PAA, poly(acrylic acid); PAH, poly(allylamine hydrochloride); SA, steary-
lamine.
membrane transport properties among different drug
compounds complicate dosing and scheduling opti-
mization, which in turn compromise drug synergy
in vivo.71 In this regard, nanoparticles offer unique
properties to enhance combinatorial antibiotic deliv-
ery and numerous applications have been investigated
to address a variety of bacterial infections (Table 1).
Liposomes are a highly versatile platform for
combinatorial delivery. Hydrophilic drugs can be
directly encapsulated in the aqueous compartments
of liposomes, while hydrophobic drugs can be incor-
porated into the lipid bilayer membranes.14 For
example, isoniazid and rifampicin, first line anti-
tubercular drugs, have been loaded in the aqueous
compartment and the lipid bilayer, respectively. The
resulting liposomal formulation has shown increased
efficacy compared to free drug counterparts at the
same dosages.72–74 Liposomal formulation can also
reduce drug toxicity to the host cells, thereby allowing
for co-delivery of combinatorial antibiotics that are
otherwise too toxic in their free forms. For example,
drug compounds such as gallium (Ga) and bismuth
derivatives are antibiotics that inhibit bacterial growth
by interrupting their iron uptake. Although they have
shown synergetic effects in combination with other
antibiotics, their usage has been limited by severe
toxicity.75 To address this challenge, Ga3+ was com-
bined with gentamicin and loaded into liposomes. The
formulation reduced Ga toxicity and improved effi-
cacy against highly resistant Pseudomonas aeruginosa
(P. aeruginosa).76 Similarly, bismuth-ethanedithiol
(BiEDT) was encapsulated together with tobramycin
into liposomes, resulting in the elimination of BiEDT’s
toxic effect on human lung cells while increasing
its antibacterial efficacy against P. aeruginosa and
Burkholderia cepacia.77–79 A recent in vivo study
showed that the same drug combination in a lipo-
some formulation enhanced efficacy in reducing
bacterial burden in rats chronically infected with P.
aeruginosa.80
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formulation reduced Ga toxicity and improved eﬃcacy against highly resistant Pseu-
domonas aeruginosa (P. aeruginosa). [76] Similarly, bismuth-ethanedithiol (BiEDT)
was encapsulated together with tobramycin into liposomes, resulting in the elimination
of BiEDT’s toxic eﬀect on human lung cells while increasing its antibacterial eﬃcacy
against P. aeruginosa and Burkholderia cepacia. [77–79] A recent in vivo study
showed that the same drug combination in a liposome formulation enhanced eﬃcacy
in reducing bacterial burden in rats chronically infected with P. aeruginosa. [80]
Moreover, liposomal formulation of combinatorial antibiotics enables ratio-
metric control over the drugs and thus unifies the pharmacokinetics of diﬀerent
drug molecules and ensures parallel tissue distribution. These advantages serve to
enhance the antimicrobial eﬃcacy of the drugs. For example, using the dosage and
dosing schedule derived from in vitro studies, the co-administration of gentamicin and
ceftazidime only resulted in an additive eﬀect in a rat model of an acute unilateral
Klebsiella pneumoniae infection. [81] In contrast, the corresponding liposomal formu-
lation encapsulating both gentamicin and ceftazidime showed a synergistic eﬀect that
led to a shorter course of treatment at lower cumulative doses. [82] The benefit of
ratiometric delivery using liposomes was also reported in other combination therapies
in treating S. aureus, [83, 84] M. tuberculosis, [72, 73] Mycobacterium avium, [85, 86]
and H. pylori. [87,88] Polymeric nanoparticles represent another emerging platform
for combinatorial antibiotic delivery to treat bacterial infection. In general, drug
molecules can be directly encapsulated into the polymeric cores. For precise ratiomet-
ric loading and controlled drug release, multiple drugs can be covalently conjugated
to the polymer backbone followed by nanoparticle preparation. [89–91] In addition,
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using emulsion techniques, both hydrophobic and hydrophilic drug molecules can
be co-encapsulated into the polymeric cores. [92,93] As a result, several polymeric
nanoparticle systems have been reported for delivering antibiotic combinations. For
example, the combination of rifampin and azithromycin was delivered with PLGA
nanoparticles and showed better eﬃcacy in vitro compared to free drugs in treating
persistent chlamydial infection. [94] Nanoparticles made of gliadin, a vegetal protein
commonly derived as a fraction of wheat gluten, were used to co-encapsulate clar-
ithromycin and omeprazole, which achieved better eﬃcacy against H. pylori bacteria
in rats. [95, 96] The gliadin nanoparticles were further conjugated with lectin and
used in triple therapy with amoxicillin, clarithromycin, and omeprazole, [97] resulting
in superior in vivo clearance of H. pylori compared to the nonconjugated formulation
and free drugs. Moreover, PLGA nanoparticles were also used for oral delivery of
anti-tuberculosis drugs (ATDs). [98,99] In these studies, three or four frontline ATDs,
including rifampicin, isoniazid, pyrazinamide, and ethambutol, were co-encapsulated
inside PLGA nanoparticles through an emulsion technique, and the resulting nanopar-
ticle formulation improved bacterial clearance in M. tuberculosis infected mice and
guinea pigs via oral administration.
1.5 Nanoparticle-enabled Antibacterial Vaccination
Vaccines can protect against or treat infections by manipulating the host’s
immune responses, and their success in controlling former epidemics worldwide
has been considered as the most eﬀective public health intervention ever achieved.
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[100, 101] The vaccine strategy also holds the promise to halt antibiotic resistance
by reducing the exposure of bacteria to widely used antimicrobial agents. [102,103]
However, the majority of existing vaccines predominantly drive the generation of
neutralizing or opsonizing antibodies against pathogens, a mechanism that is ineﬀective
against a number of infections. [104] Vaccine development against these diseases is
further hampered by incomplete understanding of the enormously complex human
immune system and the underlying mechanisms of protection. [105] To address these
challenges, nanoparticles oﬀer unique advantages for immune modulation against
bacterial infections. [106,107]
Nanoparticles have been extensively explored to overcome the instability,
undesirable systemic biodistribution, and toxicity frequently associated with the
administration of soluble molecules. [108, 109] It has been reported that conjugation
of antigens to nanoparticle surfaces facilitated B-cell activation, [110] due to a higher
quantity of antigens that were delivered to antigen presenting cells (APCs). [111] With
the advancement in nanoparticle engineering, fabrication techniques long established
for manufacturing nanoparticle-based drug delivery systems including layer-by-layer
assembly, [112, 113] facile spray-drying process, [114] and soft lithography-based
particle replication in non-wetting templates (PRINT) technology [115] have also
been increasingly applied to improve on antigen loading. Recently, natural cellular
membrane-coated nanoparticles have also been shown to detain membrane-damaging
toxins and divert them away from their cellular targets. [116, 117] Such a toxin-
detainment strategy was applied to safely deliver intact staphylococcal ↵-hemolysin to
APCs and induced superior protective immunity against toxin-mediated adverse eﬀects
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Figure 1.3: Schematic preparation of nanoparticle-detained toxins, denoted
‘nanotoxoid’, consisting of substrate-supported RBC membranes into which
pore-forming toxins can spontaneously incorporate.
in mice when compared to vaccination with heat-denatured toxins (Figure 1.3). [118]
This approach maintained a faithful antigenic presentation while removing toxin
virulence, therefore avoiding the trade-oﬀ between eﬃcacy and safety that remains a
major challenge of current toxoid development.
Besides delivering antigens, nanoparticles can concurrently carry adjuvants
to mimic natural microbes for enhanced vaccination eﬃcacy. [119,120] Particularly,
various toll-like receptor (TLR) ligands including small molecules, carbohydrates,
DNAs, and RNAs, together with antigens have been delivered using nanoparticles,
resulting in equivalent immune responses compared to soluble antigen formulations
but at significantly reduced dosages. [121–124] More importantly, nanoparticles
allow for programmable presentation of adjuvants and antigens to immune cells for
desirable responses. For example, combinations of TLR agonists, as opposed to
a single adjuvant, have been concurrently loaded into nanoparticles to mimic the
combinatorial TLR activation that occurs in natural infections, therefore resulting
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in more vigorous immune responses. [125–127] In addition, nanoparticles allow for
the sequential presentation of antigens and adjuvants to be programmed for optimal
immune responses. For example, encapsulation of antigens and TLR agonists into the
same nanoparticles has shown advantages for the induction of eﬀector T-cell responses
[123, 128] due to the manner in which antigen processing occurs in dendritic cells.
[129,130] In contrast, delivery of antigens and TLR agonists in separate nanoparticles
seemed to benefit antibody responses. [131] Recent advancement in controlling the
intra-nanoparticle architecture and adjuvant distribution has provided additional
capability for programming nanoparticle-based immune modulation. [132] For example,
when interbilayer-crosslinked multilamellar vesicles were used as synthetic vaccines,
the TLR-4 agonist monophosphoryl lipid A (MPLA) was incorporated throughout the
vesicle layers and elicited stronger serum IgG titres as compared to the vesicles carrying
the same amount of MPLA but attached only on the vesicle surfaces (Figure 1.4). [133]
Targeting vaccines to desired sites for safe and eﬀective immune responses is
another advantage of using nanoparticles for vaccine delivery. For example, a cationic
nanogel loaded with a subunit fragment of Clostridium botulinum type-A neurotoxin
has been shown to facilitate persistent antigen adherence to the nasal epithelium
and eﬀective uptake by mucosal dendritic cells. [134] This platform not only elicited
strong systemic and mucosal immune responses, but also prevented exposure of the
upper respiratory tract and the central nervous system to toxic antigens. As another
example, nanoparticles responsive to the pH gradient of the GI tract have been able
to protect antigens while in the stomach but release them in the lower GI tract for
subsequent translocation across the intestinal epithelium. [135] A similar strategy
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Figure 1.4: Schematic illustration of interbilayer-crosslinked multilamellar
vesicles (ICMVs) for vaccine delivery: (a) OVA-loaded ICMVs with MPLA only
on the external surface and (b) OVA-loaded ICMVs with MPLA throughout the
lipid multilayers.
has also shown promise for targeting antigen-transcytosing M cells overlying Peyer’s
patches for further enhanced immunity. [136] In addition, nanoparticle-based vaccine
platforms can eﬀectively target lymph node-residing immune cells. It has been shown
that smaller nanoparticles transport faster to the lymph node, [137] but larger particles
are retained longer within the lymph node. [138] Such distinct correlations indicate the
importance of size optimization in lymphatic targeting for desired immune responses.
At the single-cell level, numerous nanoparticle formulations have been designed to
escape endosomes following their uptake by APCs. [139–141] These nanoparticles
specifically deposited vaccine payloads into the cytosol and showed promise to enhance
CD8+ T-cell priming.
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1.6 Nanoparticle-based Bacteria Detection
Rapid and sensitive bacterial detection is crucial for identification of the
infection source, allowing for treatment with the appropriate antibiotics and thus
preventing the spread of the disease. [142, 143] Bacterial culture and biochemical
staining remain the current gold standard in the clinic despite laborious processing,
long procedural times, and limitations in identifying certain pathogenic species.
Among the various existing diagnostic approaches, those based on polymerase chain
reaction (PCR) and sequencing have shown particular promise as highly sensitive
tools for microbial identification. [144, 145] However, quantitative real-time PCR-
based systems are often too expensive in resource-limited settings, and the current
sequencing techniques still lack practical applicability for patient care. [146, 147]
In this regard, nanoparticles oﬀer unique opportunities for generic, accurate, and
point-of-care detection of pathogens. [148,149]
Using conventional organic fluorophores for bacterial detection is limited by
the molecules’ short lifetime and low sensitivity. To overcome these challenges,
silica nanoparticles have been used to encapsulate thousands of fluorescent molecules
in a single particle, resulting in significantly stronger fluorescence signals. [150]
This strategy has resulted in ultra sensitive bacterial detection at a single-cell level.
Meanwhile, semiconductor quantum dots (QDs) have also emerged as a promising
class of fluorophores for bacterial detection. Compared to organic fluorophores, QDs
are brighter and more stable; they also exhibit broad absorption and narrow emission
spectra, a property useful for simultaneous excitation and detection. [151] Ligand-
conjugated QDs have been extensively explored for the detection of various bacteria,
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including Escherichia coli (E. coli), S. typhimurium, Mycobacterium bovis, and oral
bacteria. [152–154] Additional strategies have been explored to further improve the
sensitivity of QD-based bacterial detection systems. For example, the binding aﬃnity
of QDs coated with zinc(II)-dipicolylamine coordination complexes, a bacterial ligand,
has been shown to correlate to the size of the QDs. [155] Based on this observation,
QDs with tailored sizes have been developed to distinguish diﬀerent mutants of the
same bacterial species. As another example, streptavidin-coated QDs have been used
to label engineered bacteriophages following an in vivo amplification and biotinylation
process. [156] This method enabled specific detection of as few as 10 bacteria per
milliliter in testing samples.
Besides fluorescence-based detection techniques, iron oxide nanoparticles have
received much attention, owing largely to their intrinsic magnetic properties. [157,158]
Iron oxide nanoparticles coated with pathogen-specific antibodies have been widely
used to isolate living bacteria from human blood samples under a magnetic field.
[159,160] More recently, this technique has been coupled with microfluidic technology
and has resulted in high-throughput bacterial detection under various clinical settings.
[161–163] Meanwhile, paramagnetic iron oxide nanoparticles that allow for signal
readout with magnetic resonance imaging (MRI) systems have become an attractive
new option for ultrasensitive bacterial detection. For in vitro diagnosis, iron oxide
nanoparticles with a diameter of 21 nm have been coupled with a DNA hybridization
technique to enhance the capturing of bacterial 16S rRNAs with a miniaturized
micro-NMR system, resulting in rapid and specific pathogen profiling in clinical
samples (Figure 1.5). [164] For in vivo diagnosis, iron oxide nanoparticles have also
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Figure 1.5: Magneto-DNA assay for the detection of bacterial 16S rRNA.
Total RNA is extracted from the specimen, and the 16S rRNA is amplified
by asymmetric RT-PCR. Single-strand DNA of the amplified product is then
captured by beads conjugated with capture probes, followed by hybridizing with
MNPs to form a magnetic sandwich complex. Samples are subsequently analyzed
using a miniaturized micro-NMR (µNMR) system.
been explored to detect a variety of pathogenic bacteria in animal models, where the
high spatial resolution and excellent soft tissue contrast of MRI provided information
on both bacterial localization and corresponding host responses. [165]
Gold nanoparticles are another emerging nanoparticle platform for bacterial
detection. These nanoparticles possess strong light scattering properties and change
their plasmon resonance spectrum upon aggregation. This phenomenon has been
widely explored for the detection of bacteria-specific DNAs, proteins, and live bacteria.
[166] For example, individual gold nanoparticles have been precisely crosslinked with
switchable linkers, which were designed to break in the presence of target subjects. [167]
As a result, this design amplified the pathogen-induced nanoparticle aggregation-
dispersion process and allowed for visible detection of E. coli at a concentration of
100 CFU/mL. In addition, gold nanoparticles can nonspecifically quench fluorescent
molecules. Based on this phenomenon, a fluorophore displacement strategy has been
developed for bacterial detection. [168] In this strategy, gold nanoparticles adsorbed
with fluorescent polymers such as poly(paraphenyleneethynylene) and polylysine
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selectively interacted with bacteria and released the bound fluorescent polymers
which were initially quenched by the gold nanoparticles. The recovered polymer
fluorescence allowed for the eﬀective identification of bacteria within minutes.
Recently, rapid progress has been made by integrating nanoparticle-based
microbial detection into miniaturized devices such as microfluidic systems and lab-
on-a-chip for broader applications. [169] These devices potentially perform assays
with adequate sensitivity, specificity and reproducibility, yet demand little user
input. [162,170] The combination of nanoparticle-based detection principles with such
devices provide unprecedented opportunities in under-developed regions to perform
routine tests, detect the presence of an infectious agent with epidemic potential, and
provide guidance for the regional disease control.
1.7 Conclusion
The advent of nanotechnology, particularly nanoparticle engineering, together
with the accumulation of knowledge on infectious diseases, has allowed for significant
advancement in the field of antibacterial drug delivery. Major eﬀorts have been devoted
to developing various nanoparticle-based delivery platforms including liposomes,
polymeric nanoparticles, dendrimers, and inorganic nanoparticles. These nanoparticle
approaches have shown excellent out- comes in treating and detecting bacterial
pathogens by enabling targeted, responsive, and combinatorial delivery of antibiotics,
eﬀective antibacterial vaccination, and rapid detection of bacteria. It is expected
that nanotechnology will continue bringing improvements to antimicrobial delivery
22
systems for eﬃcacious, patient-compliant, and cost eﬀective therapeutics as well as
the specific and sensitive detection of various infectious diseases.
Chapter 1, in full, is a reprint of the material as it appears in WIREs
Nanomedicine & Nanobiotechnology, 2014, Weiwei Gao, Soracha Thamphiwatana,
Pavimol Angsantikul and Liangfang Zhang. The dissertation author was a major
contributor and co-author of this paper.
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Chapter 2
Biointerfacing via cell
membrane-coated nanoparticles for
novel antibacterial drug delivery
system
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2.1 Coating nanoparticles with gastric epithelial cell
membrane for targeted antibiotic delivery against
Helicobacter pylori infection
2.1.1 Introduction
Helicobacter pylori (H. pylori) is one of the most prevalent bacterial pathogens
that infects more than half of the human population. [171,172] H. pylori infection has
been considered the major cause responsible for peptic ulcer disease, inflammatory
gastritis, and gastric cancer, posing a significant healthcare burden worldwide. [173,
174] Currently, triple therapy based on clarithromycin (CLR) in combination with a
proton pump inhibitor (PPI) and an antibiotic (either amoxicillin or metronidazole)
is the recommended treatment for H. pylori infection. However, mutations in H.
pylori has led to resistance to CLR and other macrolides, causing a large number
of treatment failures. [175] Meanwhile, resistance to other antibiotics including
amoxicillin, metronidazole, and levofloxacin, is also rising rapidly. As a result,
H. pylori eradication rates with standard triple therapy have declined significantly.
[176,177] Alternative agents and treatment regimens to address resistance development
are being actively studied, but the results remain mixed. [178,179] Clearly, new and
eﬀective anti-H. pylori treatments are urgently needed.
Unmet clinical needs in controlling H. pylori infection has prompted the
development of anti-H. pylori nanoparticles with distinct therapeutic advantages.
For example, nanoparticles have been made to encapsulate multiple antibiotics for
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concurrent delivery. [180, 181] With better controls over antibiotic release kinetics,
the nanotherapeutics were able to minimize resistance development through additive
or synergistic drug actions. Meanwhile, nanoparticles responsive to pH changes in
the stomach or enzymatic activities have been developed. [182–184] They increased
drug potency by only releasing drug payloads in the proximity of H. pylori infectious
site Meanwhile, nanoparticles have also been conjugated with targeting ligands such
as mannose-specific or fucose-specific lectins to target the carbohydrate receptors
on H. pylori bacteria. [185] These targeted nanoparticles oﬀered site-specific release
and gastro-retentive properties, which together boosted local drug levels for a higher
bactericidal eﬃcacy. More recently, novel liposomes containing free fatty acids, which
were prone to fusion with H. pylori bacteria, have been developed. [186,187] These
liposomes disrupted bacterial membrane and compromised the structural integrity
of the bacteria for bioactivity, and thus showed a much lower rate to elicit drug
resistance compared to conventional antibiotics. [188]
While therapeutic nanoparticles are increasingly applied to treat H. pylori
infection, technologies for nanoparticle engineering and functionalization have also
advanced significantly. [189–191] In particular, using natural cell membranes to coat
nanoparticles has recently gained much attention. This strategy combines natural
cell membranes with synthetic nanomaterials to leverage native cell functions for
therapeutic applications. [192] One area is to harness the natural adhesion property
of the source cells for targeted drug delivery. [193] For example, nanoparticles coated
with cancer cell membranes inherited homotypic adhesion and showed an innate
ability to bind with source cells for drug targeting. [194] In addition, nanoparticles
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coated with platelet membranes were shown to mimic the binding of platelets with
pathogens such as methicillin-resistant Staphylococcus aureus for targeted antibiotic
delivery. [195] Meanwhile, platelets also recognize tumor cells including circulating
tumor cells through ligand binding interactions. Therefore, platelet membrane-
coated nanoparticles were also developed for site-specific delivery of anticancer drugs.
[196] These compelling applications inspire us to develop cell membrane-coated
nanoparticles for targeted antibiotic delivery against H. pylori infection.
The adherence of H. pylori in the stomach is a pre-requisite for the bacteria to
establish persistent infection. [197] Specifically, H. pylori bacteria display a preferential
aﬃnity through adherence pedestals to gastric epithelial cells of the gastric antrum.
Various surface receptors on gastric epithelial cells have been identified as receptors
for H. pylori binding. For example, H. pylori were shown to bind with integrin  1
(CD29) in gastric epithelia cells. [198,199] An increased expression of CD29 correlated
with enhanced invasion of the bacteria. In addition, the fucosylated Lewis blood
group antigens (Leb) on gastric epithelia cells are also known as receptors for H. pylori
binding mediated through bacterial adhesin BabA. [200,201] Furthermore, H. pylori
is also known to gain adhesion through defined members of the carcinoembryonic
antigen-related cell adhesion molecules (CEACAMs) on gastric epithelial cells via
HopQ for adherence and subsequent translocation of cytotoxin-associated gene A
(CagA) for virulence. [202]
Based on these adhesion mechanisms, we hypothesize that drug-loaded nanopar-
ticles coated with plasma membranes derived from gastric epithelial cells will inherit
the native pathogen-host adhesion and therefore are capable of H. pylori target-
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ing. Herein, we derived membranes from AGS cells, a model gastric epithelia cell
line, and coated them onto polymeric cores made from poly(lactic-co-glycolic acid)
(PLGA, Figure 2.1). The resulting AGS membrane-coated nanoparticles (denoted
‘AGS-NPs’) present an external membrane coating for bacterial targeting and an
internal polymeric core for drug encapsulation and controlled release. We further
loaded AGS-NPs with CLR and demonstrated an enhanced bactericidal eﬀect in vitro
attributable to preferential binding of AGS-NPs with H. pylori. In a mouse model
of H. pylori infection, CLR-loaded AGS-NPs showed superior anti-H. pylori eﬃcacy
when compared to free CLR or a non-targeted nanoparticle formulation. Overall, we
demonstrated that AGS-NP formulation was eﬀective in delivering antibiotics to H.
pylori bacteria in an actively targeting manner and thus achieved high therapeutic
eﬃcacy.
2.1.2 Experimental Methods
AGS cell culture and membrane derivation
AGS cell line (human gastric adenocarcinoma, ATCC CRL-1739) was pur-
chased from the American Type Culture Collection (ATCC) and maintained in
Ham F-12K Medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Hyclone) and 1% penicillin-streptomycin (100 U/mL penicillium and 100 µg/mL
streptomycin, Invitrogen) at 37 C in a humidified atmosphere containing 5% CO2.
For cell membrane derivation, AGS cells were grown in T-175 culture flasks to 70-80%
confluency and detached with 2 mM ethylenediaminetetraacetic acid (EDTA, USB
Corporation) in phosphate buﬀered saline (PBS, Invitrogen) and washed in PBS
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Figure 2.1: Schematic illustrations of the preparation of gastric epithelial
cell (e.g. AGS cell) membrane-coated nanoparticles (denoted ‘AGS-NPs’) and
their use for targeted antibiotic delivery to treat Helicobactor pylori (H. pylori)
infection. To prepare AGS-NPs, cellular membranes are first derived from
AGS cells, a human stomach adenocarcinoma cell line. AGS-NPs are then
fabricated by coating poly(lactic-co-glycolic acid) (PLGA) polymeric cores with
AGS membranes, which contain key antigens for H. pylori binding. The resulting
AGS-NPs mimic natural pathogen-host binding interactions. Following the
administration into the stomach, the AGS-NPs are expected to preferentially
bind with H. pylori bacteria and release antibiotic payload onsite for enhanced
antibacterial eﬃcacy.
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three times by centrifuging at 500 ⇥ g for 10 min. The pellet was suspended in
homogenization buﬀer (HB) consisting of 75 mM sucrose, 20 mM Tris-HCl pH 7.5
(Mediatech), 2 mM MgCl2 (Sigma Aldrich), 10 mM KCl (Sigma Aldrich), and pro-
tease/phosphatase inhibitors cocktails. Cells were disrupted by a dounce homogenizer
(20 passes), then spun down at 3,200 ⇥ g for 5 min. The supernatant was saved while
the pellet was resuspended in HB and the homogenization and centrifugation were
repeated again. The supernatants were pooled and centrifuged at 7,600 ⇥ g for 25
min, after which the pellet was discarded and the supernatant was centrifuged at
29,600 ⇥ g for 35 min. The supernatant was discarded and the pellet was resuspend
in 10 mM Tris-HCl pH = 7.5 and 1 mM EDTA and centrifuged again at 29,600 ⇥ g
for 35 min. The pellet containing the plasma membrane material was then collected
and resuspended in DI water. Samples were aliquoted and stored in -80 C fridge for
subsequent studies.
Nanoparticle synthesis and characterization
To synthesize polymeric nanoparticle cores, 0.67 dl/g acid (carboxyl)- termi-
nated 50:50 poly (lactic-co-glycolic acid) (PLGA) (LACTEL Absorbable Polymers)
in acetone was nanoprecipitated in aqueous solution. To prepare fluorescently labeled
PLGA cores, 1,19-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine perchlorate
(DiD,  excitation/emission = 644/665 nm, 0.1 wt%, Life Technologies) was dissolved
together with PLGA in acetone followed by the nanoprecipitation process. The
nanoparticle solution was then put under vacuum to remover organic solvent with
continuous stirring for 2h. To synthesize AGS cell membrane-coated nanoparticles
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(AGS-NPs), PLGA nanoparticles cores were mixed with membrane vesicles at 1:2
membrane protein to polymer weight ratio, and sonicated using a bath sonicator
(FS30D, Fisher Scientific, with a frequency of 42 kHz and a power of 100 W for 5
min) to coat membranes on to polymeric cores. Following the coating, AGS-NPs
were purified by centrifugation at 16,000 ⇥ g for 10 mins to remove unbound mem-
brane fragments. AGS membrane-derived vesicles (AGS-vesicles) were prepared by
sonicating collected cell membranes without PLGA cores for 2 min. As a control
group, PLGA nanoparticles coated with polyethylene glycol (PEG-NPs) were fabri-
cated through a nanoprecipitation method previously described. Briefly, a solution
of PLGA in acetone was nanoprecipitated into an aqueous phase containing 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)- 2000]
(DSPE-mPEG2000, average Mw = 2.8 kDa, Laysan Bio, Inc., AL, 10 wt% of PLGA).
The nanoparticle solution was then placed under vacuum to remover organic solvent
with continuous stirring for 2h. Following the nanoparticle synthesis, dynamic light
scattering (DLS) studies were performed to measure the hydrodynamic size and
surface zeta potential (Malvern ZEN 3600 Zetasizer). All measurements were carried
out in triplicate at room temperature. To examine the nanoparticle miscroscopic
morphology, AGS-NP samples were visualized with transmission electron microscopy
(TEM, Tecnai G2 Sphera FEI 200 kV). Briefly, AGS-NP samples (1 mg/mL) were
dropped onto carbon-coated copper grid and left for 1 min, and then washed oﬀ with
DI water. The sample was then stained with 1 wt% uranyl acetate (Sigma Aldrich)
before imaging.
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Membrane protein characterization
An SDS-PAGE assay (Thermo Fisher Scientific) was carried out to examine
the protein profile of AGS cell lysates, AGS membranes, and AGS-NPs. Specifically,
all samples were adjusted to equivalent total protein concentrations in lithium dodecyl
sulfate (LDS) loading buﬀer. The samples were then separated on a 4-12% Bis-Tris
17-well minigel in MOPS running buﬀer using a Novex Xcell SureLock Electrophoresis
System. The protein bands were stained with InstantBlue Protein Stain (Expedeon)
for observation according to manufacturer’s protocol. Western blotting was conducted
to identify membrane proteins on AGS-NPs. Specifically, gels from the SDS-PAGE
study were transferred onto a nitrocellulose membranes (Thermo Scientific) and
probed with primary antibodies including mouse anti-human CD29 (Biolegend),
mouse anti-human Blood Group Lewis b (Santa Cruz Biotechnology), and mouse
anti-human CD66e (CEACAM5, Santa Cruz Biotechnology). Horseradish peroxidase
(HRP)-conjugated secondary antibodies including goat anti-mouse IgG (Biolegend)
and goat anti-mouse IgM (Southern Biotech) were used as secondary staining based
on the isotype of the primary antibodies. The nitrocellulose membrane was then
incubated with ECL western blotting substrate (Pierce) and developed with the
Mini-Medical/90 Developer (ImageWorks).
AGS-NP targeting to H. pylori bacteria
H. pylori Sydney strain 1 (SS1) was maintained on Columbia agar supple-
mented with 5% horse blood (Hardy Diagnostics) at 37 C under microaerobic condi-
tions (10% CO2, 85% N2, and 5% O2). Before the experiments, a single colony of
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H. pylori from the agar plate was inoculated into Brain Heart Infusion (BHI) broth
containing 5% FBS and incubated overnight at 37 C under microaerobic conditions
with moderate reciprocal shaking. Following the culture, the bacteria were harvested
by centrifugation at 5,000 ⇥ g for 10 min, washed with sterile 1X PBS twice, and
suspended to a concentration of 1 ⇥ 108 CFU/mL (OD600 = 1.0) in PBS. For the
targeting study, 500 µL of H. pylori SS1 (5 ⇥ 107 CFU) was added with 200 µL
DiD-labeled AGS-NPs or PEG-NPs (250 µg/mL in 1X PBS) and the samples were
allowed to mix for 30 min at room temperature. Unbound nanoparticles were removed
from the bacteria by repeated centrifugal and washing steps (5,000 ⇥ g and 1X PBS).
The bacteria were then suspended in 1X PBS and fixed with 2% glutaraldehyde
(Sigma Aldrich) for 2 h at room temperature. For imaging by deconvolution scanning
fluorescence microscope (DeltaVision System, Applied Precision), post-fixed bacterial
suspension was mixed at 1:1 ratio with Vectashield mounting medium containing
DAPI. Then 5 µL of the bacterial suspension was dropped on a poly-L-lysine coated
glass slide, sealed with coverslip and the fluorescence images were obtained. To quan-
tify DiD fluorescence intensity, bacterial samples were added to a 96-well plate and
read with a plate reader (Biotek Spectroscopy). AGS-NP targeting to H. pylori was
also observed with scanning electron microscopy (SEM, FEI/Philips XL30 ESEM).
Briefly, 5 µL of the post-fixed bacterial suspension was dropped onto a polished
silicon wafer and allowed to dry overnight in a biosafety cabinet. The sample was
then coated with chromium and imaged. In all experiments, bacterial sample without
adding the nanoparticles was used as a control.
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Drug loading and release studies
To load clarithromycin (CLR) into AGS-NPs, CLR and PLGA were mixed
and dissolved in acetone, followed by precipitation into water containing 1 wt% of
F68 (Invitrogen). Solutions were stirred for 4 h to evaporate the organic solvent.
Loading eﬃciency was studied by varying the weight ratio of CLR to PLGA from 5 to
30 wt%. Following the preparation, nanoparticles were washed with Amicon Ultra-4
centrifugal filters (Millipore, 10 kDa cut-oﬀ) and then used for membrane coating
as described above. To measure CLR loading yield, 1 mL of AGS-NPs (6 mg/mL)
was lyophilized. Dried AGS-NPs were first dissolved in 200 µL acetronitrile, and
then added with 200 µL methanol to extract CLR. Samples were then centrifuged at
21,000 ⇥ g. The supernatants were collected and the pellets were discarded. The
concentration of CLR in the supernatant samples was measured by high performance
liquid chromatography (HPLC, with a PerkinElmer Brownlee C18 analytical column,
4.6 ⇥ 100 mm, 3 µm particle size). The mobile phase contained methanol and 0.067
M monobasic potassium phosphate (13:7) and pH was adjusted to 4.0 with phosphoric
acid. The flow rate was kept at 1.0 mL/min and the detector wavelength was set as
205 nm.
To study the release kinetics of CLR from AGS-NPs, the samples (6 mg/mL,
200 µL) were loaded into Slide-A-Lyzer mini dialysis devices (10K MWCO, Thermo
Scientific Pierce) and then dialyzed against 2L of 1X PBS. PBS buﬀer was replaced
every 12 h during the dialysis process. At each predetermined time point, AGS-NP
solutions in three mini dialysis cups were collected and CLR concentration was
measured as described above.
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Bactericidal activity of CLR-loaded AGS-NPs against H. pylori
Bacteria were pelleted from liquid culture with centrifugation at 3000 ⇥ g for 7
min and resuspended in fresh BHI to a concentration of 5 ⇥ 107 CFU/mL. Then 200
µL of the bacterial solution was mixed with 1000 µL free CLR, CLR-loaded PEG-NPs,
CLR-loaded AGS-NPs with a final drug concentration ranging from 0 to 8 µg/mL.
Mixtures were first cultured at 37 C under microaerobic condition on reciprocal shaker
for 30 min and then centrifuged at 3,000 ⇥ g for 7 min. Bacterial pellets were washed
twice with PBS to remove unbound drugs and NPs and then resuspended with fresh
BHI, followed by an overnight incubation. After the incubation, the samples were
serial diluted 10 to 107-fold with 1X PBS. The bacterial suspensions were spotted
onto Columbia agar plates with 5% laked horse blood. The agar plates were incubated
for 3-5 days for bacterial enumeration.
Induction of H. pylori infection in mice
Six-week-old C57BL/6 male mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). Mice were housed in the Animal Facility at the University of
California San Diego under federal, state, local, and National Institutes of Health
guidelines for animal care. To induct infection, each C57BL/6 mouse received 0.3 mL
of 1 ⇥ 109 CFU/mL H. pylori in BHI broth administered intragastrically through
oral gavage every 48 h, repeated three times (on day 3, 5, and 7, respectively), and
the infection was allowed to develop for 2 weeks.
35
In vivo anti-H. pylori eﬃcacy of CLR-loaded AGS-NPs
Infected mice were randomly divided into four treatment groups (n=8) and
orally administered with CLR-loaded AGS-NPs, CLR-loaded PEG-NPs, free CLR,
(with 30 mg/kg CLR dosage) or PBS. Administration was performed once daily for 5
consecutive days. Before the treatment, mice were first administered with omeprazole
(a proton pump inhibitor) through oral gavage at a dose of 400 µmol/kg body weight,
followed by a lag time of 30 min before administration of diﬀerent treatment groups.
Forty-eight hours after last administration, mice were sacrificed and the stomachs were
excised from the abdominal cavity. The stomachs were cut along the greater curvature,
and the gastric content was removed. Stomach tissues were rinsed with 1X PBS and
weighed. Then samples were suspended in 200 µL 1X PBS and homogenized with
Bullet Blender homogenizer (Next Advance). The homogenate was serially diluted
and spotted onto Columbia agar plate with 5% laked horse blood and Skirrow’s
supplement (10 µg/mL vancomycin, 5 µg/mL trimethoprim lactate, 2,500 IU/L
polymyxin B, Oxiod). The plates were then incubated at 37 C under a microaerobic
condition for 5 days and then bacterial colonies were enumerated.
Evaluation of AGS-NP toxicity in vivo
To evaluate the acute toxicity of the AGS-NPs in vivo, uninfected C57BL/6
male mice (n=6, 25-30 g each) were orally administered with AGS-NPs once daily
for 5 consecutive days using the procedure as described above. Control mice were
administered with PBS. During the experimental period, the mouse body weight was
monitored daily. On day 6, mice were sacrificed and sections of the mouse stomach
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tissues were processed for histological examination. The stomach was cut open along
the greater curvature, and the gastric content was removed. The longitudinal tissue
sections were fixed in neutral-buﬀered 10 v/v% formalin for 15 h, transferred into
70% ethanol, and then embedded in paraﬃn. The tissue sections were cut with 5 µm
thickness and stained with hematoxylin and eosin (H&E). The stained sections were
visualized by Hamamatsu NanoZoomer 2.0HT and the images processed using NDP
viewing software.
Statistical Analysis
DLS and plate reader data represent averaged values (obtained from 3 repli-
cates) with standard deviation shown as error bars. For Western blot studies, the
experiments were performed in triplicate and a representative image was shown. To
examine the statistical significance, unpaired two-tailed t-tests were performed in
GraphPad Prism 7 with confidence level P = 0.05 deemed significant.
2.1.3 Results and Discussion
The formulation process of AGS-NPs consists of three steps. In the first step,
cytoplasm membranes of AGS cells were derived based on a previously established
process, which involves hypotonic lysis, mechanical disruption, and diﬀerential cen-
trifugation. [194, 203] In the second step, polymeric cores of PLGA were synthesized
with a nanoprecipitation method, where acetone solution containing PLGA was added
dropwise to an aqueous phase followed by evaporation. The nanoprecipitation process
also allows for encapsulation of dye molecules or antibiotics by co-dissolving these
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Figure 2.2: Physicochemical characterization of AGS-NPs. (A) Dynamic light
scattering (DLS) measurements of hydrodynamic size (diameter, nm) and surface
zeta potential (⇣, mV) of PLGA cores, AGS membrane vesicles (AGS-vesicle),
and AGS-NPs (n = 3). (B) Translation electron microscopy (TEM) image
of AGS-NPs stained with uranyl acetate. Scale bar = 100 nm. (C) Stability
of AGS-NPs in DI water or 1X PBS, determined by monitoring particle size
(diameter, nm), over a span of 24 h (n=3). (D) Western blotting analysis for
AGS membrane-specific protein markers. Samples were run at equal protein
concentrations and immunostained against membrane markers including CD29,
Leb, and CD66e.
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molecules with PLGA in acetone. In the third step, AGS cell membranes were fused
onto PLGA cores by mixing the cores with AGS membrane followed by sonication.
Following the synthesis, dynamic light scattering (DLS) measurements on AGS-NPs
showed that the diameter of the nanoparticles increased from 85.8 ± 4.4 nm of
the PLGA cores to 102.2 ± 4.0 nm after the cell membrane coating (Figure 2.2A).
Meanwhile, the surface zeta-potential increased from -41.5 ± 2.0 to -25.5 ± 3.3 mV.
An increase of approximate 16 nm of nanoparticle diameter and a change of about
20 mV of the surface zeta-potential are attributable to the addition of a bilayer
membrane onto the exterior of the PLGA cores. [194,203] Following the fabrication,
AGS-NPs were also examined under transmission electron microscopy (TEM) for
morphology. Under the microscope, AGS-NPs present a typical core-shell structure,
where a spherical core is surrounded by a unilamellar membrane coating (Figure 2.2B).
AGS-NPs were suspended in water or 1X PBS and monitored for hydrodynamic sizes
measured with DLS for 24 h. Herein, 1X PBS simulated the pH level in stomach
after proton pump inhibitor was also administered in anti-H. pylori treatment. [187]
In PBS, AGS-NPs maintained stable sizes comparable to those in water, indicating
an enhanced colloidal stability due to the membrane coating (Figure 2.2C). AGS-NPs
were further analyzed with Western blot for antigenic information (Figure 2.2D).
Specifically, we verified the presence of key membrane proteins responsible for H.
pylori binding, including CD29 (integrin  1), blood group Lewis b (Leb), and CD66e
(carcinoembryonic antigen-related cell adhesion molecule-5 or CEACAM5). Compared
to cell lysate, membrane derivation also enriched membrane protein concentration,
reflected by higher protein immunoblot intensity for AGS membrane vesicles (denoted
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AGS-vesicles) and AGS-NPs compared to that of the cell lysate. Overall, these results
show the successful coating of AGS cell membranes onto polymeric cores.
After the nanoparticle synthesis, we tested the preferential targeting of AGS-
NPs to H. pylori bacteria. As shown in Figure 2.3A, H. pylori (blue) showed
a typical rod shape when observed under a fluorescence microscope. The image
of the bacteria obtained with scanning electron microscopy (SEM) confirms the
morphology and further reveals the polar sheathed flagella. Next, we mixed the
bacteria with fluorescence-labeled AGS-NPs (red). The mixture was incubated at
37 C for 30 min. Following the incubation, the bacteria were thoroughly washed
and then observed with a fluorescence microscope. In this case, sporadic red dots in
the peripheral area of the bacteria were visible, suggesting AGS-NP retention and
co-localization with the bacteria. Under SEM, the presence of individual nanoparticles
on the bacteria was revealed, further verifying H. pylori -AGS-NP co-localization. To
confirm AGS-NP targeting, we formulated polyethylene glycol (PEG)-coated PLGA
nanoparticles (denote PEG-NPs), which are inert to bacterial binding, as a negative
control. Although PEG-NPs were also fluorescence-labeled and had comparable sizes
to AGS-NPs, they were not detected under either fluorescence microscope or SEM
after incubation with the bacteria, therefore confirming the critical role played by
AGS membrane coating for H. pylori targeting. We further quantified the overall
fluorescence intensity of the bacterial samples. As shown in Figure 2.3B, H. pylori
bacteria incubated with AGS-NPs showed a nearly 10-fold increase in fluorescence
intensity compared to that of the bacteria incubated with PEG-NPs, confirming the
occurrence of a prominent binding between AGS-NPs and H. pylori bacteria.
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Figure 2.3: AGS-NPs targeting to H. pylori bacteria (A) Fluorescence mi-
croscopy (FM, top row) and scanning electron microscopy (SEM, bottom row)
images of H. pylori bacteria after incubation with medium only, AGS-NPs, and
corresponding pegylated PLGA nanoparticles (PEG-NPs), respectively. Scale
bar = 5 µm in FM and 1 µm in SEM, respectively. (B) Fluorescence intensity
at 665 nm measured from the H. pylori bacterial samples incubated with PBS,
AGS-NPs, and PEG-NPs, respectively. In FM images and fluorescent intensity
measurements, AGS-NP and PEG-NP were labeled with DiD dye (red) and H.
pylori were stained with DAPI (blue). Bars represent means ± SD (n = 3).
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After having confirmed the preferential binding between AGS-NPs and H.
pylori bacteria, we proceeded to examine whether AGS-NPs could carry CLR, one
of the first-line antibiotics in anti-H. pylori treatment, and specifically deliver CLR
to H. pylori. In the study, drug loading was achieved by co-dissolving CLR with
PLGA polymer in acetone at desired ratios prior to nanoprecipitation. Following
evaporation of the organic solvent, the cores were coated with AGS membrane,
resulting in CLR-loaded AGS-NP (denoted AGS-NP(CLR)). In the study, we fixed
PLGA amount and varied the initial CLR input from 0 to 30 w/w% of the polymer
weight, a range where the resulting PLGA cores maintained comparable sizes and
stability. As shown in Figure 2.4A, CLR loading yield increased when drug initial
input was increased. The highest CLR loading yield of 12.43 ± 0.98% was achieved
when drug initial input was kept at 30 w/w%. We selected this formulation for the
following studies. Following drug loading, samples of free CLR and CLR released from
AGS-NP(CLR) were analyzed with high performance liquid chromatography (HPLC).
As shown in Figure 2.4B, CLR molecules released from nanoparticles elute at the
same time as that of free CLR and peak shapes of the both are similar, suggesting
that drug encapsulation and membrane coating did not cause drug degradation. The
release kinetics of CLR from AGS-NPs or bare PLGA cores were also examined
(Figure 2.4C).The study was carried out in 1X PBS to simulate the pH level in
stomach as proton pump inhibitor was also administered to block gastric acid. [187]
Without membrane coating, PLGA cores showed a prominent burst release of CLR.
In contrast, burst release was minimized when release from AGS-NP(CLR) was
measured. In addition, CLR release rate from AGS-NPs stayed lower than that from
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uncoated PLGA cores. Specifically, a cumulative 83% of CLR was release from PLGA
cores in 24 h, whereas only 68% was released from AGS-NP(CLR). A more prolonged
drug release from AGS-NP(CLR) is likely due to the coated membranes, which acts
as a barrier for drug diﬀusion out of the polymer matrix. [204]
After successful loading of CLR into AGS-NP, we next investigated the bac-
tericidal activity of AGS-NP(CLR) against H. pylori. In the study, H. pylori was
first incubated with free CLR, AGS-NP(CLR), or CLR-loaded PEG-NP (denoted
PEG-NP(CLR)), followed by washing steps to remove free CLR and unbound PEG-
NP(CLR), respectively. Bacteria were cultured and then enumerated. As shown in
Figure 2.4D, under the experimental conditions, neither free CLR nor PEG-NP(CLR)
was able to eradicate H. pylori bacteria. In contrast, bacteria incubated with AGS-
NP(CLR) showed a nonlinear correlation between bacterial viability and nanoparticle
concentrations. A drastic enhancement in bacterial killing of AGS-NP(CLR) com-
pared to control formulations demonstrated a superior antibiotic targeting eﬀect. For
this study, we defined minimal bactericidal concentration (MBC) as the minimum
concentration of the bactericidal agent required to kill 3 logs (99.9%) of the bacteria
during a 30-min incubation. Accordingly, the value of MBC of AGS-NP(CLR) was
determined to be 4 µg/mL.
Next, we evaluated the in vivo therapeutic eﬃcacy of AGS-NP(CLR) against
H. pylori. To this end, we first established a mouse model of infection with H. pylori
SS1 strain. [205,206] Specifically, we administered each C57BL/6 mouse with 3 ⇥ 108
CFU bacteria through oral gavage once every two days for four times (Figure 2.5A).
After bacterial administration, infection was allowed to develop for two weeks and
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Figure 2.4: Characterization of clarithromycin(CLR)-loaded AGS-NP (denoted
‘AGS-NP(CLR)’). (A) Quantification of CLR loading yield of AGS-NP(CLR)
when initial drug input was varied from 0 to 30 w/w%. (B) Chromatogram
of free CLR and CLR released from AGS-NP(CLR). The flow rate was kept
1.0 mL/min and a detector wavelength at 205 nm. (C) CLR release profiles
from PLGA core without membrane coating (red) and from AGS-NP(CLR).
Data points represent means ± SD (n = 3). (D) In vitro bactericidal activity
of free CLR, PEG-NP(CLR), and AGS-NP(CLR) against H. pylori bacteria,
respectively. Bars represent means ± SD (n = 3). UD = undetectable.
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then infected mice were randomly divided into four groups (n=8 for each group) and
treated with PBS, free CLR, PEG-NP(CLR), or AGS-NP(CLR). In the study, a CLR
dosage of 30 mg/kg body weight was chosen based on existing studies. [207,208] To
avoid potential drug degradation, all mice were given proton pump inhibitor through
oral gavage 30 min prior to the administration of all formulations to neutralize
gastric acid in the stomach. Each formulation was administered once a day for five
consecutive days. On day 6, mice were sacrificed and stomach tissues were processed
for bacterial quantification. Therapeutic eﬃcacy was evaluated by enumerating and
comparing H. pylori colonies. As shown in Figure 2.5B, mice treated with PBS
showed a high bacterial burden of 1.58 ⇥ 105 CFU/g of stomach tissue. Meanwhile,
mice treated with free CLR and PEG-NP(CLR) carried a bacterial burden of 5.01 ⇥
104 and 6.45 ⇥ 103 CFU/g of stomach tissue, respectively. These values correspond to
a bacterial reduction of approximately 0.53 and 1.43 orders of magnitude, respectively.
In contrast, the bacterial burden in mice treated with AGS-NP(CLR) was found to be
1.46⇥102 CFU/g of stomach tissue, approximately 3.08 orders of magnitude reduction.
The superior anti-H. pylori eﬃcacy found with AGS-NP(CLR) demonstrates the
eﬀectiveness of AGS membrane coating for drug targeting.
Lastly, we evaluated the toxicity of AGS-NP with uninfected C57BL/6 mice.
In the study, mice were orally administered with AGS-NP once daily for 5 consecutive
days with the same dosing regimen as the one used in above eﬃcacy study. Mice
administered with PBS buﬀer were used as a control group. During the study, mice
administered with AGS-NPs maintained the same body weight compared to mice
administered with PBS and all mice showed stable body weight and steady growth
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Figure 2.5: In vivo anti-H. pylori therapeutic eﬃcacy of AGS-NP(CLR). (A)
The study protocol using a C57BL/6 mouse model of H. pylori infection, which
includes H. pylori inoculation (week 1), infection development (week 2-3), and
treatment (week 4). (B) Quantification of H. pylori bacterial burden in the
stomach of infected mice treated with PBS, free CLR, PEG-NP(CLR), or AGS-
NP(CLR) (n = 6 per group). Bars represent median values. ⇤P < 0.05, ⇤⇤P <
0.01, ⇤⇤⇤P < 0.001.
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Figure 2.6: Evaluation in vivo toxicity of AGS-NP. Uninfected mice were orally
administered with the AGS-NP or PBS once daily for five consecutive days. (A)
Mouse body weight log from day 0 to day 6 during study. Error bars represent the
standard deviation of the mean (n = 6). (B) On day 6, mice were sacrificed and
sections of the stomach were processed for histological staining with hematoxylin
and eosin (H&E). Scale bars represent 250 µm in the top row and 100 µm in
the bottom row). In the images on the top row, m: mucosa, mm: muscularis
mucosa, and s: submucosa.
(Figure 2.6A). On day 7, all mice were sacrificed and the longitudinal sections of gastric
tissues obtained from the mice were collected and stained with hematoxylin and eosin
(H&E). Under microscope, tissue samples of mice from both groups show clear layers
of mucosa, muscularis mucosa, and submucosa (Figure 2.6B). When zoomed-in, the
gastric tissues from mice treated with AGS-NPs maintained an undisturbed structure
with a clear layer of epithelial cells and well-organized gastric pits, which was similar
to the gastric samples treated with PBS only. The absence of any detectable gastric
histopathologic changes or toxicity within a five-day treatment suggests that orally
administered AGS-NPs is safe.
Targeted delivery can promote drug-pathogen localization and minimizes drug
systemic exposure, therefore reducing the risk of drug resistance. [191] To achieve
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eﬀective drug targeting, one common method is to conjugate nanoparticles with
bacterium-specific ligands including small molecules, peptides, antibodies, and ap-
tamers. [189] However, the application of such ‘bottom-up’ strategy may be limited by
the availability of reliable ligands for pathogen binding as well as the robustness of the
conjugation process. In contrast, cell membrane coating approach represents an alter-
native ‘top-down’ method that leverages native cell-pathogen adhesion mechanisms
for targeting without ligand selection and conjugation. Like H. pylori, various oppor-
tunistic pathogens, such as strains of staphylococci, streptococci, and Escherichia coli,
are also known to exploit complex adhesion mechanisms for host cell adhesion and
colonization. [209, 210] Cell membrane coating is an eﬀective approach to harnessing
these biological mechanisms and replicate the binding. Using membranes from their
host cells to coat nanoparticles is expected to be applicable for antibiotic targeting
against the pathogen infections. In addition, harnessing patient’s host cell functions
for pathogen targeting may open new opportunities to enable patient-specific and
disease-specific precision medicine. [211]
In this study, we selected CLR as a model antibiotic to demonstrate the
targeted delivery ability of the AGS-NPs. As PLGA nanoparticles have extensive
applications in drug encapsulation and delivery, AGS-NPs are expected to load and
deliver other antibiotics or antibiotic combinations to further improve anti-H. pylori
eﬃcacy. [212] Herein, AGS-NPs are designed with a diameter of approximately 100
nm and a negative surface charge, as nanoparticles with a comparable size and
surface charge are known to eﬀectively penetrate mucus layer. [187,213] In addition,
cell membrane coated onto PLGA is known to neutralize bacterial toxins for anti-
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bacterial eﬃcacy [214, 215]. For H. pylori infection, such activity may also exist
and can benefit from a bacterial targeting eﬀect that reduces nanoparticle stomach
clearance and brings nanoparticles to the proximity of the bacteria. [187] Meanwhile,
nanoparticle cores made with materials such as mesoporous silica, macromolecule
gelatin, and crosslinked acrylamide have been coated with cell membranes. [192] New
coating processes, such as cell membrane vesicle-templated in situ gelation, have also
been developed. [216] Furthermore, the furture development of AGS-NPs toward
clinical use needs to address cell membrane supply issue. In this regard, the rapid
advances in methods of ex vivo cell expansion may address the large quantity of
cell membrane materials demanded for clinical studies. [217,218] Meanwhile, genetic
engineering aimed at modifying primary human cells have also advanced significantly,
oﬀering on-demand membrane function in combination with rapid and large-scale
cell expansion. [219] These breakthroughs together oﬀer a promising prospect to the
translation of AGS-NPs and cell membrane-coating technology in general.
These technological advances can be also applied to enable new antimicrobial
strategies beyond antibiotic delivery. For instance, cell membrane-coated nanopar-
ticles have been developed to neutralize bacterial toxins based on toxins’ virulent
mechanisms rather than their structures, therefore enabling broad-spectrum and
‘drug free’ antivirulence therapy. [220,221] As another ‘drug free’ strategy to combat
infection, cell membrane-coated nanoparticles have also been developed as antibac-
terial vaccines. In this case, nanoparticles coated with bacterial outer membranes
not only present the natural antigen presentation by bacteria to the immune system,
but also modulate the host immune response through size-controlled lymphatic tar-
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geting. Meanwhile, bacterium-secreted virulent toxins have been entrapped using
cell membrane-coated nanoparticles, resulting in multivalent nanotoxoids capable
of delivering diverse virulence factors in a natural, concurrent, and safe fashion for
immunity. [222,223] The nanotoxoid formulation consistently outperformed traditional
vaccine formulations prepared from denatured proteins. Overall, these developments
illustrate the promise and strength of using cell membrane coating technology to
address the therapeutic challenges of bacterial infections.
2.1.4 Conclusions
In summary, we derived natural membranes of AGS cells, a gastric epithelial
cell line, and coated them onto PLGA polymeric cores. The resulting AGS-NPs
preserved cell surface antigens used by H. pylori bacteria to adhere and colonize
the host. AGS-NPs showed preferential binding and retention with H. pylori when
compared to control nanoparticles coated with synthetic PEG. We further loaded
CLR into AGS-NPs and achieved high drug loading yield and prolonged drug release
profile from the nanoparticles. The resulting CLR-loaded AGS-NPs showed superior
bactericidal eﬀect in vitro and were able to eﬀectively reduce bacterial burden in a
mouse model of H. pylori infection. In addition, mouse body weight and stomach
histology in a toxicity test showed no adverse eﬀects from the AGS-NPs. Collectively,
these results demonstrate that AGS-NPs are an eﬀective and safe approach for
targeted antibiotic delivery to treat H. pylori infection.
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2.2 Micromotors spontaneously neutralize gastric
acid for pH-responsive payload release
2.2.1 Introduction
Gastric acid, consisting primarily of hydrochloric acid produced by parietal
cells in the gastric glands, plays a crucial role in maintaining the stomach’s digestive
function. It enables gastric proteolysis by denaturing proteins from food for break
down by digestive enzymes. It also inhibits the growth of many microorganisms which
enter the stomach and thus reduces the risk of pathogen infection. However, the harsh
gastric environment becomes a double-edged sword under certain circumstances. For
example, it creates a physiological barrier for the use and delivery of therapeutic
drugs, such as protein-based drugs and some antibiotics to the stomach. In these
cases, the drugs are exclusively combined with a proton pump inhibitor (PPI), which
reduces the production of gastric acid. The eﬀectiveness of PPIs is attributed to the
irreversible binding to the proton pumps to suppress acid secretion for approximately
12 to 24 hours. [224, 225] Long-term use of PPIs can cause adverse eﬀects such as
headache, diarrhea, and fatigue, and in more serious scenarios cause anxiety and
depression, as well as severe reaction rhabdomyolysis. [226–231] Therefore, it would be
highly desirable to develop alternative approaches which can temperately neutralize
gastric acid while not causing adverse drug eﬀects.
Recent advances in nanotechnology has led to the design of a variety of
nanocarrier systems which can respond to various biological stimuli, such as pH, for
triggered release of their payload. [232–235] In particular, the emerging synthetic
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nano/ micromotors, which are tiny devices that convert locally supplied fuels or ex-
ternally provided energy into force and movement, [236–245] have shown considerable
promise as delivery vehicles because of their active transport capacity and ability
to dynamically respond to their surroundings. [246–253] For example, recent in vivo
evaluations of synthetic micromotors demonstrated that these artificial motors can
self-propel in the stomach and intestinal fluids for enhanced retention and targeted
delivery in the gastrointestinal tract. [254, 255] These prior studies demonstrate
that the motor-based active transport systems oﬀer attractive features for localized
targeted delivery.
In this work, we introduce a new magnesium (Mg)-based micromotor, covered
by a pH-sensitive polymer coating, which can rapidly yet transiently neutralize the
acidity of the stomach fluid in vitro and in vivo. By using acid as fuel, these synthetic
motors quickly deplete protons while propelling within the stomach, which can
eﬀectively elevate the gastric pH to neutral in less than 20 minutes after the motors
are applied. More importantly, the motor-induced neutralization of the stomach
fluid further triggers the autonomous payload release from the pH-sensitive polymer
coating. In contrast to acid suppression by PPIs, the micromotors temporally alter the
local environment without blocking the function of the proton pumps. Therefore, this
approach has minimal interference upon the function of the stomach and completely
eliminates all possible adverse eﬀects associated with conventional PPIs. Since the
micromotors are made of biocompatible materials without biological activities, they
are safe to use and will not cause acute toxicity. Compared to conventional pH-
responsive nanocarriers which passively respond to the local environment, these
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micromotors can actively adjust their surroundings to reach desired conditions for
triggered payload release. Therefore, the use of micromotors, with built-in dual
capabilities of acid neutralization and pH-responsive payload release, is a unique and
highly promising platform for drug delivery to treat various gastric diseases.
2.2.2 Experimental Methods
Synthesis of EUDRAGIT R  L100-55/Au/Mg micromotors
Magnesium (Mg) microparticles (catalog # FMW20, TangShan WeiHao Mag-
nesium Powder Co.; 20± 5 µm) were used as the core to prepare the Mg-based Janus
micromotors. The Mg microparticles were initially dispersed onto glass slides coated
with a thin film of Poly(vinylpyrrolidinone) template followed by sputtering a gold
layer using a Denton Discovery- 18 sputter system. After that, the Janus micromotors
were coated with a film of a commercial pH-responsive polymer (EUDRAGIT R 
L100-55; Evonik Industries, Germany), forming the outermost layer coated on the
Mg micropsheres, using a polymer concentration of 0.67% (w/v) in ethanol. After the
ethanol was completely evaporated, the EUDRAGIT R  L100-55/Au/Mg micromotors
were collected by lightly scratching the particles oﬀ the glass slide and weighed for
use.
Synthesis of R6G-loaded Mg micromotors
For performing the in vitro studies, fluorescent Mg-based micromotors were
prepared by using a mixture of EUDRAGIT R  L100-55 polymer solution (0.67%
(w/v) in ethanol) and 20 µg/mL of rhodamine 6G dye (83697, SIGMA, USA). To
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compare with the Mg-based micromotors, inert polystyrene (PS) microparticles
(Bangs Laboratories, Fisher, IN, USA) were used as core particles, following the same
protocols for the Au and polymer coatings as described above.
In vitro pH neutralization study
In vitro pH neutralization study was performed by measuring the pH values of
a gastric fluid simulant (initial pH=1.3; 01651-Sigma-Aldrich) with a pH meter (Seven
Easy, Mettler-Toledo, Switzerland) at 1-minute intervals after adding varying amounts
of Mg micromotors. The commercial pH indicator BCECF (catalog# B1151, Thermo
Fisher, USA) was also used for the pH neutralization study. The fluorescence intensity
of BCECF in gastric fluid (pH 1.3), PBS buﬀer (pH 7.4), and neutralized gastric
fluid was measured at excitation/emission = 508/532 nm using a Tecan Infinite M200
microplate reader. The in vitro triggered release of R6G dye used as a drug- loaded
model and as an indicator of the pH responsive polymer dissolution was followed by
monitoring the fluorescence intensity of the gastric fluid simulant solution.
Micromotor propulsion studies
For recording the bright field microscopy videos and capturing the bright
field and fluorescent images, an inverted optical microscope (Nikon Instrument Inc.
Ti-S/L100) coupled with a 20⇥ and 40⇥ microscope objectives and a Hamamatsu
digital camera C11440 was used. The NIS-Elements AR 3.2 software was employed to
characterize the movement of the Mg micromotors. For the fluorescence microscopy
videos, an identical setup was used in conjunction with a Sola Light Engine (SM5-
54
LCR-VA, Lumencor) for fluorescence excitation. Nikon fluorescence filter cubes 96312
were used for green light excitation.
In vivo pH neutralization and release study
Six-week-old male ICR mice purchased from Harlan Laboratories (Indianapolis,
IN) were fasted for 6 h with free access to water prior to the experiment. For the in
vivo pH measurement of gastric content, mice were divided into 4 groups (n=3) to be
orally administered with 2.5 mg, 5 mg, or 10 mg of Mg micromotors suspended in
0.2 mL DI water. Mice administered with 0.2 mL DI water were tested in parallel
as a control. After 20 min of administration, mice were sacrificed and stomachs
were excised. The pH of the gastric content was immediately measured using a pre-
calibrated pH meter (Seven Easy, Mettler-Toledo, Switzerland). A miniaturized pH
microsensor probe (InLab R  423 Combination pH Micro Electrode), with tip diameter
3 mm, was used to ensure a full immersion of the probe tip in the stomach lumen
without touching the gastric mucosa. Three separated pH measurements were taken
from each stomach, the pH probe was removed, washed with DI water and calibrated
between measurements.
For in vivo release study, mice were fed with alfalfa-free food from LabDiet
(St. Louis, MO, USA) for 2 weeks prior to the experiment. 1,19-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine perchlorate (DiD, excitation/emission = 644/665 nm,
Life Technologies) was used as a model drug. The DiD dye (20 µg/ml) was loaded
into the pH-sensitive polymer EUDRAGIT R  L100-55. A 0.2 mL suspension of Mg
micromotors or PS microparticles coated with DiD-loaded EUDRAGIT R  L100-55
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was administered orally. 0.2 mL DI water was given to control mice. 20 mins after
administration, the stomachs were cut open along the greater curvature, excess gastric
content was removed, and then imaged using an intelligent visual inspection system
(IVIS).
Toxicity evaluation of Mg micromotors, pH neutralization and recovery
To assess the recovery of gastric pH after Mg micromotor treatment. Mice were
intragastrically administered (n=3) with 0.2 mL suspension of 5 mg Mg micromotors.
At 20 min and 24 h after administration, mice were sacrificed and stomachs were
removed from the abdominal cavity. The pH of the gastric content was immediately
measured using a precalibrated pH meter. The probe tip was carefully positioned to
avoid contact with the stomach mucosa. Control mice were orally administered with
DI water.
For in vivo imaging of pH change, mice were fed with alfalfa-free food from
LabDiet (St. Louis, MO, USA) for 2 weeks prior to the experiment. 20 mins and 24 h
after administration of 5 mg Mg micromotors, the stomachs were cut open along the
greater curvature, excess gastric content was removed. 40 micro L of 2 mg/mL pH
indicator BCECF was evenly distributed onto the opened stomach. The fluorescence
imaging of the whole stomach labeled with pH indicator was performed using IVIS.
Control mice were orally administered with DI water. To evaluate the acute toxicity
of Mg micromotor in vivo, six-week-old ICR male mice were orally administered with
0.2 mL suspension of 5 mg Mg micromotor. Mice treated with DI water were used
as a control. 24 hours after the oral administration, mice were euthanized and the
56
stomachs were removed for histological analysis. The longitudinal sections of gastric
tissue were fixed in neutral-buﬀered 10% (vol/vol) formalin for 15 h, transferred into
70% ethanol, and embedded in paraﬃn. The tissue sections were cut with 5 µm
thickness stained with hematoxylin and eosin (H&E) assay. Epithelial cell apoptosis
was evaluated by the terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick end labeling (TUNEL) assay (Boehringer Mannheim, Indianapolis,
IN). Sections were visualized by Hamamatsu NanoZoomer 2.0HT and the images
processed using NDP viewing software.
2.2.3 Results and Discussion
Figure 2.7 a schematically illustrates the structure of a Mg-based micromotor
along with its gastric acid neutralization process (through proton depletion enabled
by the micromotor reaction and propulsion) and consequent payload release from
the pH-responsive polymer coating. The new microvehicle thus consists of the Mg
motor, the pH-sensitive polymer coating, and the encapsulated cargo. It oﬀers
multiple capabilities and functions, including movement, acid neutralization, cargo
transport, and release. The Mg engine converts the acid fuel into a propulsion
force and simultaneously alters the local pH, thus causing payload release from the
pH-sensitive coating. The core of the micromotor is made of a Mg microsphere with
a diameter of about 20 mm. For the fabrication of the micromotors, a layer of Mg
microparticles was dispersed onto a glass slide, followed by an asymmetrical coating
of the microspheres by sputtering with a thin (10 nm) gold (Au) layer, which is
responsible for eﬃcient propulsion through the macrogalvanic corrosion of the Mg
57
surface. [256] After sputtering the Au layer, the Janus microspheres were coated
with a pH-sensitive polymeric (EUDRAGIT R  L100-55, dissolves at pH > 5.5) film
containing the payload. Finally, the well-separated Mg Janus micromotors were
obtained after soft mechanical scratching of the glass slide, thus leaving a small
opening which exposes the Mg surface to react with the gastric fluid, and leads to
the hydrogen-bubble generation and propulsion. The presented micromotor design
is highly biocompatible, as magnesium is an essential mineral needed for variety of
physiological functions. [257] The enteric polymer coating has been extensively used
for drug delivery and release, [255] while gold is commonly employed for imaging
and therapeutic applications. [258] The bottom section of Figure 2.7A illustrates
the in vivo acid neutralization process associated with the propulsion of the Mg-
based Janus micromotors along with the corresponding payload release from the
pH-sensitive polymer layer. Upon contact with the gastric fluid, a spontaneous
reaction between the Mg microsphere motor surface and the surrounding protons
(top left of Figure 2.7A) generates hydrogen bubbles, and eﬃcient micromotor thrust.
Such a reaction and acid neutralization are facilitated by the presence of the Au layer,
which boosts proton depletion through macrogalvanic corrosion.
Figure 2.7B shows the characterization of the Mg-based Janus micromotors.
The scanning electron microscopy (SEM) image shows a small opening (ca. 2 µm),
produced during the coating process of the micromotors, on the spherical Mg-based
micromotor to expose the Mg surface for reaction with the surrounding acidic fluid.
The presence of Mg, Au, and carbon (from the polymer coating) is also confirmed
by the corresponding energy-dispersive X-ray spectroscopy (EDX) mapping. The
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Figure 2.7: Schematic illustrations of Mg-based micromotor and its acid neutral-
ization mechanism (A) Illustrations of an acid-powered Mg-based micromotor and
its acid neutralization mechanism. The micromotor is made of a Mg microsphere
coated with a thin gold (Au) layer and a payload-encapsulated pH-sensitive
polymer layer. At acidic pH, the Mg reacts with acids and generates hydrogen
bubbles, thus propelling the motors and depleting protons in the solution. (B)
SEM and EDX characterizations of the Mg-based micromotor. Scale bar: 5
µm. (C) Microscopy image illustrating the bubble propulsion of a micromotor in
gastric fluid. Scale bar: 20 µm.
microscopy image in Figure 2.7C illustrates the micromotor movement in gastric fluid
simulant (pH 1.3). Eﬃcient hydrogen-bubble generation propels the micromotor with
an average speed of 60 µm s 1, thus indicating that these micromotors can rapidly
react and move in gastric fluid.
The ability of Mg micromotors to neutralize gastric acid and trigger release
of their payload was first tested in vitro. Figure 2.8A displays the time-dependent
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pH neutralization process associated with the built-in proton consumption during
the reaction and propulsion of Mg micromotors in simulated gastric fluid (initial
pH1.3), using 2.75mg of micromotors and 3 mL gastric fluid. The pH of the fluid
increases rapidly from 1.3 to 6.2 within 12 minutes, and then more slowly, stabilizing
around pH 7.5 after 18 minutes. These data confirm that a fast neutralization of
gastric acid can be realized within less than 20 minutes, compared to the 0.5- 1 hour
typically required by using PPIs to reach the same level of neutralization. [224] The
fluorescent pH indicator BCECF was also used to verify the fast pH neutralization of
the gastric fluid by the micromotors. As displayed in Figure 2.8B, in the absence of
Mg micromotors, the gastric fluid containing the BCECF indicator displays a light
yellow color and very weak fluorescence intensity, and is indicative of acidic conditions.
In contrast, an obvious color change to red is observed 20 minutes after adding the
Mg micromotors to the gastric fluid. The fluorescence intensity drastically increases
to a similar level to that observed in a PBS buﬀer (pH 7.4), which was used as a
control solution. These results demonstrate that the Mg micromotors can rapidly
neutralize the gastric fluid through fast proton depletion and eﬃcient propulsion.
The fast neutralization process reflects the dramatic fluid convection induced by
the collective motion of micromotors in the gastric fluid and the corresponding
bubble generation. Such motor-induced “self-stirring” has been shown to accelerate
environmental decontamination processes. [259]
To study the pH-responsive release, enabled by the active neutralization of
the gastric fluid, R6G dye was used as a model payload encapsulated within the
pH-sensitive EUDRAGIT R  L100-55 polymeric coating of the Mg micromotors. Inert
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Figure 2.8: In vitro acid neutralization and pH-triggered payload release. (A)
Time-dependent pH value of gastric fluid (3 mL, pH 1.3) in the presence of Mg
micromotors (2.75 mg). (B) Fluorescence intensity of the pH indicator BCECF
in gastric fluid (pH 1.3), gastric fluid containing 2.75 mg of the Mg micromotor,
and PBS buﬀer (pH 7.4). Insets: images of the corresponding solutions. (C)
Time-dependent fluorescence intensity of released rhodamine 6G (R6G) in the
supernatant of 3 mL gastric fluid. R6G dye is loaded in the pH-sensitive polymer
coating (starts to dissolve at pH > 5.5) as a model payload. Polystyrene (PS)-
based inert microparticles with a similar size as the Mg micromotors were used
as a negative control. (D) Fluorescence image showing the propulsion and release
processes of an R6G-loaded Mg micromotor. Scale bar: 20 µm. (E) Fluorescence
images of the released R6G in the supernatant of gastric fluid containing Mg
micromotors (left) or PS microparticles (right).
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polystyrene (PS) microspheres (diameter : 10 µm) coated with the R6G dye-loaded
polymer layer was used as a control group. Figure 2.8C displays the payload release
profile, which obtained by measuring the supernatant fluo- rescence intensity, using
the micromotors and inert (control) particles placed in the acidic gastric fluid (initial
pH 1.3). The pH change associated with the presence of the Mg micromotors results in
sustained release of R6G from the pH- sensitive polymeric coating. The fluorescence of
the gastric fluid solution thus increases gradually and reaches a plateau at 20 minutes.
In contrast, no such R6G release is observed using the inert PS microparticles which
do not react with the protons to cause a pH change, and thus the pH-sensitive polymer
coating remains stable.
The fluorescence microscopy image of Figure 2.8D displays the real-time
propulsion and payload release of R6G from a Mg micromotor in the gastric fluid.
The strong fluorescence signals observed on the micromotor body and the yellow
bubble tail confirm the gradual dissolution of the polymer and consequent release
of R6G. Figure 2.8E shows the corresponding fluorescence photographs of R6G in
1mL bulk gastric solution in the presence of Mg micromotors and an inert control
with microparticles (both coated with R6G-loaded, pH-sensitive polymer). These
images clearly show that the dye is released to the solution using micromotors but
resides in the sediment at the bottom (containing the inert microparticles). This
behavior indicates that the Mg micromotors, which actively neutralize the gastric
fluid, can trigger drug release. This behavior represents a distinct advantage of the
based on the in vitro study which showed that the Mg micromotors were able to
eﬀectively neutralize gastric acid within this time window. As shown in Figure 2.9B,
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this experiment resulted in a clear dose-dependent gastric pH change. Herein, 5
milligrams of the Mg micromotor were able to neutralize gastric acid in the mouse
stomach, thus resulting in pH 7.81 ± 0.38. This motor concentration was higher than
the 2.75 mg per 3 mL gastric acid as observed in the in vitro study. Such an increase
of the motor amount was likely due to the continuous secretion of gastric acid from
gastric glands in the mouse stomach, as well as the dynamic peristalsis wave of the
stomach tissue which counteracts and dilutes the pH neutralization eﬃcacy of the
micromotors. Lower and higher doses of Mg micromotors resulted in slightly acidic
and alkaline stomach environments (pH 4.24 for 2.5 mg Mg micromotors and pH 9.43
for 10 mg Mg micromotors, respectively). Using deionized (DI) water as a control
resulted in a constant acidic stomach pH (1.88), which further supports the fact that
no pH neutralization occurs in the absence of Mg micromotors. Since 5 milligrams
of the Mg micromotor can neutralize the gastric acid to about neutral value in the
mouse stomach, this motor dosage was chosen for further studies.
Next, we studied the in vivo pH-responsive payload release by orally ad-
ministrating fluorescently labeled Mg micromotors. DiD (1,1’-dioctadecyl-3,3,3’,3’-
tetramethyl-indodicarbocyanine perchlorate, Life Technologies) was chosen as a model
drug, and was loaded onto the pH-sensitive polymer coating. After 20 minutes of
administration, the entire stomach was excised and cut opened along the greater
curvature for fluorescence imaging. As shown in Figure 2.9C, the stomach from
mice treated with 5 milligrams of the Mg micromotor displays strong and evenly
distributed fluorescence intensity over the entire stomach, thus reflecting the pH
change resulting from the proton depletion by the active Mg micromotors. Apparently,
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micromotors and 3 mL gastric fluid. The pH of the fluid
increases rapidly from 1.3 to 6.2 within 12 minutes, and then
more slowly, stabilizing around pH 7.5 after 18 minutes. These
data confirm that a fast neutralization of gastric acid can be
realized within less than 20 minutes, compared to the 0.5–
1 hour typically required by using PPIs to reach the same level
of neutralization.[1] The fluorescent pH indicator BCECF was
also used to verify the fast pH neutralization of the gastric
fluid by the micromotors. As displayed in Figure 2b, in the
absence of Mg micromotors, the gastric fluid containing the
BCECF indicator displays a light yellow color and very weak
fluorescence intensity, and is indicative of acidic conditions. In
contrast, an obvious color change to red is observed
20 minutes after adding the Mg micromotors to the gastric
fluid. The fluorescence intensity drastically increases to
a similar level to that observed in a PBS buffer (pH 7.4),
which was used as a control solution. These results demon-
strate that the Mg micromotors can rapidly neutralize the
gastric fluid through fast proton depletion and efficient
propulsion. The fast neutralization process reflects the
dramatic fluid convection induced by the collective motion
of micromotors in the gastric fluid and the corresponding
bubble generation. Such motor-induced “self-stirring” has
been shown to accelerate environmental decontamination
processes.[36]
To study the pH-responsive release, enabled by the active
neutralization of the gastric fluid, R6G dye was used as
a model payload encapsulated within the pH-sensitive
EUDRAGIT⇠ L100-55 polymeric coating of the Mg micro-
motors. Inert polystyrene (PS) microspheres (diameter:
10 mm) coated with the R6G dye-loaded polymer layer was
used as a control group. Figure 2c displays the payload release
profile, which obtained by measuring the supernatant fluo-
rescence intensity, using the micromotors and inert (control)
particles placed in the acidic gastric fluid (initial pH 1.3). The
pH change associated with the presence of the Mg micro-
motors results in sustained release of R6G from the pH-
sensitive polymeric coating. The fluorescence of the gastric
fluid solution thus increases gradually and reaches a plateau
at 20 minutes. In contrast, no such R6G release is observed
using the inert PS microparticles which do not react with the
protons to cause a pH change, and thus the pH-sensitive
polymer coating remains stable.
The fluorescence microscopy image of Figure 2d (cap-
tured from the Supporting Video 2) displays the real-time
propulsion and payload release of R6G from a Mg micro-
motor in the gastric fluid. The strong fluorescence signals
observed on the micromotor body and the yellow bubble tail
confirm the gradual dissolution of the polymer and conse-
quent release of R6G. Figure 2e shows the corresponding
fluorescence photographs of R6G in 1 mL bulk gastric
solution in the presence of Mg micromotors and an inert
control with microparticles (both coated with R6G-loaded,
pH-sensitive polymer). These images clearly show that the
dye is released to the solution using micromotors but resides
in the sediment at the bottom (containing the inert micro-
particles). This behavior indicates that the Mg micromotors,
which actively neutralize the gastric fluid, can trigger drug
release. This behavior represents a distinct advantage of the
autonomous micromotor-based delivery concept over con-
ventional stimuli-responsive drug release systems, as the
micromotors themselves actively create the desired environ-
ment (stimuli) essential to trigger the release.
The in vivo study of Mg micromotors was further con-
ducted by using a mouse model. In the study, the pH
neutralization process was investigated by administrating
different amounts of Mg micromotors (0, 2.5 mg, 5 mg and
10 mg) to four groups of mice (n= 3 for each group). Upon
oral administration for 20 minutes, the mice were euthanized
and their stomach pH values were measured immediately
using a microelectrode sensor coupled with a pH meter (as
illustrated in Figure 3a). A 20 minute time point was selected
based on the in vitro study which showed that the Mg
micromotors were able to effectively neutralize gastric acid
within this time window. As shown in Figure 3b, this experi-
ment resulted in a clear dose-dependent gastric pH change.
Herein, 5 milligrams of the Mg micromotor were able to
neutralize gastric acid in the mouse stomach, thus resulting in
pH 7.81⌃ 0.38. This motor concentration was higher than the
2.75 mg per 3 mL gastric acid as observed in the in vitro study.
Such an increase of the motor amount was likely due to the
continuous secretion of gastric acid from gastric glands in the
mouse stomach, as well as the dynamic peristalsis wave of the
stomach tissue which counteracts and dilutes the pH neutral-
ization efficacy of the micromotors. Lower and higher doses
of Mg micromotors resulted in slightly acidic and alkaline
stomach environments (pH 4.24 for 2.5 mg Mg micromotors
and pH 9.43 for 10 mg Mg micromotors, respectively). Using
Figure 3. In vivo acid neutralization and pH-triggered payload release.
a) Schematic illustration of in vivo gastric acid neutralization process
by Mg micromotors and pH measurement using a microelectrode-
enabled pH meter. b) In vivo gastric pH values using a mouse model
(n=3) measured 20 min post administration of different amounts of
Mg micromotors. DI water was used as a negative control. c) Super-
imposed fluorescent images, of the whole stomach of mice, collected
20 min post administration of DI water, Mg micromotors, and inert PS
microparticles (both Mg micromotors and PS microparticles are
loaded with DiD dye, which is encapsulated within the pH-sensitive
polymer coating as a model drug). Scale bars: 5 mm.
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Figure 2.9: In vivo acid neutralization and pH-triggered payload release. (A)
Schematic illustration of in vivo gastric acid neutralization process by Mg mi-
cromotors and pH measurement using a icroelectrode-enabled pH meter. (B)
In vivo gastric pH values us ng a mouse model (n = 3) measured 20 min post
administration of iﬀerent amounts of Mg microm tors. DI water was used as a
negative control. (C) Superimposed fluorescent images, of the whole stomach of
mice, collected 20 min post administration of DI water, Mg micromotors, and
inert PS microparticles (both Mg micromotors and PS microparticles are loaded
with DiD dye, which is encapsulated within the pH-sensitive polymer coating as
a model drug). Scale bars: 5 mm.
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the Mg micromotor delivery system can actively tune the stomach environment to
facilitate dissolution of pH-sensitive polymer and release of the payload. In contrast,
mice treated with an equal amount of inert PS microparticles displays only some small
local areas of the stomach with low fluorescence signal, similar to the fluorescence
signal observed using the DI water control, thus reflecting the self-fluorescence of
the administered food. As expected, the inert PS microparticles do not alter the
stomach pH, and hence cannot trigger dissolution of the pH-sensitive polymer and
consequent payload release. Overall, in agreement with the early in vitro results, the
data in Figure 2.9 demonstrate the ability of Mg micromotors to neutralize gastric
acid in the stomach of live animals and trigger the dissolution of the pH-responsive
polymer coating with subsequent payload release. The micromotor thus serves as a
motile carrier which enhances transport of its payload to diﬀerent locations. The
eﬃcient local propulsion, along with the corresponding bubble tail, have been shown
to generate an eﬀective convective fluid transport to substantially enhance the delivery
of cargo compared to passive-diﬀusion systems. [259,260] Furthermore, the propulsion
of Mg micromotors provides a driving force to penetrate the mucus layer and enhance
the payload retention in the stomach, and has been illustrated in early micromotor
studies within the stomach and GI tract. [254,255]
To ensure the recovery of gastric pH after Mg micromotor treatment, the pH
of the stomach content was measured at 20 minutes and 24 hours after administration
of the motors (Figure 2.10A). After the pH change induced by the Mg micromotor,
the mean gastric pH returned to 2.16 within 24 hours post-treatment and is close to
pH 1.88 of the control group which was treated with DI water. To further confirm
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the in vivo recovery of gastric pH, the pH indicator BCECF, with a pKa ⇡ 6.98,
was employed. The stomachs were dissected along the greater curvature and excess
gastric content was removed. BCECF fluorescence dye was evenly distributed and
mixed with the gastric content on the stomach tissues. Fluorescence imaging of
BCECF was performed on the diﬀerent treatment groups (Figure 2.10B). When the
environmental pH is greater than its pKa ⇡, BCECF exhibits strong fluorescence
emission, as shown by the stomach sample treated with micromotors for 20 minutes.
In contrast, 24 hours after administrating the Mg micromotors, the gastric content
labeled with BCECF indicator showed weak fluorescence intensity, thus reflecting
the low pH conditions. The results from Figure 2.10 A,B designate the transient
pH neutralization eﬀect of the Mg micromotors and show that the normal acidity of
gastric content can be recovered following the motor treatment.
Finally, the gastric toxicity of the administrated Mg micromotors was evaluated.
5 milligrams of either the Mg micromotor or DI water were orally administered to
mice and they were monitored for general toxicity symptoms every 2 hours for the first
10 hours post-administration. No observable signs of pain such as hunched posture,
unkempt fur, or lethargy were observed in either group. The Mg micromotor’s
toxicity was further investigated by histological analysis. Hematoxylin and eosin
(H&E) stained cross-sections of glandular stomach from the micromotor-treated
group showed intact glandular mucosa with no signs of superficial degeneration of
columnar epithelial cells or erosion (Figure 2.11A). There was no observable diﬀerence
in the either the crypt and villus size and number, or mucosal thickness between
the motor-treated and water-treated groups. Moreover, lymphocytic infiltration into
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deionized (DI) water as a control resulted in a constant acidic
stomach pH (1.88), which further supports the fact that no pH
neutralization occurs in the absence of Mg micromotors.
Since 5 milligrams of the Mg micromotor can neutralize the
gastric acid to about neutral value in the mouse stomach, this
motor dosage was chosen for further studies.
Next, we studied the in vivo pH-responsive payload
release by orally administrating fluorescently labeled Mg
micromotors. DiD (1,1’-dioctadecyl-3,3,3’,3’-tetramethyl-
indodicarbocyanine perchlorate, Life Technologies) was
chosen as a model drug, and was loaded onto the pH-
sensitive polymer coating. After 20 minutes of administration,
the entire stomach was excised and cut opened along the
greater curvature for fluorescence imaging. As shown in
Figure 3c, the stomach frommice treated with 5 milligrams of
the Mg micromotor displays strong and evenly distributed
fluorescence intensity over the entire stomach, thus reflecting
the pH change resulting from the proton depletion by the
active Mg micromotors. Apparently, the Mg micromotor
delivery system can actively tune the stomach environment to
facilitate dissolution of pH-sensitive polymer and release of
the payload. In contrast, mice treated with an equal amount of
inert PS microparticles displays only some small local areas of
the stomach with low fluorescence signal, similar to the
fluorescence signal observed using the DI water control, thus
reflecting the self-fluorescence of the administered food. As
expected, the inert PS microparticles do not alter the stomach
pH, and hence cannot trigger dissolution of the pH-sensitive
polymer and consequent payload release. Overall, in agree-
ment with the early in vitro results, the data in Figure 3
demonstrate the ability of Mg micromotors to neutralize
gastric acid in the stomach of live animals and trigger the
dissolution of the pH-responsive polymer coating with sub-
sequent payload release. The micromotor thus serves as
a motile carrier which enhances transport of its payload to
different locations. The efficient local propulsion, along with
the corresponding bubble tail, have been shown to generate
an effective convective fluid transport to substantially
enhance the delivery of cargo compared to passive-diffusion
systems.[36,37] Furthermore, the propulsion of Mg micromotors
provides a driving force to penetrate the mucus layer and
enhance the payload retention in the stomach, and has been
illustrated in early micromotor studies within the stomach and
GI tract.[31,32]
To ensure the recovery of gastric pH after Mg micromotor
treatment, the pH of the stomach content was measured at
20 minutes and 24 hours after administration of the motors
(Figure 4a). After the pH change induced by the Mg micro-
motor, the mean gastric pH returned to 2.16 within 24 hours
post-treatment and is close to pH 1.88 of the control group
which was treated with DI water. To further confirm the
in vivo recovery of gastric pH, the pH indicator BCECF, with
a pKa⇡ 6.98, was employed. The stomachs were dissected
along the greater curvature and excess gastric content was
removed. BCECF fluorescence dye was evenly distributed
and mixed with the gastric content on the stomach tissues.
Fluorescence imaging of BCECF was performed on the
different treatment groups (Figure 4b). When the environ-
mental pH is greater than its pKa, BCECF exhibits strong
fluorescence emission, as shown by the stomach sample
treated with micromotors for 20 minutes. In contrast, 24 hours
after administrating the Mg micromotors, the gastric content
labeled with BCECF indicator showed weak fluorescence
intensity, thus reflecting the low pH conditions. The results
from Figure 4a,b designate the transient pH neutralization
effect of the Mg micromotors and show that the normal
acidity of gastric content can be recovered following the
motor treatment.
Finally, the gastric toxicity of the administrated Mg
micromotors was evaluated. 5 milligrams of either the Mg
micromotor or DI water were orally administered to mice and
they were monitored for general toxicity symptoms every
2 hours for the first 10 hours post-administration. No observ-
able signs of pain such as hunched posture, unkempt fur, or
lethargy were observed in either group. The Mg micromotor s
toxicity was further investigated by histological analysis.
Hematoxylin and eosin (H&E) stained cross-sections of
glandular stomach from the micromotor-treated group
showed intact glandular mucosa with no signs of superficial
degeneration of columnar epithelial cells or erosion (Fig-
ure 5a). There was no observable difference in the either the
crypt and villus size and number, or mucosal thickness
between the motor-treated and water-treated groups. More-
over, lymphocytic infiltration into the mucosa and submucosa
was not apparent, thus implicating no sign of gastric
inflammation. The potential toxicity of the Mg micromotors
was further evaluated using gastric tissue sections in a terminal
deoxynucleotidyl transferase mediated deoxyuridine triphos-
phate nick-end labeling (TUNEL) assay to examine the level
of gastric epithelial apoptosis as an indicator of gastric
mucosal homeostasis. No apparent increase in gastric epithe-
lial apoptosis was observed for micromotor-treated groups
when compared to the water control group (Figure 5b).
Overall, the in vivo toxicity studies demonstrate no interfer-
ence in gastric pH homeostasis, and no apparent gastric
Figure 4. Recovery of the gastric pH post micromotor treatment. a) In
vivo gastric pH values using a mouse model (n=3) measured 20 min
and 24 h post administration of 5 mg of the Mg micromotor. Mice
treated with water were used as a control. b) Fluorescent images of
the pH indicator BCECF superimposed on the entire stomach for the
samples in (a).
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Figure 2.10: Recovery of the gastric pH post micromotor treatment. (A) In
vivo gastric pH values using a mouse model (n = 3) measured 20 min and 24
h post administration of 5 mg of the Mg micromotor. Mice treated with water
were used as a control. (B) Fluorescent images of the pH indicator BCECF
superimposed on the entire stomach f r the samples in (A).
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the mucosa and submucosa was not apparent, thus implicating no sign of gastric
inflammation. The potential toxicity of the Mg micromotors was further evaluated
using gastric tissue sections in a terminal deoxynucleotidyl transferase mediated
deoxyuridine triphosphate nick end labeling (TUNEL) assay to examine the level
of gastric epithelial apoptosis as an indicator of gastric mucosal homeostasis. No
apparent increase in gastric epithelial apoptosis was observed for micromotor-treated
groups when compared to the water control group (Figure 2.11B). Overall, the in
vivo toxicity studies demonstrate no interfer- ence in gastric pH homeostasis, and no
apparent gastric histopathologic change or inflammation, thus suggesting that the oral
administration of Mg micromotors is safe in a mouse model. The Mg micromotors
can thus temporarily adjust the stomach pH without adverse eﬀects, thus making
them an attractive vehicle for gastric drug delivery.
2.2.4 Conclusions
We have demonstrated that acid-powered micromotors can operate as an active
microdevice to eﬃciently and temporarily adjust local physiological parameters in
vivo for diverse biomedical applications. In particular, the reaction of the motor’s
magnesium core with the gastric fluid leads to rapid proton depletion and thus acid
neutralization without aﬀecting the normal stomach function or causing adverse
eﬀects, thus making these synthetic micromotors an attractive alternative to proton
pump inhibitors. The fast and eﬃcient neutralization reflects the localized fluid
convection generated by the micromotor movement. When coupled to a pH-sensitive
payload-containing polymer coating, this pH change can lead to autonomous release
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histopathologic change or inflammation, thus suggesting that
the oral administration of Mg micromotors is safe in a mouse
model. The Mg micromotors can thus temporarily adjust the
stomach pH without adverse effects, thus making them an
attractive vehicle for gastric drug delivery.
We have demonstrated that acid-powered micromotors
can operate as an active microdevice to efficiently and
temporarily adjust local physiological parameters in vivo for
diverse biomedical applications. In particular, the reaction of
the motor s magnesium core with the gastric fluid leads to
rapid proton depletion and thus acid neutralization without
affecting the normal stomach function or causing adverse
effects, thus making these synthetic micromotors an attractive
alternative to proton pump inhibitors. The fast and efficient
neutralization reflects the localized fluid convection gener-
ated by the micromotor movement. When coupled to a pH-
sensitive payload-containing polymer coating, this pH change
can lead to autonomous release of the encapsulated cargo.
The new microvehicle thus combines self-propulsion and acid
neutralization along with cargo transport and release. Its Mg
engine converts the acid fuel into a propulsion force and
simultaneously alters the local pH to lead to payload release
from the pH-sensitive coating. Such a micromotor-based
delivery vehicle can thus actively adjust the local environment
to achieve desired conditions for triggered payload release.
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Figure 5. Toxicity evaluation of Mg micromotors. 5 mg of the Mg
micromotor and DI water were orally administered to mice. After 24 h,
mice were sacrificed and sections of the mouse stomach were
processed and stained with a) H&E assay and b) TUNEL assay. Scale
bars, 100 mm.
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Figure 2.11: Toxicity evaluation of icromotors. 5 mg of the Mg micromotor
and DI water were orally dministered to mice. Af 24 h, were sacrificed
and sections of the mouse stomach were processed and stained with (A) H&E
assay and (B) TUNEL assay. Scale bars, 100 µm.
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of the encapsulated cargo. The new microvehicle thus combines self-propulsion and
acid neutralization along with cargo transport and release. Its Mg engine converts
the acid fuel into a propulsion force and simultaneously alters the local pH to lead
to payload release from the pH-sensitive coating. Such a micromotor-based delivery
vehicle can thus actively adjust the local environment to achieve desired conditions
for triggered payload release.
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2.3 Micromotor-enabled active drug delivery for in
vivo treatment of stomach infection
2.3.1 Introduction
Recent advances in the nano and micromotor field [261–264] in terms of
improvement of biocompatibility and biological function have led to their growing
use in biomedicine [265–267], including therapeutic payload delivery [268–273], micro-
surgery [274,275], isolation of biological targets [276], operation within living cells
[277, 278], and removal of toxicant molecules and organisms [279–281]. Although
significant progress has been accomplished to demonstrate the in vitro capabilities of
nano/micromotors to transport therapeutic cargos to target destinations, tremendous
eﬀort is still required to translate the proof-of-concept research to in vivo biomedical
applications.
In recent years, the utility and performance of these motor-based active
transport systems have been tested in live animals. For example, our group has
demonstrated the attractive in vivo performance of zinc-based and magnesium (Mg)-
based micromotors under in vivo conditions [282–284]. These studies have shown that
artificial micromotors can self-propel in the stomach, and intestinal fluids for enhanced
retention in the gastric mucous layer [282] and targeted delivery in the gastrointestinal
(GI) tract [283]. Walker et al. [285] presented the ability of magnetic micropropellers
to move through gastric mucin gels, by mimicking the mucus penetration strategy of
Helicobacter pylori (H. pylori). In addition, Nelson’s group has demonstrated that
magnetically actuated microswimmers can swarm in vivo [271], whereas Martel’s
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group has shown that microorganisms can be transformed into natural robots under
magnetic guidance towards therapeutic cargo delivery into deep tumor regions [272].
These prior in vivo studies of synthetic motors have significantly advanced motor
research and cleared a path towards direct evaluation of disease-oriented therapeutic
eﬃcacy associated with motor-enabled active drug delivery. However, this still remains
an alluring but unmet goal for biomedical researchers.
This work demonstrates, to the best of our knowledge, the first attempt to
apply Mg-based micromotors, loaded with antibiotic drug clarithromycin (CLR), for
in vivo treatment of H. pylori infection in a mouse model. Given the built-in proton
depletion function, this motor-based therapy is able to undergo the harsh gastric
environment to achieve antibacterial eﬃcacy without involving the commonly used
proton pump inhibitors (PPIs). The H. pylori bacteria, found in about half of the
world’s population, can cause stomach infection and subsequently lead to diverse
gastric and extragastric diseases [286, 287]. In most cases, the administration of
antibiotics for the treatment of H. pylori infection is combined with the use of PPIs
to reduce the production of gastric acid [288], because the gastric acid could make
antibiotics less eﬀective. The eﬀectiveness of PPIs is attributed to the irreversible
binding to proton pumps and thus to suppress acid secretion [289, 290], which in
long term use can lead to adverse eﬀects such as headache and diarrhea and in
more serious scenarios cause anxiety or depression [291–294]. Therefore, it would be
highly beneficial to develop an alternative therapeutic regimen with equivalent or
advantageous therapeutic eﬃcacy as the current antibiotic treatments while excluding
the use of PPIs.
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The reported Mg-based micromotors rely on the combination of a CLR-loaded
poly(lactic-co-glycolic acid) (PLGA) layer and a chitosan polymer layer covering on a
propellant Mg core to oﬀer high drug-loading capacity, along with biodegradability.
The positively charged chitosan outer coating enables adhesion of the motor onto
the stomach wall [295], facilitating eﬃcient localized autonomous release of CLR
from the PLGA polymer coating. In contrast to acid suppression by PPIs, Mg-
based micromotors can temporally and physically alter the local acidic environment
by quickly depleting protons while propelling within the stomach [284]. By using
acid as fuel, these synthetic motors rapidly deplete protons while propelling within
the stomach, which can eﬀectively elevate the gastric pH to neutral in < 20 min
after the motors are applied [284]. Testing in a mouse model has demonstrated
that these motors can safely and rapidly neutralize gastric acid without causing
noticeable acute toxicity or aﬀecting the stomach function, and that the normal
stomach pH can be restored within 24h post motor administration. Such elimination
of the PPI administration is coupled with significant reduction of bacteria burden, as
demonstrated in vivo in a mouse model. Using a mouse model of H. pylori infection,
the propulsion of the drug-loaded Mg-based micromotors in gastric fluid along with
their outer chitosan layer are shown to greatly enhance the binding and retention
of the drug-loaded motors on the stomach wall. As these micromotors are propelled
in the gastric fluid, their Mg cores are dissolved, leading to self-destruction of these
motors without harmful residues, as is demonstrated by the toxicity studies.
Overall, we take advantage of the eﬃcient propulsion of Mg-based micromo-
tors in the acidic stomach environment, their built-in proton depletion ability, their
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active and prolonged retention within the stomach wall, and their high drug-loading
capacity, to demonstrate to the best of our knowledge the first actual in vivo thera-
peutic application of chemically powered micromotors. in vivo studies examine the
therapeutic eﬃcacy, distribution, and retention of the micromotors in the mouse
stomach compared with passive drug-loaded microparticles and other control groups,
along with the corresponding in vivo toxicity profile. These results illustrate the
attractive therapeutic capabilities of acid-driven micromotors, which open the door
for in vivo therapeutic applications of body-fluid propelled micromotors towards the
treatment of a variety of diseases and disorders.
2.3.2 Experimental Methods
Synthesis of Mg-based micromotors.
The Mg-based micromotors were prepared using magnesium (Mg) microparti-
cles (catalog # FMW20, TangShan WeiHao Magnesium Powder Co.; average size,
20 ± 5 µm) as the core. The Mg microparticles were initially washed with acetone
to eliminate the presence of impurities. After being dried under a N2 current, the
Mg microparticles were dispersed onto glass slides (2 mg of Mg microparticles per
glass slide), followed by ALD of TiO2 (at 100  C for 120 cycles) using a Beneq TFS
200 system. As such an ALD process utilizes gas phase reactants, it leads to uniform
coatings over the Mg microparticles, whereas still leaving a small opening at the
contact point of the particle to the glass slide. After that, the Janus micromotors
were coated with 120 µL of 1% (w/v) PLGA (Sigma-Aldrich, P2191) prepared in
ethyl acetate (Sigma-Aldrich, 270989) and containing 40 mg mL  1 CLR (TCI CO.,
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Ltd. C220). It should be noted that diﬀerent CLR amounts (between 4 mg and 6
mg) were tested to optimize the drug-loading. The PLGA@CLR coating was dried
fast to avoid crystallization of the drug. Finally, the Janus micromotors were coated
with a thin layer of 0.05% (w/v) Chit (Sigma-Aldrich, C3646) prepared in water
and containing 0.1% (w/v) sodium dodecyl sulfate (SDS) (Sigma-Aldrich, 62862)
and 0.02% (v/v) acetic acid (Sigma-Aldrich, 695092), forming the outermost layer
coated on the Mg microparticles. Finally, the Mg-based micromotors were collected
by lightly scratching the microparticles oﬀ the glass slide.
Synthesis of dye-loaded Mg-based micromotors.
For performing the characterization of the Mg-based micromotors along with
the in vivo retention studies, fluorescent Mg-based micromotors were prepared by
combining both 1% PLGA and 0.05% Chit solutions with 5 µg mL  1 1,1’-dioctadecyl-
3,3,3’,3’-tetra- methylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD,  ex
= 644 nm/   em = 665 nm, Life Technologies, D7757) and 1 µg mL  1 fluorescein
isothiocyanate- dextran (FITC,  ex = 492 nm/  em = 520 nm, Sigma-Aldrich, 46945)
dyes, respectively. To compare with the Mg-based micromotors, inert silica (Si)
microparticles (Nanocs, Inc., Cat. No. Si01-20u-1; 20 µm size) were used as core
particles, following the same protocol described above.
Micromotor characterization.
Bright-field and fluorescent images of the Mg-based micromotors and inert
silica microparticles were captured using a EVOS FL microscope coupled with a
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20⇥ and 40⇥ microscope objectives and fluorescence filters for red and green light
excitation. Scanning electron microscopy (SEM) images of the Mg-based micromotors
were obtained with a Phillips XL30 ESEM instrument, using an acceleration voltage
of 10 kV. EDX mapping analysis was performed using an Oxford EDX detector
attached to SEM instrument and operated by INCA software.
Micromotor propulsion studies.
Autonomous Mg-based micromotors propulsion in simulated gastric fluid
(Sigma-Aldrich, 01651) was obtained by diluting 25 times the simulated gastric fluid
according to the commercial specifications (final pH 1.3), and adding 1% Triton
X-100 (Fisher Scientific, FairLawn, NJ, USA) as surfactant. An inverted optical
microscope (Nikon Eclipse 80i upright microscope) coupled with diﬀerent microscope
objectives (10⇥ , 20⇥ , and 40⇥ ) and a QuantEM:512SC camera were used for
recording the autonomous micromotor propulsion in the gastric fluid simulant. The
speed of the Mg-based micromotors was characterized using the MetaMorph 7.1
software (Molecular Devices, Sunnyvale, CA, USA).
In vitro anti-H. pylori activity.
H. pylori Sydney strain 1 (HPSS1) was cultured from frozen stock and routinely
maintained on Columbia agar supplemented with 5% (vol/vol) laked horse blood
at 37  C under microaerobic conditions (10% CO2, 85% N2, and 5% O2). For
experiments, broth cultures of H. pylori were prepared by subculturing fresh colonies
from agar plates into brain-heart infusion (BHI) supplemented with 5% fetal bovine
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serum (FBS) and incubated overnight at 37  C under microaerobic conditions with
moderate reciprocal shaking. An overnight broth culture of H. pylori was centrifuged
at 5000⇥ g for 10 min to obtain a bacterial pellet. After removal of culture medium
by centrifugation, the obtained bacteria pellet was then suspended in an appropriate
amount of fresh BHI with 5% FBS for future use. The bactericidal activity against H.
pylori of free CLR and CLR-loaded Mg-based micromotors (PLGA@CLR-TiO2-Mg)
were tested in vitro. All samples were treated in 0.1 N HCl for 1 h and serially
diluted to desired concentrations with PBS (pH 7). Bare Mg-based micromotors
(PLGA-TiO2-Mg) with corresponding amount of micromotors were used as negative
control. The samples were added with 1 ⇥ 106 CFU mL 1 H. pylori in BHI with
5% FBS to make final concentrations of 0-16 µg mL 1 CLR, followed by incubation
at 37  C under microaerobic conditions with moderate reciprocal shaking for 24 h.
Then, a series of 10-fold dilutions of the bacterial suspension was prepared, and
inoculated onto a Columbia agar plates supplemented with 5% laked horse blood.
The plates were cultured for 4 days before the colony-forming unit (CFU) of H. pylori
was quantified. All measurements were made in triplicate.
in vivo micromotor retention.
Prior to the experiment, C57BL/6 mice (n = 3) were fed with alfalfa-free
food from LabDiet (St Louis, MO, USA) for 2 weeks. The in vivo retention study
was performed by using dye-loaded Mg-based micromotors prepared by the protocol
described above. A 0.3 mL suspension of Mg-based micromotors with DiD-labeled
PLGA and FITC-labeled chitosan coatings were intragastrically administered. A
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group of mice was administered with DI water as a negative control. Following 30 min
and 2 h of oral administrations, the mice were killed and their entire stomachs were
excised and cut opened along the greater curvature. Then, the tissues were rinsed
with PBS, flattened, and visualized using a Keyence BZ-X700 fluorescence microscope.
The bright-field and corresponding fluorescence images were obtained at 665 and 520
nm (DiD and FITC, respectively) for each sample. Subsequently, the tissues were
transferred to 1 mL PBS and homogenized. Analysis of the amount of micromotors
retained in the stomachs was carried out by measuring the fluorescence intensity of
their embedded DiD-labeled PLGA and FITC-labeled chitosan using Synergy Mx
fluorescent spectrophotometer (Biotek, Winooski, VT, USA). All animal experiments
were in compliance with the University of California San Diego Institutional Animal
Care and Use Committee (IACUC) regulations.
in vivo therapeutic eﬃcacy against H. pylori infection.
Six-week-old C57BL/6 male mice were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA). Each C57BL/6 mouse received 0.3 mL of 1 ⇥ 106 CFU mL
 1 H. pylori in BHI broth administered intragastrically through oral gavage every
48 h, repeated three times (on day 3, 5, and 7, respectively), and the infection was
allowed to develop for 2 weeks [296]. For the in vivo anti-H. pylori therapeutic study,
mice were randomly divided in five treatment groups (n = 6) to be orally administered
once daily for five consecutive days with CLR-loaded Mg-based micromotors, CLR-
loaded inert silica microparticles, free CLR+PPI, blank Mg-based micromotors or DI
water. For free CLR+PPI group, each day of treatment mice were first administered
78
with omeprazole (a PPI) through oral gavage at a dose of 400 µmol kg 1 [296–299],
followed by a lag time of 30 min before administration of CLR. CLR-loaded Mg-
based micromotors, CLR-loaded inert silica microparticles and free CLR (with 30
mg kg  1 CLR dosage) were also administered through oral gavage once daily for
five consecutive days [296]. Blank Mg-based micromotors and DI water served as
movement control and negative control, respectively. Forty-eight hours after last
administration39, [300–302], mice were killed and stomachs were excised from the
abdominal cavity. The stomachs were cut along the greater curvature, and the gastric
content were removed and rinsed with PBS. For H. pylori recovery, each gastric tissue
was weighed before suspended in 200 µL PBS and homogenized. The homogenate was
serially diluted and spotted onto Columbia agar plate with 5% laked horse blood and
Skirrow’s supplement (10 µg mL  1 vancomycin,5 µg mL  1 trimethoprim lactate,
and 2500 IU/L polymyxin B; Oxiod). The plates were then incubated at 37  C
under microaerobic conditions for 5 days, and bacterial colonies were enumerated.
Statistical analysis was performed using one-way ANOVA. No statistical methods
were used to predetermine sample size. Studies were done in a non-blinded fashion.
Replicates represent diﬀerent mice subjected to the same treatment (n = 6). All
animal experiments were in compliance with the University of California San Diego
Institutional Animal Care and Use Committee (IACUC) regulations.
Toxicity evaluation of Mg-based micromotors.
To evaluate the acute toxicity of the Mg-based micromotors in vivo, uninfected
C57BL/6 male mice (n = 6) weighing 25-30 g were orally administered with CLR-
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loaded micromotors once daily for five consecutive days. Mice administered with DI
water were tested in parallel as a negative control. During the experimental period,
the mouse body weight was monitored by weighing the mice daily. On day 6, mice
were killed and sections of the mouse stomach, small and large intestine tissues were
processed for histological examination. The stomach was cut open along the greater
curvature, and the gastric content was removed. The small and large intestines were
cut to small sections as duodenum, jejunum, ileum, proximal, and distal colon and
rinsed inside with PBS to remove internal residues. The longitudinal tissue sections
were fixed in neutral-buﬀered 10% (vol/vol) formalin for 15 h, transferred into 70%
ethanol, and embedded in paraﬃn. The tissue sections were cut with 5 µm thickness
and stained with H&E assay. The stained sections were visualized by Hamamatsu
NanoZoomer 2.0HT and the images processed using NDP viewing software. All
animal experiments were in compliance with the University of California San Diego
Institutional Animal Care and Use Committee (IACUC) regulations.
2.3.3 Results and Discussion
Drug-loaded Mg-micromotors preparation and characterization.
Figure 2.12A schematically illustrate the preparation steps of the drug-loaded
Mg-based micromotors. The cores of the micromotors are made of Mg microparticles
with an average size of 20 µm. In the study, a layer of Mg microparticles was dispersed
onto a glass slide, followed by an asymmetrical coating of the microspheres with a thin
TiO2 layer using atomic layer deposition (ALD). The ALD process leads to a TiO2
uniform coating over the Mg-microspheres, while leaving a small opening (essential for
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Recent advances in the nano and micromotor ﬁeld
1–4 in
terms of improvement of biocompatibility and biological
function have led to their growing use in biomedicine5–7,
including therapeutic payload delivery8–13, micro-surgery14, 15,
isolation of biological targets16, operation within living cells17, 18,
and removal of toxicant molecules and organisms19–21. Although
signiﬁcant progress has been accomplished to demonstrate
the in vitro capabilities of nano/micromotors to transport
therapeutic cargos to target destinations, tremendous effort is still
required to translate the proof-of-concept research to in vivo
biomedical applications.
In recent years, the utility and performance of these
motor-based active transport systems have been tested in live
animals. For example, our group has demonstrated the attractive
in vivo performance of zinc-based and magnesium (Mg)-based
micromotors under in vivo conditions22–24. These studies have
shown that artiﬁcial micromotors can self-propel in the stomach,
and intestinal ﬂuids for enhanced retention in the gastric mucous
layer22 and targeted delivery in the gastrointestinal (GI) tract23.
Walker et al.25 presented the ability of magnetic micropropellers
to move through gastric mucin gels, by mimicking the mucus
penetration strategy of Helicobacter pylori (H. pylori). In addition,
Nelson’s group has demonstrated that magnetically actuated
microswimmers can swarm in vivo11, whereas Martel’s group
has shown that microorganisms can be transformed into
natural robots under magnetic guidance towards therapeutic
cargo delivery into deep tumor regions12. These prior in vivo
studies of synthetic motors have signiﬁcantly advanced
motor research and cleared a path towards direct evaluation
of disease-oriented therapeutic efﬁcacy associated with
motor-enabled active drug delivery. However, this still remains an
alluring but unmet goal for biomedical researchers.
This work demonstrates, to the best of our knowledge, the
ﬁrst attempt to apply Mg-based micromotors, loaded with
antibiotic drug clarithromycin (CLR), for in vivo treatment of
H. pylori infection in a mouse model. Given the built-in proton
depletion function, this motor-based therapy is able to undergo
the harsh gastric environment to achieve antibacterial efﬁcacy
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Figure 2.12: Synthesis and characterization of drug-loa d Mg-based micro-
motors. (A) Schematic preparation of the micromotors: Mg microparticles
dispersion over a glass slide, TiO2 atomic layer deposition (ALD) over the Mg
microparticles, drug-loaded PLGA deposition over the Mg-TiO2 microparticles,
and Chitosan polymer deposition over the Mg-TiO2-PLGA microparticles. (B)
Schematic of in vivo propulsion and drug delivery of the Mg-based micromotors
in a mouse stomach. (C) Time-lapse images of the propulsion of the drug-loaded
Mg-based micromotors in simulated gastric fluid (pH 1.3). (D) Schematic dissec-
tion of a drug-loaded micromotor consisting of a Mg core, a TiO2 shell coating, a
drug-loaded PLGA layer, and a chitosan layer. (E) Scanning electron microscopy
(SEM) image of a drug-loaded Mg-based micromotor. (F), (G) Energy-dispersive
X-ray spectroscopy (EDX) images illustrating the distribution of (F) magnesium
and (G) titanium in the micromotor. (H)-(K) Microscopy images of dye-loaded
Mg-based micromotor: (H) optical image and fluorescence images showing the
dye-loaded Mg-based micromotors in the (I) DiD channel (PLGA layer),(J) FITC
channel (chitosan layer), along with an overlay of the two channels (K)
81
contact with the acid fuel) at the sphere-glass contact point [303], which forms a Janus
microstructure. Such TiO2 layer acts as a shell scaﬀold that maintains the micromotor
spherical shape and the opening size during the propulsion, leading to consistent and
prolonged operation. The Mg- TiO2 Janus microparticles were then coated with a
PLGA film containing the CLR antibiotic payload. After the drug-loading step, the
microparticles were coated with an outer thin chitosan layer (thickness 100nm) that
ensures eﬃcient electrostatic adhesion of the micromotors to the mucosal layer on the
stomach wall while protecting the CLR-loaded PLGA layer. Finally, the resulting
CLR-loaded Mg-based micromotors were separated and collected by soft mechanical
scratching of the glass slide, leaving a small opening for spontaneous Mg-acid reaction
when the motors are placed in an acidic solution. This reaction generates hydrogen
microbubbles and leads to eﬃcient propulsion in the stomach fluid [284]. The small
opening enables also a slow reaction process and gradual dissolution of the Mg core,
leading to a prolonged micromotor lifetime of 6 min. The in vivo self-propulsion in the
gastric fluid of a stomach and the corresponding drug delivery process from the PLGA
layer of the Mg-based micromotors are illustrated schematically in Figure 2.12B.
The ability of drug-loaded Mg-based micromotors to eﬃciently propel in gastric
acid was first tested in vitro by using a simulated gastric fluid (pH 1.3). The
microscopic images in Figure 2.12C illustrate the fast and prolonged autonomous
propulsion of a CLR-loaded Mg-based micromotor in the gastric fluid simulant.
The eﬃcient hydrogen bubble generation propels the micromotors rapidly, with an
average speed of 120 µm s  1 (corresponding to a relative speed of 6 body lengths
 1), and indicates that the Mg-based micromotors can react and move fast in the
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gastric fluid. Such eﬃcient micromotor propulsion is essential for the motors to
reach stomach wall and thus achieving significant therapeutic eﬃcacy. Importantly,
the acid-Mg reaction responsible for the autonomous propulsion also spontaneously
depletes protons in gastric fluid and thus neutralizes the stomach pH without using
PPIs [284]. Figure 2.12D schematically illustrates the structure of a drug-loaded
Mg-based micromotor, showing the Mg core, covered mostly with the TiO2 shell layer,
drug-loaded PLGA layer, and an outer chitosan layer. The drug-loaded Mg-based
micromotors were carefully characterized. The scanning electron microscopy (SEM)
image of a drug-loaded micromotor (shown in Figure 2.12E) confirms the presence of
a small opening ( 2 µm) on the spherical micromotor, produced during the coating
process, that exposes the Mg core of the micromotor to the gastric fluid and facilitates
the hydrogen bubble thrust. Energy-dispersive X-ray (EDX) spectroscopy mapping
analysis was carried out to confirm the motor composition. The resulting EDX images,
shown in Figure 2.12F and 2.12G, illustrate the presence and distribution of magnesium
and titanium, respectively. A fluorescence study was carried out to confirm eﬃcient
drug-loading within the PLGA layer, and the coating of the micromotor with the
protective and adhesive chitosan layer. This was accomplished by preparing Mg-based
micromotors with the PLGA and chitosan coatings containing the fluorescent dyes
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate
salt (DiD,  ex = 665 nm), and fluorescein isothiocyanate-dextran (FITC,  ex =
520 nm), respectively. An optical image of a dye-loaded micromotor is displayed in
Figure 2.12H. The corresponding fluorescence images show the dye-loaded Mg-based
micromotor in the DiD and FITC channels (Figure 2.12I and 2.12J, respectively);
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an overlay of the two channels is displayed in Figure 2.12K. The high-fluorescent
intensity of the loaded dyes confirms the successful coating of the micromotor with
both PLGA and chitosan layers, along with the high cargo-loading capacity of the
micromotor.
Drug-loading optimization and in vitro bactericidal activity.
The CLR-loading onto the Mg-based micromotors was optimized to achieve
a clinically relevant therapeutic concentration of the drug (15-30 mg kg  1 day
 1)37. Figure 2.13A shows a schematic displaying the loading of CLR onto the
micromotors. Briefly, the Mg- TiO2 microparticles dispersed onto a glass slide ( 2
mg of Mg microparticles per glass slide) were coated with a PLGA solution prepared
in ethyl acetate, which was mixed with CLR (see detailed experimental protocol in
“Experimental Methods” section). Rapid evaporation under nitrogen current leads to
the formation of a homogeneous PLGA-CLR coating over the Mg-TiO2 microparticles
(microscope images of the coated micromotors are displayed in Figure 2.13B). The
microparticles were further coated with chitosan before quantifying the CLR-loading
eﬃciency of the micromotors. To optimize the drug-loading, Mg-based micromotors
were coated with PLGA solutions containing diﬀerent amounts of CLR (between 4
and 6 mg). By studying diﬀerent combinations of the PLGA-CLR solution volume
and CLR concentration, the highest CLR-loading eﬃciency (26%), corresponding to
1032 ± 37 µg per 2 mg micromotor, was obtained when coating the microparticles
with 120µL of the PLGA solution containing 4.8 mg of CLR (Figure 2.13C, II). This
formulation oﬀered optimal CLR-loading and was selected for subsequent in vitro
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and in vivo anti-H. pylori studies.
Once confirmed that the micromotors were capable to load antibiotic cargo
with high-loading eﬃciency, an in vitro bactericidal activity of CLR-loaded Mg-based
micromotors against H. pylori was performed. To mimic the gastric environment,
samples were treated in 0.1 N HCl for 1 h prior to incubation with bacteria. This also
ensured the dissolution of micromotors and consecutive drug release. Figure 2.13D
shows the enumerated amount of bacteria after being treated by CLR-loaded Mg-based
micromotors or free CLR solution with varying concentrations of CLR. According to
the results, drug-loaded micromotors exhibited a comparable bactericidal activity to
free drug solution over the whole range of concentrations used in the study. Specifically,
we determined the minimal bactericidal concentration (MBC) values of the samples,
defined as the minimal concentration of an antimicrobial agent that kills 3 logs (99.9%)
of the bacteria. The MBC value for CLR-loaded Mg-based micromotors was found to
be 0.25 µg mL  1, which was unaltered from the MBC value of free CLR. Moreover,
bare Mg-based micromotors, with corresponding amount of motors and treated under
the same conditions as the free CLR and CLR-loaded Mg-micromotors, were used as
negative controls. From Figure 2.13D, the bare motors had negligible eﬀect on the
viability of H. pylori over the studied range, which supports that the bactericidal
eﬀect of CLR-loaded Mg-based micromotors is solely due to the loaded antibiotics,
and not due the other compositions of the micromotor carrier or the micromotor
acidic environment. Overall, Figure 2.13D verifies that the activity of the loaded drug
was not compromised compared to free drug. Our in vitro results verified also that
drug-loaded micromotors, made of Mg and other degradable materials, eventually
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respectively. An optical image of a dye-loaded micromotor is
displayed in Fig. 1h. The corresponding ﬂuorescence images show
the dye-loaded Mg-based micromotor in the DiD and FITC
channels (Fig. 1i and j, respectively); an overlay of the two
channels is displayed in Fig. 1k. The high-ﬂuorescent intensity
of the loaded dyes conﬁrms the successful coating of the
micromotor with both PLGA and chitosan layers, along with
the high cargo-loading capacity of the micromotor.
Prior to in vivo therapeutic application of the Mg-based
micromotors, several in vitro studies were performed. Initially,
the ability of drug-loaded micromotors to efﬁciently propel in
gastric acid was tested in vitro. Supplementary Fig. 1a–d displays
time-lapse images (corresponding to Supplementary Movie 4)
showing the motion of the drug-loaded Mg-based micromotors in
simulated gastric ﬂuid adjusted to different pH values (0.75, 1.25,
1.5, and 1.75, respectively). Time-lapse images in Supplementary
Fig. 1e–h show the lifetime of a drug-loaded micromotor in
gastric ﬂuid simulant (pH ~1.3) to be ~6min. Supplementary
Fig. 1i displays the pH-dependent speed of the micromotor in the
gastric ﬂuid simulant. The micromotor speed drastically decreases
upon changing the pH of the gastric ﬂuid solution from pH
1.5–1.75. Assuming that the stomach pH is 1.3, the drug-loaded
Mg-based micromotors can efﬁciently move at this condition
with an average speed of ~120 μm s−1 (~6 body length s−1).
Drug-loading optimization and in vitro bactericidal activity.
The CLR-loading onto the Mg-based micromotors was optimized
to achieve a clinically relevant therapeutic concentration of
the drug (15–30 mg kg−1 day−1)37. Figure 2a shows a schematic
displaying the loading of CLR onto the micromotors. Brieﬂy,
the Mg-TiO2 microparticles dispersed onto a glass slide (~2 mg of
Mg microparticles per glass slide) were coated with a PLGA
solution prepared in ethyl acetate, which was mixed with CLR
(see detailed experimental protocol in “Methods” section). Rapid
evaporation under nitrogen current leads to the formation of
a homogeneous PLGA-CLR coating over the Mg-TiO2
microparticles (microscope images of the coated micromotors are
displayed in Fig. 2b). The microparticles were further coated
with chitosan before quantifying the CLR-loading efﬁciency of
the micromotors. To optimize the drug-loading, Mg-based
micromotors were coated with PLGA solutions containing
different amounts of CLR (between 4 and 6 mg). By studying
different combinations of the PLGA-CLR solution volume and
CLR concentration, the highest CLR-loading efﬁciency (26%),
corresponding to 1032 ± 37 µg per 2 mg micromotor, was
obtained when coating the microparticles with 120 µL of
the PLGA solution containing 4.8 mg of CLR (Fig. 2c, II). This
formulation offered optimal CLR-loading and was selected
for subsequent in vitro and in vivo anti-H. pylori studies.
Once conﬁrmed that the micromotors were capable to
load antibiotic cargo with high-loading efﬁciency, an in vitro
bactericidal activity of CLR-loaded Mg-based micromotors
against H. pylori was performed. To mimic the gastric environ-
ment, samples were treated in 0.1 N HCl for 1 h prior to
incubation with bacteria. This also ensured the dissolution of
micromotors and consecutive drug release. Figure 2d shows the
enumerated amount of bacteria after being treated by CLR-loaded
Mg-based micromotors or free CLR solution with varying
concentrations of CLR. According to the results, drug-loaded
micromotors exhibited a comparable bactericidal activity to free
drug solution over the whole range of concentrations used in the
study. Speciﬁcally, we determined the minimal bactericidal
concentration (MBC) values of the samples, deﬁned as the
minimal concentration of an antimicrobial agent that kills 3
logs (99.9%) of the bacteria. The MBC value for CLR-loaded
Mg-based micromotors was found to be 0.25 μg mL−1, which was
unaltered from the MBC value of free CLR. Moreover, bare
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Fig. 2 Antibiotic drug loading of the Mg-based micromotors and in vitro bactericidal activity. a Schematic displaying the loading clarithromycin (CLR) onto
the Mg-based micromotors. PLGA polymer dissolved in ethyl acetate is mixed with CLR, and the solution is deposited over the Mg-TiO2 microparticles
resulting in the formation of a thin PLGA-CLR coating. b Microscope images showing the PLGA-CLR ﬁlm over the Mg-based micromotors. Scale bars 100
µm and 40 µm, respectively. c Quantiﬁcation of CLR-loading amount and yield of the micromotors prepared with different CLR solutions: (I) 100 µL of 40
mgmL−1 CLR solution, (II) 120 µL of 40mgmL−1 CLR solution, and (III) 200 µL of 30mgmL−1 CLR solution. All the CLR-loaded Mg-based micromotors
were coated with a thin chitosan layer; all samples were dissolved in acid for 24 h before the drug-loading measurement. d In vitro bactericidal activity of
free CLR, CLR-loaded Mg-based micromotors, and blank Mg-based micromotors (without CLR drug) against H. pylori bacteria. Error bars estimated as a
triple of s.d. (n = 3)
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Figure 2.13: Antibiotic drug loading of the Mg-b sed micromotors and in vitro
bactericidal activity. (A) Schematic displaying t e loading clarithromycin (CLR)
onto the Mg-based micromotors. PLGA polymer dissolved in ethyl acetate is
mixed with CLR, and the solution is deposited over the Mg-TiO2 microparticles
resulting in the f mation of a thin PLGA-CLR coating. (B) Microscope im ges
showing the PLGA-CLR film over the Mg-based micromotors. Scale bars 100
µm and 40 µm, respectively. (C) Quantification of CLR-loading amount and
yield of th micromot r prepared with diﬀerent CLR solutions: (I) 100 µL of 40
mg mL 1 CLR solution, (II) 120 µL of 40 mg mL 1 CLR solution, and (III) 200
µL of 30 mg mL 1 CLR solution. All the CLR-loaded Mg-based micromotors
were coated with a thin chitosan layer; all samples were dissolved in acid f r
24 h before the drug-loading measuremen . (D) In vi ro bactericidal activity of
free CLR, CLR-loaded Mg-based micromotors, and blank Mg-based micromotors
(without CLR drug) against H. pylori bacteria. Error bars estimated as a triple
of s.d. (n = 3)
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destroy themselves and disappear in the acidic environment after releasing the CLR,
with no apparent residues in the tissue. The findings validate the potential use of
these drug-loaded micromotors for therapeutic applications.
In vivo micromotor retention in mouse stomach.
After the optimization of drug-loading onto the Mg-based micromotors and
the confirmation of eﬀective in vitro bactericidal activity, the micromotors were
further investigated under in vivo setting. First, the in vivo retention properties
of the Mg-based micromotors on stomach tissue were examined at diﬀerent post-
administration times, and compared with control groups administered with DI water
(Figure 2.14). For this purpose, Mg-based micromotors prepared with DiD-labeled
PLGA and FITC-labeled chitosan coatings were administered to a group of mice (n =
3), and following 30 min and 2 h of the samples administration, the mice were killed
and the entire stomach was excised and opened. Subsequently, the luminal lining
was rinsed with PBS and flattened for imaging. Accordingly, Figure 2.14A shows
bright-field and fluorescence images of the luminal lining of freshly excised mouse
stomach at 0 min after oral gavage of DI water, and at 30 min and 2h after oral
gavage of Mg-based micromotors. As can be observed, the images corresponding to
the dye-loaded Mg-based micromotors show an intense fluorescent signal in both red
and green light channels, which indicates eﬃcient distribution and retention of the
micromotors in the mouse stomach. The continuous propulsion of the micromotors
and the adhesive properties of the chitosan coating help to achieve a homogeneous
distribution of the micromotors in the stomach. The corresponding fluorescence
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Mg-based micromotors, with corresponding amount of motors
and treated under the same conditions as the free CLR and
CLR-loaded Mg-micromotors, were used as negative controls.
From Fig. 2d, the bare motors had negligible effect on the viability
of H. pylori over the studied range, which supports that the
bactericidal effect of CLR-loaded Mg-based micromotors is solely
due to the loaded antibiotics, and not due the other compositions
of the micromotor carrier or the micromotor acidic environment.
Overall, Fig. 2d veriﬁes that the activity of the loaded drug was
not compromised compared to free drug. Our in vitro results
veriﬁed also that drug-loaded micromotors, made of Mg and
other degradable materials, eventually destroy themselves and
disappear in the acidic environment after releasing the CLR,
with no apparent residues in the tissue. The ﬁndings validate the
potential use of these drug-loaded micromotors for therapeutic
applications.
In vivo micromotor retention in mouse stomach. After the
optimization of drug-loading onto the Mg-based micromotors
and the conﬁrmation of effective in vitro bactericidal activity, the
micromotors were further investigated under in vivo setting.
First, the in vivo retention properties of the Mg-based
micromotors on stomach tissue were examined at different
post-administration times, and compared with control groups
administered with DI water (Fig. 3). For this purpose, Mg-based
micromotors prepared with DiD-labeled PLGA and FITC-labeled
chitosan coatings were administered to a group of mice (n= 3),
and following 30 min and 2 h of the samples administration, the
mice were killed and the entire stomach was excised and opened.
Subsequently, the luminal lining was rinsed with PBS and
ﬂattened for imaging. Accordingly, Fig. 3a shows bright-ﬁeld and
ﬂuorescence images of the luminal lining of freshly excised mouse
stomach at 0 min after oral gavage of DI water, and at 30 min and
2 h after oral gavage of Mg-based micromotors. As can be
observed, the images corresponding to the dye-loaded Mg-based
micromotors show an intense ﬂuorescent signal in both red and
green light channels, which indicates efﬁcient distribution
and retention of the micromotors in the mouse stomach.
The continuous propulsion of the micromotors and the adhesive
properties of the chitosan coating help to achieve a homogeneous
distribution of the micromotors in the stomach. The
corresponding ﬂuorescence quantiﬁcation of the dye-loaded
micromotors retained in the mouse stomach after 30 min and
2 h oral gavage of the sample is displayed in Fig. 3b. The graphic
represents the higher ﬂuorescence signals obtained at 665 and
520 nm (corresponding to DiD and FITC dyes, respectively) for
each sample. These results indicate that the micromotors can
effectively propel in gastric ﬂuid and are retained in the stomach
wall, including the antrum, where the H. pylori bacteria reside.
Such highly enhanced retention in the stomach, which is a major
advantage of motor-enabled delivery, has been carefully examined
in our early studies22–24. The powerful propulsion leads to tissue
penetration and binding, so that the drug-loaded motor could
reach the whole stomach wall for enhanced retention.
In vivo anti-H. pylori therapeutic efﬁcacy. We proceeded to test
the in vivo therapeutic efﬁcacy of the drug-loaded Mg-based
micromotors against H. pylori infection. Prior to the therapeutic
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Figure 2.14: Retention of the Mg-based micromotors in mouse stomachs. (A)
Bright-field and fluorescenc ages f the luminal lining of freshly excised mouse
stomachs at 0 min after oral gavage of deionized (DI) water (control), and at 30
min and 2 h after oral gavage of the Mg-based micromotors. Scale bar 5 mm.
(B) Corresponding fluorescence quantification of all the images shown in (A).
Error ba s estimated as a tripl of s.d. (n = 3)
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quantification of the dye-loaded micromotors retained in the mouse stomach after
30 min and 2 h oral gavage of the sample is displayed in Figure 2.14B. The graphic
represents the higher fluorescence signals obtained at 665 and 520 nm (corresponding
to DiD and FITC dyes, respectively) for each sample. These results indicate that the
micromotors can eﬀectively propel in gastric fluid and are retained in the stomach
wall, including the antrum, where the H. pylori bacteria reside. Such highly enhanced
retention in the stomach, which is a major advantage of motor-enabled delivery, has
been carefully examined in our early studies [282–284]. The powerful propulsion leads
to tissue penetration and binding, so that the drug-loaded motor could reach the
whole stomach wall for enhanced retention.
In vivo anti-H. pylori therapeutic eﬃcacy.
We proceeded to test the in vivo therapeutic eﬃcacy of the drug-loaded Mg-
based micromotors against H. pylori infection. Prior to the therapeutic study, we
developed H. pylori infection in a mouse model using C57BL/6 mice. Each mouse was
inoculated with 3 ⇥ 108 CFU H. pylori SS1 in brain-heart infusion (BHI) broth by
oral gavage three times on day 3, 5, and 7 (Figure 2.15A) [296, 304]. Two weeks after
inoculation, the H. pylori -infected mice were divided into five groups (n = 6, for each
group) and orally administered with DI water, blank Mg-based micromotors (without
CLR drug), free CLR drug with PPI (CLR+PPI), CLR-loaded silica microparticles, or
CLR-loaded Mg-based micromotors once a day for five consecutive days. On each day
of treatment, mice in the free CLR+PPI group received 400 µmol kg  1 of omeprazole
(as PPI treatment) 30min before administrating CLR, to neutralize gastric acid and
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study, we developed H. pylori infection in a mouse model using
C57BL/6 mice. Each mouse was inoculated with 3 × 108 CFU
H. pylori SS1 in brain–heart infusion (BHI) broth by oral gavage
three times on day 3, 5, and 7 (Fig. 4a)38, 39. Two weeks after
inoculation, the H. pylori-infected mice were divided into ﬁve
groups (n= 6, for each group) and orally administered with DI
water, blank Mg-based micromotors (without CLR drug), free
CLR drug with PPI (CLR+PPI), CLR-loaded silica microparticles,
or CLR-loaded Mg-based micromotors once a day for
ﬁve consecutive days. On each day of treatment, mice in the
free CLR+PPI group received 400 µmol kg−1 of omeprazole
(as PPI treatment) 30 min before administrating CLR, to
neutralize gastric acid and prevent potential degradation of
CLR. Such PPI dosage has been reported to be effective both in
reducing the gastric acidity in mouse models40, as well as in
preserving the effectiveness of co-administered antibiotics39, 41, 42.
After the treatment course, the bacterial burden was evaluated by
enumerating and comparing H. pylori counts recovered from
each mouse stomach. The mean bacterial burden from
two negative control groups treated with DI water and blank
Mg-based motors were 2.1 × 107 and 1.4 × 107 CFU g−1 of
stomach tissue, respectively (Fig. 4b, black and orange color,
respectively). Meanwhile, a bacterial burden of 3 × 106 CFU g−1
was measured from the mice treated with CLR-loaded silica
microparticles, which did not show statistical difference to the
negative controls. In contrast, when the mice were treated with
CLR-loaded Mg-based micromotors, the bacterial burden was
quantiﬁed as 2.9 × 105 CFU g−1, a signiﬁcant reduction compared
with the negative control and CLR-loaded silica microparticle
groups. The substantial improvement in H. pylori reduction
demonstrates the beneﬁt of acid-powered Mg-based micromotors
compared with static micron-sized carriers. A bacterial burden of
2.8 × 106 CFU g−1 was obtained for the positive control mice
with free CLR+PPI treatment. Although the difference between
CLR-loaded Mg-based micromotors and the free CLR+PPI
groups was not statistically signiﬁcant, the CLR-loaded
micromotors reduced the H. pylori burden in mice compared
with in the negative controls by ~1.8 orders of magnitude,
whereas the free CLR+PPI group reduced it only by ~0.8 orders
of magnitude. These results might be derived from the beneﬁt
of the propulsion-enabled active drug delivery performed by
the Mg-based micromotors in the stomach. These results
demonstrate that the Mg-based micromotors can effectively
propel and distribute throughout the stomach of living mice to
signiﬁcantly reduce H. pylori levels.
In vivo toxicity evaluation of Mg-based micromotors. Finally,
the toxicity proﬁle of the Mg-based micromotors in the stomach
as well as in the lower GI tract was evaluated. Healthy mice were
orally administered with Mg-based micromotors or DI water
once daily for ﬁve consecutive days. Throughout the treatment,
no signs of distress such as squinting of eyes, hunched posture,
unkempt fur, or lethargy were observed in both groups. Initially,
the toxicity proﬁle of the Mg-micromotors in the mouse
was evaluated through changes in body weight. During the
experimental period, mice administered Mg-micromotors
maintained a constant body weight compared with the
mice administered DI water (Fig. 5a). On day 6, mice were killed
and their stomachs and lower GI sections were processed
for histological staining. Longitudinal sections of the glandular
stomach (Fig. 5b), three major segments of small intestine
(duodenum, jejunum, and ileum, Fig. 5c–e, respectively) and the
two major segments of large intestine (proximal and distal colon,
Fig. 5f–g, respectively) were stained with hematoxylin and
eosin (H&E). The stomach and lower GI sections of the
micromotor-treated group showed undamaged structure of
columnar epithelial cells with no signs of superﬁcial degeneration
or erosion (Fig. 5b–g, left). There was no noticeable difference in
the gastric and intestinal mucosal integrity, in terms of
thickness as well as size and number of crypt and villus, between
the motor-treated and DI water-treated groups (Fig. 5b–g, left vs.
right part). No lymphocytic inﬁltration into the mucosa
and submucosa was observed, indicating no sign of gastric
inﬂammation. The in vivo toxicity studies of Mg-based
micromotors showed no effect on the mouse body weight,
apparent alteration of GI histopathology or observable
inﬂammation, suggesting that the treatment of Mg-based
micromotors is safe in the mouse model.
Conclusions
In this work we conducted the ﬁrst, to the best of our knowledge,
study to evaluate the therapeutic efﬁcacy of a drug-loaded
Mg-based micromotor for in vivo treatment of H. pylori infection
in a mouse model. Through these in vivo experiments,
we demonstrated that acid-powered Mg-based micromotors
could efﬁciently be loaded with clinical doses of drugs, retain in
the mouse stomach wall, and perform an appreciable
in vivo bactericidal activity. Our results showed that the active
propulsion of drug-loaded Mg-based micromotors in the acidic
media of the stomach and motor-tissue interaction lead to
efﬁcient drug delivery and hence to a signiﬁcant reduction of
bacteria burden compared to passive drug carriers. Furthermore,
such drug-loaded micromotors function in gastric condition
for the H. pylori infection treatment without the need of PPIs.
We also demonstrated that there were no toxicological con-
sequences of the micromotors in the mouse models. Overall, our
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Figure 2.15: In vivo anti-H. pylori therapeutic eﬃcacy. (A) The study protocol
including H. pylori inocul io and i fec ion dev lopme t in C57BL/6 mice,
followed by the treatments. (B) Quantification of bacterial burden in the stomach
of H. pylori-infected mice treated with DI water (black color), bare Mg-based
micromotors (orange color), free CLR+PPI (green color), CLR- loaded silica
microparticles (blue color), and CLR-loaded Mg-b sed micromotors (red color),
respectively (n = 6 per group). Bars represent median values. ⇤P < 0.05, ⇤⇤P <
0.01, ns no sta istical significance
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prevent potential degradation of CLR. Such PPI dosage has been reported to be
eﬀective both in reducing the gastric acidity in mouse models [297], as well as in
preserving the eﬀectiveness of co-administered antibiotics [296,298,299]. After the
treatment course, the bacterial burden was evaluated by enumerating and comparing
H. pylori counts recovered from each mouse stomach. The mean bacterial burden
from two negative control groups treated with DI water and blank Mg-based motors
were 2.1 ⇥ 107 and 1.4 ⇥ 107 CFU g  1 of stomach tissue, respectively (Figure 2.15B,
black and orange color, respectively). Meanwhile, a bacterial burden of 3 ⇥ 106 CFU
g  1 was measured from the mice treated with CLR-loaded silica microparticles, which
did not show statistical diﬀerence to the negative controls. In contrast, when the
mice were treated with CLR-loaded Mg-based micromotors, the bacterial burden was
quantified as 2.9 ⇥ 105 CFU g  1, a significant reduction compared with the negative
control and CLR-loaded silica microparticle groups. The substantial improvement in
H. pylori reduction demonstrates the benefit of acid-powered Mg-based micromotors
compared with static micron-sized carriers. A bacterial burden of 2.8 ⇥ 106 CFU g  1
was obtained for the positive control mice with free CLR+PPI treatment. Although
the diﬀerence between CLR-loaded Mg-based micromotors and the free CLR+PPI
groups was not statistically significant, the CLR-loaded micromotors reduced the
H. pylori burden in mice compared with in the negative controls by 1.8 orders
of magnitude, whereas the free CLR+PPI group reduced it only by 0.8 orders
of magnitude. These results might be derived from the benefit of the propulsion-
enabled active drug delivery performed by the Mg-based micromotors in the stomach.
These results demonstrate that the Mg-based micromotors can eﬀectively propel and
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distribute throughout the stomach of living mice to significantly reduce H. pylori
levels.
In vivo toxicity evaluation of Mg-based micromotors
Finally, the toxicity profile of the Mg-based micromotors in the stomach as well
as in the lower GI tract was evaluated. Healthy mice were orally administered with
Mg-based micromotors or DI water once daily for five consecutive days. Throughout
the treatment, no signs of distress such as squinting of eyes, hunched posture, unkempt
fur, or lethargy were observed in both groups. Initially, the toxicity profile of the
Mg-micromotors in the mouse was evaluated through changes in body weight. During
the experimental period, mice administered Mg-micromotors maintained a constant
body weight compared with the mice administered DI water (Figure 2.16A). On
day 6, mice were killed and their stomachs and lower GI sections were processed for
histological staining. Longitudinal sections of the glandular stomach (Figure 2.16B),
three major segments of small intestine (duodenum, jejunum, and ileum, Figure 2.16C-
2.16E, respectively) and the two major segments of large intestine (proximal and
distal colon, Figure 2.16F-2.16G, respectively) were stained with hematoxylin and
eosin (H&E). The stomach and lower GI sections of the micromotor-treated group
showed undamaged structure of columnar epithelial cells with no signs of superficial
degeneration or erosion (Figure 2.16B-2.16G, left). There was no noticeable diﬀerence
in the gastric and intestinal mucosal integrity, in terms of thickness as well as size
and number of crypt and villus, between the motor-treated and DI water-treated
groups (Figure 2.16B-2.16G, left vs. right part). No lymphocytic infiltration into
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results indicate that micromotors may be adapted to the devel-
opment of new and safe therapeutic treatments against stomach
diseases such as H. pylori infection. As our early studies have
shown that the Mg-based micromotors can propel efﬁciently and
position precisely in the GI tract23, 24, we believe the
presented motor-enabled delivery approach is promising to treat
diverse GI tract diseases. Extending the propulsion methods
with new alternative biocompatible fuels43, 44 or fuel-free
actuation11–13 might be able to expand the active-delivery
concept to different parts of the body. We also envision
that the micromotor approach will be useful for eliminating
hard-to-treat bacterial bioﬁlms,45, 46 with the efﬁcient motor
propulsion leading to bioﬁlm penetration towards enhanced
antibiotic delivery. Although the present results are promising,
this work is still at its early stage. As a new active gastric delivery
technology, future studies are required to further elucidate the
micromotor’s in vivo delivery performance and functions, and to
compare with other standard therapies against H. pylori infection
or other gastric diseases. Nonetheless, this work opens the door to
the use of synthetic motors as an active-delivery platform for
in vivo treatment of diseases and will likely trigger intensive
research interests in this area.
Methods
Synthesis of Mg-based micromotors. The Mg-based micromotors were prepared
using magnesium (Mg) microparticles (catalog #FMW20, TangShan WeiHao
Magnesium Powder Co.; average size, 20 ± 5 μm) as the core. The Mg
microparticles were initially washed with acetone to eliminate the presence of
impurities. After being dried under a N2 current, the Mg microparticles were
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Fig. 5 In vivo toxicity evaluation of the Mg-based micromotors. Uninfected mice were orally administered with the Mg-based micromotors or DI water
once daily for ﬁve consecutive days. aMouse body weight log from day 0 to day 6 of the toxicity study. Error bars represent the s.d. of the mean (n= 6). On
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Figure 2.16: In vivo toxicity ev luation the Mg-based micromotors. Unin-
fected mice were orally administered with the Mg-based micromotors or DI water
once daily for five consecutive days. (A) Mouse body weight log from day 0 to
day 6 of the toxicity study. Error bars represent the s.d. of the mean (n = 6).
On day 6, mice were killed and sections of the mouse stomach (B), small (C)-(E)
and large (F), (G) intestine tissues were processed for histological staining with
hematoxylin and eosin (H&E). Scale bars Mg-motor, 250 and 100 µm (left and
right column, espectively); DI water, 250 and 100 µm (l ft a d right column,
respectively)
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the mucosa and submucosa was observed, indicating no sign of gastric inflammation.
The in vivo toxicity studies of Mg-based micromotors showed no eﬀect on the mouse
body weight, apparent alteration of GI histopathology or observable inflammation,
suggesting that the treatment of Mg-based micromotors is safe in the mouse model.
2.3.4 Conclusions
In this work we conducted the first, to the best of our knowledge, study to
evaluate the therapeutic eﬃcacy of a drug-loaded Mg-based micromotor for in vivo
treatment of H. pylori infection in a mouse model. Through these in vivo experiments,
we demonstrated that acid-powered Mg-based micromotors could eﬃciently be loaded
with clinical doses of drugs, retain in the mouse stomach wall, and perform an
appreciable in vivo bactericidal activity. Our results showed that the active propulsion
of drug-loaded Mg-based micromotors in the acidic media of the stomach and motor-
tissue interaction lead to eﬃcient drug delivery and hence to a significant reduction
of bacteria burden compared to passive drug carriers. Furthermore, such drug-
loaded micromotors function in gastric condition for the H. pylori infection treatment
without the need of PPIs. We also demonstrated that there were no toxicological
con- sequences of the micromotors in the mouse models. Overall, our results indicate
that micromotors may be adapted to the development of new and safe therapeutic
treatments against stomach diseases such as H. pylori infection. As our early studies
have shown that the Mg-based micromotors can propel eﬃciently and position precisely
in the GI tract [283,284], we believe the presented motor-enabled delivery approach is
promising to treat diverse GI tract diseases. Extending the propulsion methods with
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new alternative biocompatible fuels [305,306] or fuel-free actuation [271–273] might
be able to expand the active-delivery concept to diﬀerent parts of the body. We also
envision that the micromotor approach will be useful for eliminating hard-to-treat
bacterial biofilms, [307, 308] with the eﬃcient motor propulsion leading to biofilm
penetration towards enhanced antibiotic delivery. Although the present results are
promising, this work is still at its early stage. As a new active gastric delivery
technology, future studies are required to further elucidate the micromotor’s in vivo
delivery performance and functions, and to compare with other standard therapies
against H. pylori infection or other gastric diseases. Nonetheless, this work opens
the door to the use of synthetic motors as an active-delivery platform for in vivo
treatment of diseases and will likely trigger intensive research interests in this area.
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Chapter 3
Biointerfacing via cell
membrane-coated nanoparticles for
novel pathologic countermeasure
applications
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3.1 Neutralization of cholera toxin with
nanoparticle decoys for treatment of cholera
3.1.1 Introduction
Diarrheal diseases are a major cause of morbidity and mortality in developing
regions, with an estimated 3-5 million cases and over 100,000 deaths per year [309,310].
Diarrhea accounts for 1 in 9 childhood deaths worldwide, making it the second leading
cause of death among children under the age of five. As an example, in diarrheal
patients attending a hospital in Mirpur, Bangladesh, Vibrio cholerae was found
to be the causative agent of diarrheal disease in 23% of patients [311]. Current
treatments involve rehydration with oral or intravenous replacement electrolyte
solutions [312,313]. While this method has reduced mortality rates in children with
acute diarrheal diseases, in general, stool volume and diarrheal durations are not
decreased [314]. Administration of antibiotics in conjunction with electrolyte solutions
can reduce the volume and duration of diarrhea [315], but extensive use of antibiotics
may lead to the emergence of antibiotic-resistant strains of bacteria, threatening
the utility of existing antibiotics [316]. Therefore, an urgent need exists to develop
alternative treatments.
V. cholerae is usually contracted through ingestion of contaminated water or
food in which the bacterium is present [313]. While bacterial colonization is limited
to the lumen and epithelial surface of the intestinal tract, the disease symptoms
are primarily caused by bacterially produced toxins. Most prominently, V. cholerae
secretes cholera toxin (CT), which is composed of an A subunit responsible for
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toxicity and a pentameric B subunit (CTB) responsible for receptor binding [317].
CTB binds to GM1 gangliosides on the surface of intestinal epithelial cells, which
subsequently leads to endocytosis of the entire protein complex [318]. The A1 subunit
(CTA1) is cleaved from the rest of the toxin through the reduction of a disulfide
bond [319]. CTA1 then catalyzes ADP-ribosylation of the GS↵ protein [320], leading
to its activation, stimulation of adenylyl cyclases, and a sustained increase in epithelial
cyclic AMP levels [321]. This series of events culminates in a massive eﬄux of chloride
ions and an inhibition of sodium absorption by the epithelium, which leads to the
rapid outflow of water into the intestinal lumen, and the attending severe diarrhea
and dehydration [322].
Since the GM1 ganglioside host receptors play a key role in the CT-mediated
pathogenesis of cholera, it constitutes an attractive target for novel antimicrobial
strategies [323]. The recent emergence of nanotechnology is beginning to have a
profound impact on modern medicine [324]. Nanoparticle systems have shown to be
superior in facilitating drug solubility, systemic circulation, and drug release, and
in their ability for diﬀerential cell targeting compared to free drugs [325, 326]. In
addition, nanoparticles can be engineered to serve as decoys or sinks for microbial
toxins, opening up new possibilities for treating toxin-mediated diseases [327, 328].
To determine whether this concept can be applied to cholera as a prototypic model
for intestinal diseases caused by enterotoxins, we set out to develop a nanotechnology-
based strategy for CT neutralization and treatment of cholera. The work described
here demonstrates that nanoparticle decoys are a promising new therapeutic avenue
for toxin-mediated diarrheal diseases.
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3.1.2 Experimental Methods
Ethics statement
Laboratory mice were used for parts of the study. Anesthesia was done with
isoflurane inhalation, and buprenorphine was given before surgery for preventive pain
management. Mice were euthanized by CO2 inhalation and cervical dislocation. All
animal studies were reviewed and approved by the UC San Diego Institutional Animal
Care and Use Committee.
Preparation of nanoparticles
GM1 ganglioside-coated poly(lactic-co-glycolic acid) (PLGA) hybrid nanoparti-
cles (GM1-NPs) were prepared by nanoprecipitation as previously described [326,329]
with several modifications. Briefly, a PLGA stock solution was prepared by dissolving
PLGA pellets (LACTEL Absorbable Polymers, Pelham, AL) in acetonitrile at a
concentration of 2.5 mg/mL. A GM1 ganglioside stock solution was prepared by
dissolving GM1 (Carbosynth, San Diego, CA) in deionized water at 10 mg/mL.
To prepare the aqueous phase for GM1-NP synthesis, the desired amount of GM1
stock solution was added into deionized water to yield a final GM1 concentration of
10% (w/v) of the PLGA polymer. A predetermined volume of the PLGA solution
was then added dropwise (1 ml/min) into the aqueous GM1 solution under gentle
stirring. The nanoparticles were allowed to self-assemble for 2 h with continuous
stirring while the organic solvent was allowed to evaporate under vacuum. To re-
move the remaining free molecules and organic solvent, the nanoparticle suspensions
were washed in deionized water three times using an Amicon Ultra centrifuge filter
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(Millipore, Billerica, MA) with a molecular weight cut-oﬀ of 100 kDa. Nanoparticles
were resuspended in deionized water and used immediately or stored at 4 C (up to
4 weeks) for later use. As a control, PLGA nanoparticle cores (PLGA-NPs) were
prepared with the nanoprecipitation method described above, but without GM1 in
the aqueous solution. As another control, polyethylene glycol (PEG) modified PLGA
nanoparticles (PEG-NPs) were fabricated with a coat of 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)- 2000] (DSPE-mPEG2000;
average molecular weight 2.8 kDa, Laysan Bio, Inc., AL) through nanoprecipitation
as previously described [329]. The aqueous phase contained a DSPE- mPEG2000
concentration of 10% (w/v) of the PLGA polymer. All stated concentrations for
nanoparticles refer to the concentration of the PLGA polymer in the respective
formulation.
Physical characterization of nanoparticles
Nanoparticle stability was analyzed in deionized water and phosphate-buﬀered
saline (PBS). For stability in water, nanoparticles were synthesized as described
above at a final polymer concentration of 1 mg/mL. To test the stability in PBS,
nanoparticles at 2 mg/mL in water were added to an equal volume of 2 ⇥ PBS. Particle
size distribution and zeta-potential were measured by dynamic light scattering using
a Malvern ZEN 3600 Zetasizer. Transmission electron microscopy of nanoparticles
was done by depositing a suspension (2 mg/mL) on a glow-discharged, carbon-coated
400-mesh copper grid. The grid was washed with distilled water and stained with
1% (w/v) uranyl acetate. Imaging was carried out on a Zeiss Libra 120 PLUS energy
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filter transmission electron microscope.
Cholera toxin binding studies
Binding of FITC-labeled CTB (Sigma-Aldrich, St. Louis, MO) was tested by
incubating the diﬀerent nanoparticle suspensions with 10 µg/mL CTB in in 400 µl of
PBS (pH 7.2) for 30 min. Each sample was transferred to an Amicon Ultra centrifuge
filter and centrifuged at 8,000 rpm in a Beckman Coulter microfuge 22R centrifuge for 5
min. Fluorescence was determined using a Synergy Mx fluorescent spectrophotometer
(Biotek, Winooski, VT). Bound CTB was calculated with the formula: CTB bound
(%) = (1 - CTB in supernatant/total CTB input) ⇥ 100%. All experiments were
performed in triplicate. Bound CTB was plotted against nanoparticle concentrations,
and a curve was fitted with the binding-saturation equation in GraphPad Prism.
To investigate the CT binding and neutralization capability, 400 µl of PBS
solution containing 1 or 0.25 mg/mL of nanoparticles was mixed with 5 µl of diﬀerent
concentrations of FITCTB, and incubated for 30 min at 37 C . Each sample was
processed as described above, and bound CTB was calculated, plotted against CTB
input concentrations, and fitted with a binding-saturation equation. To determine
the binding capacity of diﬀerent nanoparticle formulations, 400 µl of PBS solution
containing 1 mg/mL of GM1-NPs or PEG-NPs were incubated with 10 µg/mL CTB
for 30 min at 37 C . CTB incubated in PBS solution was used as the negative control.
Each sample was processed and analyzed as described above, and the bound CTB
was calculated.
To determine stability of toxin binding to the nanoparticles, 1 ml of a PBS
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solution containing 1 mg/mL of GM1-NPs was incubated with 10 µg/mL FITC-CTB
for 30 min at 37 C . The sample were transferred to an Amicon Ultra centrifuge
filter and centrifuged at 8,000 rpm for 5 min, and the CTB-loaded nanoparticles were
resuspended in 1 ml of a pool of undiluted luminal content obtained from the small
intestine of several male and female adult C57BL/6 mice. After 24 h incubation at
37 C , particles were dialyzed for 24 h against a PBS solution using a PTFE Dialyzer
(Harvard Apparatus) and Nucleopore hydrophilic membrane (Whatman) with a
molecular weight cut-oﬀ of 200 kDa. Retention of FITC-CTB on the nanoparticles
was measured by fluorescence spectroscopy. GM1-NPs incubated in PBS and free
CTB incubated in luminal content were used as positive and negative (background)
control, respectively. Data are expressed as bound FITC-CTB after 24 h relative to
the initial amount bound before incubation. Experiments were done in triplicate.
Confocal microscopy of nanoparticles
To visualize nanoparticles and toxin colocalization, fluorescently-labeled GM1-
NPs and PEG-NPs were prepared using 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-
dicarbocyanine perchlorate fluorescent dye (DiD; excitation/emission 644/665 nm;
Life Technologies, Carlsbad, CA) for incorporation into the polymer solution at a
concentration of 10 µg/mL during the preparation. Labeled GM1-NPs and PEG-NPs
(1 mg/mL) were then incubated with 10 µg/mL CTB as described for the toxin
binding studies. After 30 min incubation, nanoparticle solutions were washed three
times in deionized water using an Amicon Ultra centrifuge filter, and the samples were
visualized by confocal fluorescence microscopy using an Olympus FV1000 microscope
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with a 100x oil objective. To obtain stable images, the particles were dispersed in
glycerol to significantly decrease their spontaneous movements.
Cell culture studies
Vibrio cholerae strain N16961 (serogroup O1, biovar El Tor; ATCC) was grown
overnight at 37 C in Luria Bertani broth supplemented with trimethylamine N-oxide
without agitation at 37 C in an atmosphere of 5% CO2 and 95% air. These conditions
have been shown to induce CT expression [330]. Human HCA7 colon cancer cells
(ATCC) were grown in 75-cm2 culture flasks in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin
at 37 C in 5% CO2 and 95% air. Cells were plated into 48-well plates at 5 ⇥ 105
cells/well, and monolayers were grown overnight before experiments.
For toxin neutralization, we mixed diﬀerent concentrations of CT (List Biolog-
ical Laboratories, Campbell, CA) and nanoparticles, incubated for 1 h, and added the
mixture to the cell monolayers. After 2 h, supernatants were collected and assayed
for cAMP by enzyme immunoassay (Cyclic AMP ELISA Kit, Cayman Chemical Co.,
Ann Arbor, MI). All cAMP measurements were done without additional acetylation.
For neutralization experiments with live bacteria, nanoparticles were added to
epithelial cell monolayers, which were then immediately inoculated with V. cholerae
at a multiplicity-of- infection of 30, as determined by measuring optical density at 600
nm (OD600). After 2 h of infection, cAMP levels were determined in the supernatants
by enzyme immunoassay.
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Intestinal ligated loops
Ligated loops of the middistal small intestine were prepared in anesthetized
adult C57BL/6 mice as described previously [331]. Briefly, mice were fasted for 4-6
h before anesthesia and surgery, and given 0.1% buprenorphine for preventive pain
management. After shaving and disinfection of the abdomen, a small abdominal
incision was made, and a small intestinal loop was identified and ligated with two
small surgical clips placed 2-3 cm apart. Agents were injected into the loop with a
30G needle in a 200 µl volume, and the abdominal cavity was closed with sutures.
Loops were excised at diﬀerent times, and the luminal loop volume was determined
and related to the length of the loop. For CT tests, a solution of 12.5 µg/mL CT
was incubated with and without 250 µg/mL GM1-NPs or PEG-NPs for 1 h at room
temperature, and the mixture, or PBS as a control, was injected into the ligated
loops. For tests with live bacteria, V. cholerae were prepared as described above,
and injected in modified Luria Bertani broth at 105 bacteria per loop, either alone or
with 1.8 mg/loop of GM1-NPs or PEG-NPs. Broth alone was used as a control.
Statistics
Data were analyzed using Prism 5 (GraphPad Software, La Jolla, USA). Means
were compared with Student’s t-test or analysis of variance (Anova). P values <0.05
were considered as significant.
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3.1.3 Results and Discussion
Construction and physical characterization of GM1-coated nanoparticle
decoys
Hybrid nanoparticles, comprised of a polymeric core and a lipid shell, combine
the merits of both polymeric nanoparticles and liposomes while avoiding some of
their limitations [326]. Compared to the aqueous cores of conventional liposomes, a
solid polymeric core provides better control over the mechanical stability, particle
morphology, size distribution, and drug release kinetics [329]. Therefore, we applied
hybrid nanoparticle fabrication to the formulation of GM1-NPs as schematically
outlined in Figure 3.1A. Briefly, an organic solution of PLGA as the polymeric core
constituent was added dropwise under gentle stirring to a solution of GM1 in water
to yield a final 1:2 volume ratio of organic to aqueous solution. The mixture was
vortexed vigorously for 3 min followed by solvent evaporation under reduced pressure.
The remaining organic solvent and free molecules were removed by centrifugation. As
controls, two other types of nanoparticles were prepared: PLGA-NPs and PEG-NPs.
PEG-NPs have a PLGA core coated with DSPE-mPEG2000 [332], a lipid modified
with polyethylene glycol that is not expected to bind CT. PLGA-NPs are comprised
of only a PLGA core without a lipid shell.
Analysis of the nanoparticles by dynamic light scattering revealed a narrow
size distribution of the GM1-NPs, with a measured hydrodynamic diameter of 100
nm (Figure 3.1B), which was similar to the previously reported size of the control
PEG-NPs [329]. By comparison, the bare PLGA core had a slightly smaller diameter
of 75 nm (Figure 3.1B), suggesting that the increased size of the GM1-NPs was due
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Figure 3.1: Preparation and physical characterization of GM1-coated nanoparti-
cles. (A) Schematic of GM1-NP fabrication. Poly(lactic-co-glycolic acid) (PLGA)
dissolved in acetonitrile (CH3CN) is added to an aqueous solution containing
GM1. After acetonitrile evaporation, nanoparticles with a polymeric core and a
lipid shell are formed. (B) Intensity-weighted size distribution of representative
preparations of GM1-NPs and control PEG-NPs, and PLGA-NPs with a PLGA
core but without a lipid shell. (C) Zeta potential of the indicated nanoparticle
preparations (n = 3; mean ± SD; ⇤p<0.05 vs. PLGA-NPs). (D) Nanoparticle
size measurements over two weeks of incubation in distilled water or PBS (n =
3; mean ± SD). (E) Transmission electron micrograph of GM1-NPs.
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to the additional GM1 gangliosides coated as an exterior layer onto the PLGA core.
Furthermore, GM1-NPs as well as the control PEG-NPs, had a significantly more
negative surface zeta-potential of -40 to -50 mV compared to -25 mV of PLGA-NPs
(Figure 3.1C), which is also indicative of a diﬀerence in the nanoparticle surface
characteristics due to the lipid coating of the GM1-NPs compared to the bare PLGA
cores.
To test the stability of the nanoparticles in aqueous solution, they were
incubated in water or PBS for up to two weeks and analyzed by dynamic light
scattering. All three nanoparticle preparations were stable in water for the entire
test period, but only the two lipid-coated preparations were stable in PBS, while
the bare PLGA-NPs rapidly formed aggregates (Figure 3.1D). These findings clearly
distinguished GM1-NPs from the uncoated PLGA-NPs and suggested that the GM1
layer surrounding the GM1-NPs can provide steric and electronic repulsion to prevent
detrimental particle aggregation that would interfere with in vitro and in vivo studies.
Transmission electron microscopy confirmed that the GM1-NPs were dispersed as
single particles with a core/shell structure characteristic of a unilamellar membrane
coating around a nanoparticle core (Figure 3.1E).
Binding characteristics of cholera toxin to GM1 nanoparticle decoys
To determine the ability of GM1-NPs to bind CT, we incubated them, as
well as control PEG-NPs, with fluorescently (FITC)-labeled CTB. Unbound CTB
was removed by centrifugal filtration, and bound FITC was assayed by fluorescence
spectroscopy. Over 95% of input CTB was bound to GM1-NPs, whereas the control
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PEG-NPs had only background levels of fluores-cence (Figure 3.2A), showing the
specificity of CTB binding to the GM1-NPs. We also constructed GM1-NPs and
PEG-NPs in which a far-red fluorescent dye, DiD, was encapsulated in the PLGA
core, and incubated them with FITC-CTB under the same conditions. Fluorescence
imaging revealed co-localization of DiD and FITC in the GM1-NPs, whereas no FITC
staining was observed in the PEG-NPs (Figure 3.2B). These results confirm that
CTB binds specifically to GM1-NPs.
Toxin binding was concentration-dependent in regard to CTB and GM1-NPs
(Figure 3.2C and 3.2D). Fitting of a one-site specific binding model revealed a
maximal binding capacity (Bmax) of ⇠10 7 mol CTB per mg GM1-NP (equivalent
to ⇠ mg CTB/mg NP). Taken together, these results show that GM1-NPs are stable
in a physiologically relevant salt solution, and can bind CTB in a specific and a
high-capacity manner.
Functional neutralization of cholera toxin by GM1 nanoparticle decoys
Having shown specific CTB binding to GM1-NPs, we next investigated whether
the particles could block the functional impact of CT holotoxin on intestinal epithelial
cells. A fixed concentration of CT was mixed with diﬀerent concentrations of GM1-NPs
or PEG-NPs, and the mixtures were added to monolayers of human HCA7 intestinal
epithelial cells. As a functional read-out for CT bioactivity, we determined levels of
secreted cAMP in the supernatants, which correlate closely with intracellular cAMP
levels [333]. GM1-NPs neutralized the ability of CT to activate cAMP production
and secretion in a concentration-dependent fashion, while the GM1-free control PEG-
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Figure 3.2: Specific binding of cholera toxin B subunit to GM1-NPs. (A) GM1-
NPs and control PEG-NPs were incubated with FITC-labeled CTB for 30 min,
washed by centrifugation, and analyzed by fluorescence spectroscopy for bound
CTB. PBS without nanoparticles served as a background control (n = 3; mean
± SD). (B) DiD-labeled GM1-NPs and PEG-NPs were incubated with FITC-
CTB, and imaged by fluorescence microscopy. (C) Increasing concentrations of
FITC-CTB were incubated with the indicated fixed amounts of GM1-NPs, and
specific binding was analyzed by fluorescence spectroscopy (n = 3; mean ± SD).
(D) Increasing amounts of GM1-NPs were incubated with a fixed amount (10
µg/mL) of CTB, and specific binding was analyzed by fluorescence spectroscopy
(n = 3; mean ± SD).
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NPs had no eﬀect (Figure 3.3A). Half-maximal neutralization of 10 ng/mL CT was
achieved at 28 ng/mL GM1-NPs (as measured by their PLGA content). As a further
demonstration of the specificity and saturability of the CT/GM1-NP interaction, we
observed that increased CT concentrations could overwhelm the neutralizing capacity
of GM1-NPs, so a CT concentration of 361 ng/mL was required in the presence of
1,000 ng/mL of GM1-NPs to recover 50% of the maximal CT response seen in the
absence of nanoparticles (Figure 3.3B). Control PEG-NPs had no neutralizing eﬀect
under these conditions (although decreasing CT concentrations led to the expected
diminishment of the epithelial cAMP response).
Neutralization of purified CT was a necessary precondition for practical utility
of GM1-NPs, but the particles must be eﬀective against CT produced by live bacteria
to have therapeutic potential. Therefore, we infected HCA7 epithelial monolayers
with live, CT-secreting V. cholerae in the absence or presence of nanoparticles,
and measured cAMP secretion in the culture supernatants. GM1-NPs significantly
attenuated the cAMP response compared to PEG-NPs, although attenuation was
incomplete (Figure 3.3C). Nanoparticles alone without bacteria had no eﬀect on
cAMP production. Given the intense exposure of the epithelial monolayers to high
numbers of bacteria without physiological mixing that occur with normal intestinal
motility and the absence of a normal mucus layer, these data strongly suggest that the
GM1-NPs can significantly neutralize CT produced by live bacteria in close contact
with epithelial cells.
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Figure 3.3: Neutralization of CT activity with GM1-NPs. (A) A fixed con-
centration (10 ng/mL) of CT was combined with increasing amounts of the
indicated nanoparticles, and the mixtures were added to confluent monolayers
of human HCA7 intestinal epithelial cells. After 2 h, levels of secreted cAMP
were determined in the supernatants by ELISA (n = 3; mean ± SD). (B) A fixed
amount (1 µg/mL) of the indicated nanoparticles were combined with increasing
concentrations of CT, the mixtures were added to HCA7 monolayers for 2 h, and
levels of secreted cAMP levels were measured by ELISA (n = 3; mean ± SD).
(C) GM1-NPs or control PEG-NPs were added to HCA7 monolayers, which were
then infected for 2 h with live V. cholerae or left uninfected, and secreted cAMP
was determined (n = 3; mean ± SD; ⇤p<0.05 vs PEG-NPs).
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Stability of GM1 nanoparticle decoys under physiologically relevant con-
ditions
To be eﬀective in the intestinal lumen, where V. cholerae resides and secretes
CT, nanoparticles have to be stable and functional in the presence of the relevant
physiological factors at that site. Of particular importance are bile acids whose
amphoteric nature promotes lipid solubilization and digestive enzymes that can break
down lipids and other complex molecules. Therefore, we tested whether GM1-NPs
remained intact and active upon exposure to these luminal factors. Incubation of
GM1-NPs in a solution containing concentrated porcine bile had no impact on particle
size or their ability to bind FITC-labeled CTB (Figure 3.4A and 3.4B). Furthermore,
incubation of CTB-loaded GM1-NPs for 24 h with luminal fluid (containing bile acids,
various digestive enzymes, and some commensal bacteria) from the small intestine of
mice did not detach the toxin, indicating that toxin binding to the nanoparticles was
stable and not aﬀected by luminal factors (Figure 3.4C; similar observations were
made after 48 h of incubation). This conclusion was confirmed by the observation
that exposure of the nanoparticles to fecal homogenates (which also contain bile acids
and digestive enzymes, as well as large numbers of commensal bacteria and their
enzymatic products) did not compromise the ability of GM1-NPs to functionally
neutralize CT in respect to epithelial cAMP induction (Figure 3.4D). Together, these
results demonstrate that the GM1-NPs display stable and prolonged functionality
in the presence of intestinal luminal factors, suggesting that they are suitable for in
vivo applications to neutralize CT.
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Figure 3.4: Functional stability of GM1-NPs in the presence of intestinal
luminal factors. (A) Intensity-weighted size distribution of GM1-NPs incubated
30 min in distilled water or diluted porcine bile solution (1:16 dilution in water).
(B) Fluorescence imaging of DiD-labeled GM1-NPs absorbed with FITC-CTB
and incubated for 30 min in 1:16 diluted porcine bile solution. (C) GM1-NPs
were loaded with FITC-CTB for 30 min, washed, and resuspended in luminal
fluid from the small intestine of normal adult mice, or PBS as a control. After
incubation for 24 h at 37 C , particle-bound and free FITC-CTB were separated
by dialysis, and bound FITC-CTB was measured by fluorescence spectroscopy
and related to the initial amount bound (mean ± SD, n = 3). Background
readings were obtained with free FITC-CTB without GM1-NPs. (D) Fecal
homogenates from mice were mixed 1:1 with GM1-NPs or PEG-NPs in culture
media, and incubated for 1 h at 37 C , after which CT (10 ng/mL) was added for
an additional 1 h before addition to HCA7 monolayers. After 2 h, cAMP levels
in the supernatants were determined by ELISA (mean ± SD, n = 3; ⇤p<0.05 vs
PEG-NPs).
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Attenuation of intestinal secretory response to CT and live V. cholerae
by GM1 nanoparticle decoys in vivo
To evaluate the therapeutic eﬃcacy of the nanoparticles in vivo, we utilized
ligated intestinal loops in adult mice as a model. Constructed in the distal small
intestine, these loops allow undisturbed exposure of the intestine to defined microbial
stimuli and therapeutic interventions in the physiologically relevant environment
without confounding variables related to intestinal motility or variable susceptibility
of adult mice to sustained infection with the target microbe. In a first test, we
injected the loops with CT in the absence or presence of GM1-NPs or PEG-NPs.
CT alone induced a robust fluid response in the lumen of the loops, which was not
aﬀected by the control PEG-NPs (Figure 3.5A). In contrast, GM1-NPs completely
blocked the fluid response to CT, indicating that the nanoparticles were as eﬀective
in vivo as they were in vitro. Subsequently, we infected the loops with live V.
cholerae with and without nanoparticles. Increased fluid secretion was observed after
infection, which was significantly attenuated by treatment with GM1-NPs but not
with control PEG-NPs (Figure 3.5B and 3.5C). In parallel to the attenuated fluid
response, levels of secreted cAMP in the intestinal lumen were significantly decreased
with GM1-NP treatment compared to control PEG-NPs after V. cholerae infection
(Figure 3.5D). Neither of the nanoparticles had an impact on baseline fluid secretion
without infection.
115
Figure 3.5: In vivo eﬃcacy of GM1-NPs against CT and live V. cholerae.(A)
Ligated intestinal loops were prepared in the distal small intestine of adult
C57BL/6 mice, and injected with PBS as a control, or with 2.5 µg CT, without
and with prior addition of GM1-NPs or control PEG-NPs. Fluid accumulation
in the loops was determined after 4 h, and related to loop length (each point
represents one animal, horizontal lines are geometric means; ⇤p<0.05 vs PEG-
NPs). (B) Loops were injected with PBS as a control, or live V. cholerae with
GM1-NPs or control PEG-NPs. Fluid accumulation was determined after 16 h
(each point represents one animal, horizontal lines are geometric means; ⇤p<0.05
vs PEG-NPs). (C) Images of representative intestinal loops. (D) cAMP was
measured in the luminal fluid collected from loops after injection of live V.
cholerae with GM1-NPs or control PEG-NPs (n = 3; mean ± SD; ⇤p<0.05 vs
PEG-NPs).
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3.1.4 Conclusions
Cholera continues to be a major public health challenge in many regions of the
world [313]. Medical strategies to combat this scourge can be divided into preventive
approaches, which seek to protect individuals from infection, and therapeutic ap-
proaches, which attenuate disease symptoms in infected persons. For prevention, the
FDA recently approved the first cholera vaccine, Vaxchora, composed of attenuated
live bacteria, but the vaccine is currently only eﬀective for V. cholerae serogroup 01
and, as a live agent, has the potential to cause disease itself, either in attenuated form
in predisposed individuals or potentially upon reversion to a more virulent form [334].
In this regard, quality controls of live microbial agents as therapeutic agents can be
challenging. As an alternative, attenuating medical strategies employ well-controlled
interventions to ameliorate symptoms and assure survival while allowing mucosal
immune defenses to clear the infection. The classical treatment is oral or intravenous
rehydration [312], in which bacterially-induced diarrheal processes proceed unhin-
dered, but the devastating systemic consequences of dehydration are prevented by
providing suﬃcient electrolytes and water during the acute disease stage. Although
usually eﬀective for promoting survival, severe disease symptoms can still occur for
days.
As an alternative attenuation strategy, we show here that a nanotechnology-
based intervention can be eﬀective at targeting the bacterially-produced CT, which is
the primary cause of diarrheal symptoms in cholera [313]. By coating nanoparticles
with the CT-binding lipid, GM1, the particles were able to bind and neutralize
the toxin, thereby preventing its eﬀects on epithelial electrolyte and fluid secretion
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Figure 3.6: Model of therapeutic eﬀect of GM1-NPs.GM1-coated nanoparticles
act as decoys to absorb CT produced by V. cholerae before it can bind to
epithelial cells to stimulate cAMP production and epithelial chloride secretion,
and inhibit sodium absorption.
in vitro and in vivo (Figure 3.6). This strategy represents a novel interventional
approach whose mechanisms of action are physiologically distinct from vaccination,
rehydration, or antibiotics, thus significantly broadening the medical armamentarium
against cholera.
Neutralization strategies for microbial toxins have been proposed and imple-
mented with diﬀerent technological means, including antibodies and live bacteria. For
cholera, Escherichia coli has been engineered to produce GM1 lipid on its surface [335].
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The recombinant E. coli was shown to bind CT and attenuate V. cholerae-induced
disease in animal models [323, 335], thus underlining our findings. However, live
microbes as therapeutic agents are problematic due to the diﬃculties in performing
quality controls in manufacturing [336]. Furthermore, genetically engineered live
bacteria, particularly those that belong to the normal intestinal microbiota, may
colonize the intestine permanently [337], raising concerns about long-term microe-
cological consequences of such interventions. In contrast, our nanoparticles were
constructed exclusively from tractable reagents that can be readily quality-controlled.
The fabrication process is eﬀective and high-yield, thereby minimizing potentially
oﬀensive by-products and the accompanying need for extensive purification schemes.
Furthermore, the nanoparticles do not replicate and are thus not retained for extended
periods in the intestine beyond the treatment period.
In the nanoparticle design, we considered that many glycosylated lipid deriva-
tives, such as gangliosides, contain sialic acid residues on their sugar chains that are
prominently positioned and critical for attachment of cholera toxin [338]. Conse-
quently, it was important that the GM1-oligosaccharides were located on the outside
of the nanoparticle core in the proper orientation, so the lipid arrangement would
resemble as much as possible the naturally occurring cell-surface location and aﬃnity
of GM1 to which CT normally binds. We were able to achieve the desired lipid
location and orientation on the polymeric nanoparticle surface through a modified
nanoprecipitation method [326,329], in which GM1-gangliosides with their inherent
amphiphilic property self-assembled in a single-step synthesis on the hydrophobic
nanoparticle surface to produce a lipid monolayer on the interface of the nanoparticle
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core and the hydrophilic GM1-oligosaccharides present on the outer shell.
The fabricated GM1-nanoparticles represent a novel class of core-shell struc-
tured lipid- polymer hybrid nanoparticles, which are known for combining the strengths
of both liposomes and polymeric nanoparticles [326]. The lipid shell incasing the
core mimics biological membranes and can mediate specific interactions with the
environment, such as the reported interaction between the shell GM1 and soluble
CT. Meanwhile, the nanoparticle core serves as structural support that provides
controlled morphology, size tunability, and narrow size distribution [339]. In addition,
lipid-polymeric nanoparticles have excellent physical stability [329, 340, 341], mak-
ing GM1-NPs promising for their use in tropical environments. In terms of safety,
PLGA polymer, which makes up the GM1-NP core, is a safe and FDA-approved
biodegradable polymer [342], and GM1-ganglioside is extracted from natural cell
membranes. Hence, it is likely that the GM1-nanoparticles are biocompatible and
safe for prospective clinical translation.
Since cholera is often a disease aﬀecting poor people in developing countries,
cost-eﬀective manufacturing is critical for clinical utility. PLGA has long been
produced for pharmaceutical applications [343,344], and a variety of manufacturing
processes have been used in industry for nanoparticle formulations [345–347]. Such
processes could be adapted to large-scale GM1-NP production, facilitating downstream
translational development. Optimal formulation will require further development,
but the platform technology has great flexibility. For example, nanoparticles can be
administered directly, as shown for formulations such as poly (lactic-co-glycolic acid)
nanoparticles and polyacrylic acid nanoparticles to treat colitis or hypercalcemia
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[348, 349]. Alternatively, nanoparticles could be loaded into capsules [350, 351] or
a pH-responsive polymer matrix for targeting to specific sections of the intestinal
tract [352].
Our nanoparticle strategy has implications for treating other enteric infections
in which microbially-produced toxins play an important and central pathophysiological
role. For example, the heat-labile enterotoxin of enterotoxigenic E. coli, the most
common cause of traveler’s diarrhea, also binds GM1 ganglioside [353]. Structural
analysis of CTB and the binding subunit of LT bound to GM1-pentasaccharide
revealed that the residues contacting the terminal galactose sugar are conserved
between the two toxins [354], suggesting that nanoparticle-based intervention would
predictably also be eﬀective in enterotoxigenic E. coli-induced disease. For other
toxin-mediated enteric diseases, such as those caused by shiga toxin from Shigella
dysenteriae [355], similar nanotechnology strategies using the appropriate lipids may
also be a promising new therapeutic avenue.
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3.2 Macrophage-like nanoparticles concurrently
absorbing endotoxins and proinflammatory
cytokines for sepsis management
3.2.1 Introduction
Sepsis is a life-threatening complication of bacterial infection characterized by
uncontrolled systemic inflammatory response [356]. Sepsis precipitates a collapse of
cardiovascular function, leading to multiple organ dysfunction or failure [357, 358].
Despite many eﬀorts devoted to finding an eﬀective treatment, the mortality rate in
sepsis is very high, and the number of hospitalizations resulting from the condition
continues to rise [359, 360]. Endotoxin, an important pathogenic trigger of Gram-
negative bacterial sepsis, induces a systemic inflammatory response characterized
by production of proinflammatory cytokines and nitric oxide, fever, hypotension,
and intravascular coagulation, culminating in septic shock [361]. Emerging evidence
suggests that the systemic spread of endotoxin from sites of infection, rather than
bacteremia itself, is crucial in the pathogenesis of this dramatic immune dysregulation
[362,363]. Since higher levels of endotoxin correlate to worsened clinical outcomes
[364, 365], eﬀective endotoxin removal is a critical component of successful sepsis
management.
Endotoxin neutralization and elimination present various challenges. While
all endotoxins share a common architecture, they vary greatly in their structural
motifs across bacterial genus, species, and strain [366,367]. Accordingly, endotoxin
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interactions with ligands can diﬀer substantially, which poses challenges for structure-
based neutralization strategies. Antibiotics eﬀective in neutralizing endotoxin such
as polymyxins have limits on their clinical utility due to their strong nephrotoxicity
and neurotoxicity [368, 369]. Attaching these molecules to solid-phase carriers for
hemoperfusion can retain their endotoxin-binding properties while minimizing the
toxic eﬀects, but clinical evidence of therapeutic eﬃcacy has yet to be established
[370,371]. In addition, such solid-phase perfusion strategies are impractical in resource-
limited environments [372].
Recently, cell membrane-coated nanoparticles have emerged as a biomimetic
nanomedicine platform, enabling a broad range of biodetoxification applications
[373,374]. In particular, nanoparticles coated with membranes derived from red blood
cells (denoted RBC nanosponges) have taken advantage of functional similarities
shared by various bacterial pore-forming toxins to neutralize their cytolytic activity
regardless of molecular structure [375, 376]. These unique core-shell nanoparticles
exhibit prolonged systemic circulation, preventing further bioactivity of the absorbed
toxins and diverting them away from their intended cellular targets. RBC nanosponges
have also been developed as therapeutic detoxification agents to neutralize pathological
antibodies in autoimmune diseases [377] and organophosphate nerve agents [378].
The therapeutic potential of membrane-coated nanoparticles for broad-spectrum
detoxification inspired us to develop biomimetic nanoparticles for endotoxin removal,
potentially enabling eﬀective sepsis management. In sepsis, endotoxin, also referred
to as lipopolysaccharide (LPS), is released from the bacteria during cell division,
cell death, or under antibiotic treatment, whereupon it is recognized as a pathogen-
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associated molecular pattern (PAMP) by sentinel immune cells, including monocytes
and macrophages [379,380]. In the bloodstream, LPS-binding protein (LBP) binds
with high aﬃnity to LPS via lipid A, and the LPS-LBP complex subsequently engages
the pattern recognition receptor (PRR) CD14 present on the macrophage cell sur-
face [381,382]. Following this binding interaction, LPS can induce various changes in
immune cell activity. For example, LPS induces a dose-dependent production of nitric
oxide (NO), which can be cytotoxic at high levels [365]. LPS binding to macrophages
also activates the PRR Toll-like receptor 4 (TLR4), which plays a significant role
in the regulation of bacterial phagocytic uptake [383], intracellular traﬃcking, and
macrophage cell death [384,385]. Furthermore, LPS-induced engagement of TLR4
activates the nuclear factor-B (NF-B) transcription factor, resulting in the produc-
tion and release of potent proinflammatory cytokines, such as tumor necrosis factor
(TNF), interleukin 6 (IL-6), and IFN-  [386,387].
Compelled by the critical roles played by macrophages and their PRR in endo-
toxin signaling, here we develop biomimetic nanoparticles consisting of a biodegradable
polymeric nanoparticle core coated with cell membrane derived from macrophages
(denoted M -NPs, Figure 3.7A). M -NPs possess an antigenic exterior identical to
the source macrophage cells, thus inheriting their capability to bind to endotoxins.
In addition, M -NPs act as decoys to bind to cytokines, inhibiting their ability to
potentiate downstream inflammation cascades, i.e., pathological “cytokine storm.”
These two functionalities together enable eﬀective intervention during uncontrolled
immune activation, providing a therapeutic intervention with significant potential for
the management of sepsis.
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3.2.2 Experimental Methods
Macrophage Membrane Derivation.
The murine J774 cell line was purchased from the American Type Culture
Collection (ATCC) and maintained in Dulbecco’s modified Eagle medium (DMEM)
(Invitrogen) supplemented with 10% FBS (HyClone) and 1% penicillin-streptomycin
(pen-strep) (Invitrogen). Plasma membrane was collected according to a previously
published centrifugation method [388]. Specifically, cells were grown in T-175 culture
flasks to full confluency and detached with 2 mM EDTA (USB Corporation) in PBS
(Invitrogen). The cells were washed with PBS three times (500 ⇥ g for 10 min each)
and the cell pellet was suspended in homogenization buﬀer containing 75 mM sucrose,
20 mM Tris-HCl (pH = 7.5, MediaTech), 2 mM MgCl2 (Sigma-Aldrich), 10 mM KCl
(Sigma-Aldrich), and one tablet of protease/phosphatase inhibitors (Pierce, Thermo
Fisher Scientific). The suspension was loaded into a Dounce homogenizer and the
cells were disrupted with 20 passes. Then the suspension was spun down at 3,200 ⇥
g for 5 min to remove large debris. The supernatant was collected and centrifuged
at 20,000 ⇥ g for 25 min, after which the pellet was discarded and the supernatant
was centrifuged at 100,000 ⇥ g for 35 min. After the centrifugation, the supernatant
was discarded and the plasma membrane was collected as an oﬀ-white pellet for
subsequent experiments. Membrane protein content was quantified with a Pierce
BCA assay (Life Technologies).
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M -NP Preparation and Characterization.
M -NPs were formulated in two steps. In the first step, ⇠80-nm polymeric
cores were prepared using 0.67 dL/g carboxyl-terminated 50:50 PLGA (LACTEL
absorbable polymers) through a nanoprecipitation method. The PLGA polymer
was first dissolved in acetone at a concentration of 10 mg/mL. Then 1 mL of the
solution was added rapidly to 3 mL of water. For fluorescently labeled PLGA
cores, 1,1’-dioctadecyl-3,3,3’,3’- tetramethylindodicarbocyanine perchlorate (DiD,
excitation/emission = 644 nm/ 665 nm; Life Technologies) was loaded into the
polymeric cores at 0.1 wt%. The nanoparticle solution was then stirred in open air
for 4 h to remove the organic solvent. In the second step, the collected macrophage
membranes were mixed with nanoparticle cores at a membrane protein-to-polymer
weight ratio of 1:1. The mixture was sonicated with a Fisher Scientific FS30D bath
sonicator at a frequency of 42 kHz and a power of 100 W for 2 min. Nanoparticles
were measured for size and size distribution with DLS (ZEN 3600 Zetasizer, Malvern).
All mea surements were done in triplicate at room temperature. Serum and PBS
stabilities were examined by mixing 1 mg/mL of M -NPs in water with 100% FBS
and 2⇥ PBS, respectively, at a 1:1 volume ratio. Membrane coating was confirmed
with transmission electron microscopy (TEM). Briefly, 3 µL of nanoparticle suspension
(1 mg/mL) was deposited onto a glow-discharged carbon-coated copper grid. Five
minutes after the sample was deposited, the grid was rinsed with 10 drops of distilled
water, followed by staining with a drop of 1 wt% uranyl acetate. The grid was
subsequently dried and visualized using an FEI 200 kV Sphera microscope.
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Membrane Protein Characterization.
M -NPs were purified from free vesicles, membrane fragments, and unbound
proteins by centrifugation at 16,000 ⇥ g. Macrophage cell lysates, membrane vesicles,
and M -NPs were mixed with lithium dodecyl sulfate (LDS) loading buﬀer to the
same total protein concentration of 1 mg/mL as determined with a Pierce BCA assay
(Life Technologies). Electrophoresis was carried out with NuPAGE Novex 4-12% Bis-
Tris 10-well minigels in Mops running buﬀer with an XCell SureLock Electrophoresis
System (Invitrogen). Western blot analysis was performed by using primary antibodies
including rat anti-mouse CD14, rat anti-mouse CD126, rat anti-mouse CD130, rat anti-
mouse CD284, Armenian hamster anti-mouse CD120a, Armenian hamster anti-mouse
CD120b, and Armenian hamster anti-mouse CD119 (BioLegend). Corresponding IgG-
horseradish peroxidase (HRP) conjugates were used for the secondary staining. Films
were developed with ECL Western blotting substrate (Pierce) on a Mini-Medical/90
Developer (ImageWorks).
LPS and Cytokines Binding Studies.
To study whether LPS binding with M -NPs was dependent on LBP, CD14,
or TLR4, the mixture of M -NPs (1 mg/mL) and FITC-LPS (from E. Coli O111:B4,
125 ng/mL; Sigma) in 1⇥ PBS was added with FBS (10% as the source of LBP),
anti-CD14 (10 µg/mL; BioLegend), or anti- TLR4 (10 µg/mL; Invivogen), respectively.
The solution was incubated at 37  C for 30 min. Following the incubation, M -NPs
were spun down with ultracentrifugation (16,000 ⇥ g). The fluorescence intensity from
FITC-LPS remaining in the supernatant was measured. The fluorescence intensity
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from a FITC-LPS solution of 125 ng/mL served as 100%. The mixtures without
adding FBS or antibodies were used as the controls. An equivalent amount of M -
ghost (protein mass) was used as a control to assess the loss of membrane function
during coating. The mixture added with nonspecific IgG from human serum was also
included as a negative control to exclude the eﬀect of the nonbinding domains of the
antibody that may contribute to LPS inhibition. All experiments were performed in
triplicate.
To quantify LPS removal with M -NPs, M -NPs (0.4 mg, 4 mg/mL) were
mixed with LPS from E. Coli K12 (Invivogen) with varying amount of 5, 10, 25, and
50 ng (50, 100, 250, and 500 ng/mL), respectively, in 1⇥ PBS containing 10% FBS.
In a parallel experiment, the removal was studied by fixing LPS amount at 50 ng
(250 ng/mL) but varying the amount of M -NPs at 0.1, 0.2, 0.3, and 0.4 mg (0.5,
1, 1.5, and 2 mg/mL), respectively. In both cases, the mixtures were incubated for
30 min and then spun down at 16,000 ⇥ g for 15 min to pellet the nanoparticles.
The free LPS content in the supernatant was quantified by using limulus amebocyte
lysate (LAL) assay (Thermo Fisher Scientific) per manufacturer’s instructions. All
experiments were performed in triplicate.
To determine M -NP binding with cytokines, including IL-6, TNF-↵, and
IFN-  100 µL of M -NP samples (1 and 4 mg/mL) mixed with IL-6 (2,000 pg/mL),
TNF-↵ (370 pg/mL), or IFN-  (880 pg/mL) in PBS containing 10% FBS were
incubated at 37  C for 30 min. Following the incubation, the samples were centrifuged
at 16,000 ⇥ g for 15 min to pellet the nanoparticles. Cytokine concentrations in
the supernatant were quantified by using ELISA (BioLegend). All experiments were
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performed in triplicate.
LPS Neutralization in Vitro.
Murine TLR4 reporter cells (HEK-Blue mTLR4 cells, Invivogen) were first
used to determine LPS neutralization by M -NPs. Cells were cultured in DMEM
supplemented with 10% FBS, 1% pen-strep, 100 µg/mL normocin, 2 mM L-glutamine,
and 1⇥ HEK-Blue selection (Invivogen). In the study, 2.5 ⇥ 104 cells were seeded
in each well of a 96-well plate with 160 µL HEK-Blue detection medium, followed
by adding 20 µL of 100 ng/mL LPS in PBS. Then 20 µL of nanoparticle solution of
M -NPs, RBC-NPs, or PEG-NPs (all at a concentration of 10 mg/mL), was added
into each well. Control wells were added with 20 µL PBS. Cells without any treatment
served as the background. The mixture was incubated for 12 h. SEAP was quantified
by measuring the absorbance at 630 nm with an Infinite M200 multiplate reader
(Tecan). All experiments were performed in triplicate.
Production of iNO was also used to evaluate LPS neutralization with M -
NPs. Briefly, 2 ⇥ 104 J774 cells were seeded in each well of a 96-well plate. The cells
were incubated with 10 µM of 2, 7’-dichlorofluorescin-diacetate (DCFH-DA) (Sigma)
in culture medium for 1 h and then washed three times with the culture medium.
Then the wells were added with 180 µL of medium containing 10 ng/mL of LPS.
Then 20 µL of nanoparticle solution of M -NPs, RBC-NPs, or PEG-NPs (all at a
concentration of 10 mg/mL), was added into each well. Twenty microliters of PBS
was added to control wells. Cells without any treatment served as the background.
The plate was incubated at 37  C for 5 h. The production of iNO was quantified
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by measuring the fluorescence intensity at 520 nm using an excitation wavelength of
485 nm (Infinite M200 multiplate reader, Tecan). All experiments were performed in
triplicate.
LPS neutralization with M -NPs was further evaluated by examining E-
selectin expression on HUVECs. Specifically, HUVECs were cultured to confluence in
a 96-well plate. Then 200 µL of LPS (250 ng/mL) mixed with M -NPs, RBC-NPs,
or PEG-NPs (4 mg/mL) in culture medium was added to the cells and the plate
was incubated at 37  C . Cells added with LPS and PBS were used as controls.
Three wells were used per sample. After 1, 2, 3, and 4 h of incubation at 37  C ,
medium was removed and cells were washed with PBS. Then the cells were fixed
with 4% paraformaldehyde (Sigma) at room temperature for 15 min. Following
the fixation, cells were washed twice with PBS and blocked with 1% BSA (Sigma).
Subsequently, the reagent was decanted and 50 µL of primary antibody (mouse
anti-human E-selectin, 1:10 dilution in 1% BSA; BioLegend) was added to each well
and incubated at 37  C for 45 min. Wells were then rinsed three times with 1⇥ PBS
before the addition of 50 µL of secondary antibody (HRP-conjugated anti-mouse
IgG, 1:10 dilution in 1% BSA; BioLegend) followed by an incubation for 45 min at
37  C . After this, wells were again rinsed three times with 1⇥ PBS and after the
final rinse, 100 µL of 3,3’,5,5’- tetramethylbenzidine (TMB) substrate solution was
added to each well. The plate was incubated at 37  C followed by measuring the
absorbance at 450 nm. To visually examine E-selectin expression, cells following
the same treatment as the above experiment were incubated at 37  C for 4 h and
rinsed twice with PBS, fixed with 4% paraformaldehyde for 15 min, permeabilized in
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0.2% Triton X-100 (Sigma) in buﬀer for 10 min, and then incubated with 1% BSA in
PBS for 30 min. Cells were then stained with mouse anti-human E-selectin for 1 h,
washed three times with 1⇥ PBS, and then incubated with anti-mouse IgG Alexa
488 conjugates in 1% BSA in PBS for 1 h. Cell nuclei were stained with DAPI (1
mg/mL stock solution; Thermo Fisher Scientific). Fluorescence images were taken
with an EVOS fluorescence microscope (Thermo Fisher Scientific).
Animal Care and Injections. All animal studies were approved under the
guidelines of the University of California San Diego (UCSD) Institutional Animal
Care and Use Committee. Mice were housed in an animal facility at UCSD under
federal, state, local, and NIH guidelines for animal care. In the study, no inflammation
was observed at the sites of injection.
Pharmacokinetics and Biodistribution Studies.
The experiments were performed on 6-wk-old male ICR mice (Harlan Lab-
oratories). To determine the circulation half-life, 150 µL of DiD-labeled M -NPs
(3 mg/mL) was injected i.v. through the tail vein. At 1, 15, and 30 min, and 1, 2,
4, 8, 24, 48, and 72 h postinjection, one drop of blood (⇠30 µL) was collected from
each mouse via submandibular puncture with heparin-coated tubes. Then 20 µL of
blood was mixed with 180 µL PBS in a 96- well plate for fluorescence measurement.
Pharmacokinetic parameters were calculated to fit a two-compartment model. For
biodistribution study, 150 µL of DiD-labeled M -NPs (3 mg/mL) was injected i.v.
through the tail vein. At 24, 48, and 72 h postinjection, organs including the liver,
kidneys, spleen, brain, lungs, heart, and blood were collected from six randomly
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selected mice. The collected organs were weighed and then homogenized in PBS for
fluorescence measurement. All fluorescence measurements were carried out with an
Infinite M200 multiplate reader (Tecan).
LPS Neutralization in vivo.
The eﬃcacy of M -NPs in neutralizing LPS was first evaluated with a mouse
endotoxemia model with 6-wk-old male BALB/c mice (Harlan). To evaluate the
eﬃcacy through cytokine production, mice were injected with 5 µg/kg LPS through
the tail vein. After 15 min, M -NPs, RBC-NPs, or PEG-NPs were injected at
200 mg/kg. Following the injections, blood samples (<30 µL) were collected at
predetermined time points via submandibular puncture. Untreated mice and mice
injected with LPS alone were used as controls. Cytokines, including IL-6 and TNF-↵,
in the plasma were quantified by ELISA as described above. In each group, six
mice were used. To evaluate eﬃcacy through survival, mice were first sensitized
with D-galactosamine hydrochloride (Sigma-Aldrich) via i.p. injection at a dosage
of 800 mg/kg. After 30 min of sensitization, LPS and nanoparticles were injected
intravenously. Ten mice were used in each group.
LPS neutralization eﬃcacy was also evaluated with a mouse bacteremia
model.
Specifically, 6-wk-old female C57BL/6 (The Jackson Laboratory) mice were
injected intraperitoneally with 1 ⇥ 107 CFU of uropathogenic E. Coli (UPEC)
CFT073 suspended in 100 µL of 1⇥ PBS. After 30 min, mice were randomly placed
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into two groups (n = 10), and each mouse was injected with 500 µL of M -NPs at
a concentration of 10 mg/mL in 10% sucrose solution intraperitoneally. Mice were
killed 4 h after the injection. Blood and organs were collected and homogenized
with a Mini Beadbeater-16 (BioSpec) in 1 mL of PBS. Proinflammatory cytokines in
the blood, including IL-6, TNF-↵, and IFN- , were quantified by a cytometric bead
array per manufacturer’s instructions (BD Biosciences). For bacterial enumeration,
homogenized samples were serially diluted with PBS (from 10- to 107-fold) and plated
onto agar plates. After 24 h of culture, bacterial colonies were counted. To evaluate
eﬃcacy through survival, the same experimental procedure was carried out and
survival was monitored over a period of 60 h (n = 10).
3.2.3 Results and Discussion
The preparation of M -NPs was divided into two steps. In the first step, cell
membranes from J774 mouse macrophages were derived and purified using a pro-
cess involving hypotonic lysis, mechanical disruption, and diﬀerential centrifugation.
In the second step, we used a sonication method to form membrane vesicles and
subsequently fused them onto poly(lactic-co-glycolic acid) (PLGA) cores to create
M -NPs. Following membrane fusion, the diameter of the nanoparticles measured
with dynamic light scattering (DLS) increased from 84.5 ± 1.9 nm to 102.0 ± 1.5 nm,
corresponding to the addition of a bilayered cell membrane onto the polymeric cores
(Figure 3.7B). Meanwhile, the surface zeta potential changed from -41.3 ± 3.6 mV
to -26.7 ± 3.1 mV, likely due to charge screening by the membrane. The engineered
M -NPs were stained with uranyl acetate and visualized with transmission electron
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microscopy (TEM), revealing a spherical core-shell structure, in which the PLGA core
was wrapped with a thin shell (Figure 3.7C). Following their formulation, M -NPs
were suspended in 1⇥ PBS and 50% serum, respectively, and demonstrated excellent
stability in size and membrane coating over 72 h, as monitored by DLS (Figure 3.7D).
Improved colloidal stability is attributable to the stabilizing eﬀect of hydrophilic
surface glycans on the macrophage membrane. Together, these results demonstrate
the successful coating of PLGA cores with unilamellar macrophage membranes.
Through membrane coating, M -NPs inherit key biological characteristics
of the source cells. By Western blot analysis, we verified that M -NPs maintained
critical membrane proteins responsible for LPS binding, including CD14 and TLR4
(Figure 3.7E). Representative cytokine-binding receptors were also preserved, including
CD126 and CD130 for IL-6, CD120a, and CD120b for TNF, and CD119 for IFN- .
Indeed, the membrane derivation process resulted in significant protein enrichment
for these molecules. Following i.v. administration, the systemic circulation time
of M -NPs was measured by labeling the nanoparticles with a hydrophobic DiD
fluorophore (Figure 3.7F). At 24 h and 48 h, respectively, M -NPs showed 29% and
16% retention in the blood. Based on a two-compartment model applied in previous
studies to fit nanoparticle circulation results, the elimination half-life was calculated
as 17.2 h [389, 390]. To further evaluate their potential for systemic applications,
we investigated the in vivo tissue distribution of the M -NPs (Figure 3.7G). When
analyzed per organ, M -NPs were distributed mainly in the blood and the liver. Per
gram of tissue, M -NPs were principally contained in the liver and spleen, two primary
organs of the reticuloendothelial system (RES). Meanwhile, significant fluorescence
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Figure 3.7: Formulation and characterization of macrophage membrane-coated
nanoparticles (M -NPs). (A) Schematic representation of using M -NPs to
neutralize endotoxins and proinflammatory cytokines as a two-step process for
sepsis management. (B) Hydrodynamic size (diameter, nanometers) and surface
zeta potential (⇣, millivolts) of PLGA polymeric cores before and after coating
with macrophage membrane as measured by dynamic light scat- tering (n = 6).
(C) TEM images of M -NPs negatively stained with uranyl acetate. (Scale bar:
100 nm.) (Inset) The zoomed-in view of a single M -NP. (Scale bar: 10 nm.) (D)
Stability of M -NPs in 1⇥ PBS or 50% FBS, determined by monitoring particle
size (diameter, nanometers), over a span of 72 h. (E) Representative protein
bands of macrophage cell lysate, membrane vesicles, and M -NPs resolved using
Western blotting. (F) DiD-labeled M - NPs were injected i.v. via the tail vein of
mice. At various time points, blood was collected and measured for fluorescence
(excitation/emission = 644/ 670 nm) to evaluate the systemic circulation lifetime
of the nanoparticles (n = 6). (Inset) The semilog plot of fluorescence signal at
various time points. (G) Biodistribution of the M -NPs collected by injecting
DiD-labeled M -NPs i.v. into the mice. At each time point (24, 48, and 72 h),
the organs from a randomly grouped subset of mice were collected, homogenized,
and quantified for fluorescence. Fluorescence intensity per gram of tissue and
relative signal per organ were compared (n = 6).
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was also observed in the blood. As the blood fluorescence decreased, a corresponding
increase in signal was observed in the liver, suggesting the uptake of M -NPs by the
RES over time.
We next examined the ability of M -NPs to bind to LPS, which is known to
first form high-aﬃnity complexes with LBP. These complexes then bind to TLR4
through CD14, which are both present on the cell surface of macrophages. To
test the eﬀect of LBP on LPS binding to M -NPs, we mixed the nanoparticles
with FITC-LPS conjugate, incubated the mixture at 37  C , then collected the
M -NPs by ultracentrifugation to compare their FITC fluorescence intensity to
that of the supernatant. As shown in Figure 3.8A, in the absence of LBP, nearly
80% of LPS remained in the solution. However, with addition of LBP, 90% of LPS
was pelleted into the supernatant, indicating a significant increase in binding to
M -NPs. Meanwhile, when M -ghost instead of M -NPs was used (equivalent
protein amount), the reduction of LPS was comparable, indicating the preservation
of membrane activity during nanoparticle formulation. In addition, while nonspecific
IgG from human serum showed no eﬀect to LPS binding, the amount of unbound LPS
remaining in the supernatant increased upon addition of anti-CD14 or anti-TLR4
antibodies, indicating that both macrophage PRRs mediated binding interactions
between LPS and M -NPs (Figure 3.8B). Overall, compared with macrophages,
M -NPs showed similar dependence on LBP, TLR4, and CD14 in binding with LPS,
suggesting that M -NPs inherit the biological characteristics of the source cells.
Next, we quantified the LPS removal capacity of M -NPs through two sets of
experiments. First, we fixed the quantity of M -NPs at 0.4 mg and incubated them
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Figure 3.8: In vitro LPS and proinflammatory cytokine removal with M -NPs.
(A) LPS removal with M -NPs with and without LPS binding protein (LBP)
supplemented from FBS. M ghost with an equivalent amount of protein was
included as a control to assess membrane activity loss. (B) LPS removal with
M -NPs with and without nonspecific IgG and antibodies blocking CD14 and
TLR4, respectively. (C) Quantification of LPS removal with a fixed amount of
M -NPs (0.4 mg) while varying the amount of added LPS. (D) Quantification
of LPS removal with a fixed amount of LPS (25 ng) while varying the amount
of added M -NPs. (E-G) Removal of proinflammatory cytokines, including (E)
IL-6, (F) TNF-↵, and (G) IFN- , with M -NPs. In all studies, three samples
were used in each group.
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with varying amounts of LPS (5, 10, 25, and 50 ng, respectively). After collecting
nanoparticles with ultracentrifuge, it was found that 0.4 mg M -NPs neutralized up
to 25 ng LPS (Figure 3.8C). In the second experiment, we fixed the total amount
of LPS at 25 ng and varied the amounts of M -NPs (0, 0.1, 0.2, 0.3, and 0.4 mg,
respectively). When the M -NP concentration was increased from 0.1 to 0.4 mg,
a linear decrease of LPS remaining in the supernatant was observed, with 0.4 mg
M -NPs again required to neutralize 25 ng LPS (Figure 3.8D). Together, the dual
assays indicate a removal capacity of 62.5 ng LPS per milligram of M -NPs.
The ability of M -NPs to sequester proinflammatory cytokines, including IL-6,
TNF↵, and IFN- , was also investigated. Solutions with known initial concentrations
of the cytokines were added to diﬀerent concentrations of M -NPs and incubated at
37  C for 30 min, at which time nanoparticles were removed by ultracentrifugation
and the amount of cytokine remaining in the supernatant was quantified. As shown
in Figure 3.8 E-G, 1 mg of M - NPs removed 105.1 pg of IL-6, 4.3 pg of TNF, and
6.5 pg of IFN-  from the mixture, corresponding to cytokine removal eﬃciencies of
52.6%, 11.6%, and 14.8%, respectively. When 4 mg of M -NPs was added, 194.4
pg of IL-6, 6.7 pg of TNF↵, and 13.9 pg of IFN-  were removed from the mixture,
corresponding to cytokine removal yields of 97.2%, 18.1%, and 31.6%, respectively.
Thus, M - NPs can eﬀectively sequester various types of proinflammatory cytokines
in a concentration-dependent manner.
To evaluate functional neutralization of LPS, we used engineered HEK293
TLR4 reporter cells that produce secreted embryonic alkaline phosphatase (SEAP)
in response to TLR4 activation (Figure 3.9A). When free LPS was added into
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the cell culture, pronounced TLR4 activation was observed within 5 h. However,
when LPS was incubated with M -NPs before their addition to the culture, TLR4
activation was abrogated. Incubation of LPS with RBC-NPs and PLGA nanoparticles
functionalized with synthetic polyethylene glycol (PEG-NPs) were ineﬀective in
inhibiting TLR4 activation, confirming that LPS neutralization was specific to M -
NPs. LPS induces macrophage overproduction of intracellular nitric oxide (iNO)
by inducible NO synthase [365], which triggers further inflammatory cascades in
activated cells. Macrophages incubated with free LPS showed a continual increase of
iNO, whereas LPS incubated with M -NPs was unable to enhance iNO production,
revealing a clear inhibitory eﬀect (Figure 3.9B); control RBC-NPs or PEG-NPs had
no such activity.
Endothelial cells respond to minute LPS exposures by rapidly inducing ex-
pression of the cell adhesion molecule E-selectin [391]. We incubated cultured human
umbilical vein endothelial cells (HUVECs) with LPS and quantified E-selectin expres-
sion by enzyme immunoassay. As shown in Figure 3.9C, 10 ng/mL LPS caused a
continuous increase in HUVEC E-selectin expression; but this increase was completely
blocked by coincubation with 1 mg/mL of M -NPs. Control RBC-NPs and PEG-NPs
did not inhibit the overexpression of E-selectin by HUVECs, confirming the specificity
of M -NPs in LPS neutralization. Three hours after adding LPS, cells were also
stained with antibodies to fluorescently label E- selectin. Under the microscope,
HUVECs incubated with LPS alone, LPS with RBC-NPs, and LPS with PEG-NPs,
showed strong labeling in the cytoplasmic and nuclear peripheral regions with a
fluorescent anti-E-selectin antibody; in contrast, little expression was observed on
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Figure 3.9: In vitro and in vivo LPS neutralization with M -NPs. (A-C) LPS-
inducible cell functions, including (A) TLR4 activation on HEK293 cells, (B)
intracellular nitric oxide (iNO) production from J774 macrophages, and (C)
E-selectin expression of HUVECs, were studied by stimulating corresponding
cells with LPS alone or LPS mixed with M -NPs, RBC-NPs, or PEG-NPs,
respectively. (D) Fluorescent images collected from samples in C after 4 h of
in- cubation. Cells were stained with mouse anti-human E-selectin, followed by
staining with anti-mouse IgG Alexa 488 conjugates (green) and DAPI (blue).
(Scale bars: 5 µm.) Three samples were used in each group. (E and F) For in
vivo evaluation, (E) levels of proinflammatory cytokines, including TNF-↵ and
IL-6, in plasma (n = 6) and (F) survival (n = 10) were studied after injecting
mice with LPS alone or LPS mixed with M -NPs, RBC-NPs, or PEG-NPs.
Untreated mice were also included as a control group.
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HUVECs incubated with LPS together with M -NPs (Figure 3.9D). These results
further confirm the capability of M -NPs to functionally neutralize LPS.
LPS neutralization by M -NPs in vivo was evaluated in mice by examining
inhibition of acute inflammatory responses to endotoxin. LPS (5 µg/kg) was injected
via tail vein and blood collected at various time points to measure the level of
proinflammatory cytokines, including TNF↵ and IL-6 by ELISA. Cytokine levels
reached maximums 3 h following injection of LPS alone, returning to baseline levels
by 6 h. In the treatment group where M -NPs at a dosage of 80 mg/kg were injected
immediately after LPS, no increase in cytokine levels was observed. In contrast,
when M -NP treatment was replaced with RBC-NPs or PEG- NPs, cytokine levels
followed similar kinetics to the LPS-only group. These studies demonstrate potent
and specific LPS neutralization by the M -NPs in vivo.
To further validate the in vivo LPS neutralization capability of M -NPs, we
sensitized mice to lethal eﬀects of LPS using 800 mg/kg D-galactosamine hydrochloride
[392], 30 min before LPS ± nanoparticle injection. A single dose of LPS (5 µg/kg)
caused 100% mortality in the D-galactosamine-sensitized mice within 32 h of injection.
Mice in the treatment groups (n = 10) received an i.v. injection of M -NPs, RBC-
NPs, or PEG-NPs at a dose of 200 mg/kg. In the group treated with M -NPs, 60%
of mice survived the lethal LPS challenge, whereas RBC-NPs and PEG-NPs failed to
significantly improve survival rate in the LPS-challenged mice. These results together
validate the potential of M -NPs as endotoxin bioscavengers.
Finally, the therapeutic potential of M -NPs was examined in a live infection
model of Gram-negative bacterial sepsis. Mice were challenged intraperitoneally with
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Figure 3.10: In vivo therapeutic eﬃcacy of M -NPs evaluated with a mouse
bacteremia model. (A) Survival curve of mice with bacteremia after treatment
with M -NPs (n = 10). (B) Bacteria enumeration in blood, spleen, kidney,
and liver at 4 h after M -NPs were intraperitoneally injected. (C and D)
Proinflammatory cytokines, including IL-6, TNF-↵, and IFN- , from the blood
and spleen were quantified with a cytometric bead array (ns, not significant; ⇤P
< 0.05, ⇤⇤P < 0.01).
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a lethal dose of Escherichia coli (1 ⇥ 107 cfu) and treated with either M -NPs
(300 mg/kg) or 10% sucrose solution as the vehicle control 30 min after bacterial
challenge. In this lethal challenge model, all animals in the control group treated
with sucrose solution died, whereas 4 of 10 animals treated with a single dose of
M -NPs reached the experimental endpoint of 60 h, revealing a significant survival
benefit (P < 0.05, Figure 3.10A). In another cohort of mice, we examined acute
bacterial dissemination to key organs, including the blood, spleen, kidney, and liver,
4 h after bacterial challenge ± M -NP treatment. In the blood and spleen of the
mice treated with M -NPs, bacterial counts were significantly lower compared with
those of the control group, whereas the kidney and liver from mice of both groups
showed comparable bacterial counts (Figure 3.10B). Reduction of bacterial burden in
the blood and spleen conferred by M -NPs corresponded to a significant reduction
of proinflammatory cytokines, including IL-6, TNF-↵, and IFN- , in these organs
(Figure 3.10C). Reversal of the pathologic processes of septicemia and cytokine storm
to favor improved bactericidal clearance is certainly multifactorial, but may include
reduced development of macrophage LPS tolerance by its sequestration, competitive
inhibition of immunosuppressive cytokines such as IL-10, and absorption of bacterial
cytotoxins (e.g.,E. Coli pore-forming ↵-hemolysin) or immunosuppressive factors
[e.g.,E. Coli TIR-containing protein C (TcpC)].
3.2.4 Conclusions
In summary, we have demonstrated a therapeutic potential of M -NPs for
sepsis control through an apparent two-step neutralization process: LPS neutraliza-
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tion in the first step followed by cytokine sequestration in the second step. M -NPs
function as an LPS and cytokine decoy, binding the proinflammatory factors through
their cognate PRR and cytokine receptors in a manner decoupled from signal trans-
duction and transcriptional activation of macrophage inflammatory cascades. By thus
inhibiting the systemic inflammatory response, M -NPs confer a significant survival
benefit during septic shock. Unlike conventional endotoxin neutralization agents that
compete with endotoxin binding pathways and may be associated with significant
clinical toxicity, M -NPs take advantage of the common functionality of endo- toxin
binding to macrophages, allowing for a “universal” neutralization approach across dif-
ferent Gram-negative bacterial genus, species, and strains. The top-down fabrication
of M -NPs eﬀecively replicates endotoxin-binding motifs on the target cells that are
otherwise diﬃcult to identify, purify, and conjugate. Coating macrophage membranes
onto nanoparticle surfaces significantly increases the surface-to-volume ratio of given
membrane materials, which is critical for eﬃcient endotoxin neutralization.
In theory, similar first-step benefits as an adjunctive therapeutic agent could be
aﬀorded by M -NPs against Gram-positive bacterial sepsis pathogens, by scavenging
lipoteichoic acids and peptidoglycan via cognate PRRs TLR2/6, or fungal sepsis
pathogens, by scavenging cell wall  -glucans with cognate PRR Dectin-1; although
these indications remain to be studied in the manner undertaken with LPS/E. coli
in the current paper. Moreover, in septic shock caused by any pathogen, second-
step cytokine sequestration properties could be seen to mitigate the pathologic
damage of cytokine storm. Given a likely i.v. route of administration, however,
the pharmacodynamics eﬃcacy of M -NPs against tissue foci of infection such as
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pneumonia, peritonitis, or bone/soft tissue infections would have to be validated.
Meanwhile, novel LPS-binding ligands have been engineered and applied for endotoxin
neutralization and detoxification in sepsis [393]. With a lipid-like structure, they
can be introduced onto M -NPs through methods such as lipid insertion [394] or
membrane hybridization [395], both of which have been validated for functionalizing
nanoparticles coated with diﬀerent cell membranes. Overall, M -NPs represent
a promising biomimetic detoxification strategy that may ultimately improve the
clinical outcome of sepsis patients, potentially shifting the current paradigm of clinical
detoxification therapy.
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3.3 Biomimetic Platelet-Camouflaged Nanorobots
for Binding and Isolation of Biological Threats
3.3.1 Introduction
Robots have become commonplace in today’s world through their application
to diverse domains such as manufacturing, service, defense, and healthcare. These
automated devices can locomote themselves and perform diﬀerent tasks in various
environments across diﬀerent scales. The eﬃcient locomotion capacity and advanced
biological functionality of natural microscopic subjects, such as motile cells like
leukocyte and spermatozoa, have inspired scientists to recreate this form of locomotion
and function using artificial robots with similar dimensions. Over the last decade,
considerable progress in materials science and nanotechnology has led to remarkable
advances in the development and operation of manmade nanorobots mimicking
their natural counterparts. [396–405] Synthetic nanorobots based on a variety of
materials and nanostructures have demonstrated eﬃcient locomotion capacity by
harvesting thrust from either localized chemical reactions or from external stimuli.
[406–412] Like their natural counterparts, these versatile manmade nanorobots possess
advanced locomotive capabilities, including precise speed egulation and spatial motion
control, along with self-organization and collective movement, allowing for tremendous
potential applications, ranging from targeted drug delivery, [413–415] to environmental
remediation, [416, 417] and nanoscale manipulations for lithography and imaging.
[418,419] As advanced nanorobot capabilities are being developed, proper attention
must be given to overcome key challenges for their operation in real-life biological
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environments. [420,421] Although some types of nanorobots have been functionalized
with various bioreceptors for imparting specific recognition of target biomolecules,
[422] the viability of these nanorobots relies largely on synthetic nanomaterials,
which are susceptible to immune response or biofouling processes in physiological
systems, and may eventually hinder their eﬀectiveness. Therefore, new bioinspired
and bioengineered approaches, based on the incorporation of natural materials into
the nanorobot design, may provide a unique and robust means to address these
limitations associated with synthetic materials.
Biomimetic design approaches have recently emerged as a novel paradigm
to address the aforementioned limitations of synthetic nanomaterials for biomedical
operation. [423, 424] By taking inspiration from nature, especially the circulating
cells such as erythrocytes, leukocytes, and platelets, essential biological functions
of these natural cells can be potentially imparted into synthetic systems. One
exciting research area is to mimic cellular membranes, which play very important
roles in cells’ biointerfacing with the incredibly complex biological environment.
Particularly, human platelets have inspired the design of functional nanocarriers owing
to their many functions responsible for immune evasion, [425,426] subendothelium
adhesion, [427, 428] pathogen interactions, [429, 430] as well as their essential role
in hemostasis. [431] Therefore, the platelet membrane cloaking method, that is
wrapping natural platelet cell membranes onto the surface of synthetic nanostructures
and nanodevices, has provided a new attractive approach for developing functional
nanoparticles with a bioengineered interface for diverse biomedical applications. [432]
Here we demonstrate the preparation of platelet-membrane- cloaked nanomo-
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tors (denoted “PL-motors”), by enclosing magnetic helical nanomotors with the plasma
membrane of human platelets, for adsorption and isolation of platelet-targeted biolog-
ical agents (Figure 3.11A). The PL-motors are synthesized using a template-assisted
electrochemical deposition method followed by a cell membrane cloaking technique.
The prepared PL-motors possess a membrane coating containing a wide variety of
functional proteins associated with platelets. Magnetic propulsion oﬀers fuel-free
remote actuation and navigation abilities desired of biomimetic nanomotors. [398]
Bridging the biological functions of platelet membrane with the locomotion capac-
ity of synthetic nanomotors thus results in a powerful dynamic biomimetic system.
The PL-motors oﬀer remarkable biocompatibility and eﬃcient propulsion in various
untreated biological fluids. Significantly, these platelet-mimicking nanomotors can
evade the body’s immune system and display a rapid locomotion in whole blood with
no apparent biofouling, mimicking the movement of natural motile cells. Moreover,
coupling the eﬃcient propulsion of these biomimetic nanomotors with the unique
surface chemistry properties of natural platelets enables attractive detoxification
capabilities. To exemplify their biological function, we demonstrate that the PL-
motors can be used to eﬀectively adsorb Shiga toxin (Stx) using a Vero cell assay
(VCA), resulting from the strong platelet-Stx binding enabled by the protein receptors
presented on the platelet membrane. The PL-motors display also enhanced binding
to platelet- adhering pathogens, which can be used for rapid bacteria isolation or
targeted drug delivery. These platelet-membrane- camouflaged nanomotors with
advanced fuel-free locomotion capabilities are thus expected to dramatically expand
the domain of biomedical nanorobotic operations in physiological systems and to
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open new opportunities to nanomedicine.
3.3.2 Experimental Methods
Preparation and Characterization of PL-Motors
The PL-motors were prepared by enclosing magnetic helical nanomotors
with the plasma membrane of human platelets. Platelet membrane derivation was
performed as previously described. [432] Briefly, platelets were isolated from whole
blood and then resuspended in PBS mixed with protease inhibitor tablets. The whole
blood we used was human type O-blood with 1.5 mg mL 1 EDTA purchased from
BioreclamationIVT. The platelet membrane was derived by a repeated freeze-thaw
process and washed by centrifugation in PBS solution mixed with protease inhibitor
tablets. Aliquots of platelet suspensions were first frozen at -80  C , thawed at room
temperature, and pelleted by centrifugation at 4000 ⇥ g for 3 min. Following three
repeated washes, the pelleted platelet membranes were suspended in water and stored
at -80  C until use.
Helical nanomotors were synthesized using a template-assisted electrochemical
deposition method. Before electrochemical deposition, a 75 nm gold film was sputtered
on one side of a 400 nm pore size polycarbonate (Millipore, HTTP02500) membrane
to serve as a working electrode using the Denton Discovery 18 (Moorestown, NJ,
USA). A Pt wire and an Ag/AgCl (with 1 M KCl) were used as counter and reference
electrodes, respectively. The sputtered membrane was then assembled in a plating
cell with an aluminum foil serving as a contact. All electrochemical deposition steps
were carried out at room temperature (22 C ). Pd/Cu nanorods were deposited at -0.1
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pathogen interactions,[34,35] as well as their essential role in 
hemostasis.[36] Therefore, the platelet membrane cloaking 
method, that is wrapping natural platelet cell membranes onto 
the surface of synthetic nanostructures and nanodevices, has 
provided a new attractive approach for developing functional 
nanoparticles with a bioengineered interface for diverse bio-
medical applications.[37]
Here we demonstrate the preparation of platelet-membrane-
cloaked nanomotors (denoted “PL-motors”), by enclosing 
magnetic helical nanomotors with the plasma membrane of 
human platelets, for adsorption and isolation of platelet-targeted 
biological agents (Figure 1A). The PL-motors are synthesized 
using a template-assisted electrochemical deposition method 
followed by a cell membrane cloaking technique. The pre-
pared PL-motors possess a membrane coating containing a 
wide variety of functional proteins associated with platelets. 
Magnetic propulsion offers fuel-free remote actuation and navi-
gation abilities desired of biomimetic nanomotors.[3] Bridging 
the biological functions of platelet membrane with the locomo-
tion capacity of synthetic nanomotors thus results in a powerful 
dynamic biomimetic system. The PL-motors offer remarkable 
biocompatibility and efficient propulsion in various untreated 
biological fluids. Significantly, these platelet-mimicking 
nanomotors can evade the body’s immune system and display 
a rapid locomotion in whole blood with no apparent biofouling, 
mimicking the movement of natural motile cells. Moreover, cou-
pling the efficient propulsion of these biomimetic nanomotors 
with the unique surface chemistry properties of natural plate-
lets enables attractive detoxification capabilities. To exemplify 
their biological function, we demonstrate that the PL-motors 
can be used to effectively adsorb Shiga toxin (Stx) using a Vero 
cell assay (VCA), resulting from the strong platelet-Stx binding 
enabled by the protein receptors presented on the platelet mem-
brane. The PL-motors display also enhanced binding to platelet-
adhering pathogens, which can be used for rapid bacteria 
isolation or targeted drug delivery. These platelet-membrane-
camouflaged nanomotors with advanced fuel-free locomotion 
capabilities are thus expected to dramatically expand the domain 
of biomedical nanorobotic operations in physiological systems 
and to open new opportunities to nanomedicine.
To obtain the nanostructures with desired geometric configu-
ration and material components, we combine template-assisted 
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Figure 1. Preparation and characterization of platelet-membrane-cloaked magnetic helical nanomotors (denoted “PL-motors”). A) Schematic of 
PL-motors for binding and isolation of platelet-specific toxins and pathogens. B) Preparation of PL-motors: i) Pd/Cu co-electrodeposition in a poly-
carbonate membrane with pore size of 400 nm. ii) Dissolution of Cu using nitric acid and release of the helical Pd nanostructures. iii) Deposition of 
Ni/Au bilayer on the Pd helical nanostructure. iv) Collection of the helical nanostructures. v) Modification of the bare helical nanomotor surface with 
3-mercaptopropionic acid (MPA). vi) Fusion of platelet-membrane-derived vesicles (denoted “PL-vesicles”) to the MPA-modified surface of the helical 
nanomotor. C) Representative SEM images of the fabricated bare nanomotors without platelet coating (left) and PL-motors (right). Scale bars, 100 nm. 
D) Fluorescent images of PL-motors covered with rhodamine-labeled platelet membranes. Scale bars, 20 µm (left) and 1 µm (right). E) Fluorescence 
quenching assay to determine the platelet membrane coverage of the PL-motors. Fluorescence spectra of i) FITC-thiol only, ii) FITC-thiol and PL-motor 
mixture, and iii) FITC-thiol and bare motor mixture. F) The measured weight of protein content on bare motors and PL-motors (both 10 mg mL−1) 
stored in 1X PBS at 4 °C for 24 h. Error bars represent the standard deviation from three different measurements. UD, undetectable. G) Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS–PAGE) analysis of proteins presents on the PL-vesicles and the PL-motors. The samples were run at 
equal protein content and stained with Coomassie Blue.
Fi ure 3.11: Preparation and charact rization of platelet-membrane-cloake
magnetic helical nanomotors (denoted “PL-motors”). (A) Schematic of PL-
motors for binding and isolation of platelet-specific toxins and pathogens. (B)
Prep ration of PL-moto s: i) Pd/Cu co-electrodeposition in polyca bonate
membrane with pore size of 400 nm. ii) Dissolution of Cu using nitric acid and
release of th helical Pd nanostr ctur s. iii) Dep sition of Ni/Au bilayer on
the Pd helical nanostructure. iv) Collection of the helical nanostructures. v)
Modific tion of the bare helical nanomotor surface with 3-mercaptopropionic acid
(MPA). vi) Fusion of platelet-membrane-derived vesicles (denoted “PL-vesicles”)
to the MPA-modified surface of the helical nanomotor. (C) Representative SEM
images of the fabricated bare nanomotors without platelet coating (left) and
PL-motors (right). Scale bars, 100 nm. (D) Fluoresce t imag s f PL-m tors
covered with rhodamin -labeled platelet embranes. Scal bars, 20 µm (left)
and 1 µm (right). (E) Fluorescence quenching assay to determine the platelet
membrane coverage of the PL-motors. Fluorescence spectra of i) FITC-thiol only,
ii) FITC-thiol and PL-motor mixture, and iii) FITC-thiol and bare motor mixture.
(F) The measured weight of protein content on bar motors and PL-motors (both
10 mg mL 1) stored in 1X PBS at 4  C for 24 h. Error bars represent the
standard deviation from three diﬀerent measurements. UD, undetectable. (G)
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis
of roteins presents on he PL-vesicles and the PL-mo ors. The samples were
run at equal protein content and stained with Coomassie Blue.
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V from the PdCl2/Cu Cl2 plating solution mixture containing 20 ⇥ 10 3 M Cu Cl2,
30 ⇥ 10 3 M Pd Cl2, and 0.1 M HCl with a total charge of 3C. After electrochemical
deposition, the sputtered gold layer was completely removed by hand polishing with
3-4 micro m alumina slurry. The templates were dissolved in methylene chloride
for 10 min to completely release the nanostructures. The latter were collected by
centrifugation at 9000 rpm for 3 min and washed three times with methylene chloride,
ethanol, and deionized water each, with a 3 min centrifugation after each wash. Then
the Cu (of the Pd/Cu nanorods) was dissolved using an 8 M HNO3 solution for 10
min, resulting in the formation of Pd nanohelices with 400 nm diameter and 3-5
µm length. The Pd nanostructures were then dispersed on glass slides, and coated
with a 5 nm thick Ni layer by electron beam evaporation (using a deposition speed
of 0.05 nm s 1), and sputtered with a 5 nm Au layer. Afterward, the resulting
magnetic nanomotors were incubated overnight with MPA (Sigma-Aldrich). Then,
the MPA-modified helical nanomotors were incubated with platelet-membrane-derived
vesicles (diameter 50-100 nm) under ultrasonication for 20 min. Scanning electron
microscopy (SEM) images of bare helical nanomotors and PL-motors were obtained
with a Phillips XL30 environmental scanning electron microscope (ESEM) instrument,
using an acceleration voltage of 10 kV.
To further confirm the presence and cloaking of platelet membrane onto the
surface of the motors, Platelet vesicles were labeled with DMPE-RhB (Avanti Polar
Lipids, Inc.) and then incubated with the helical nanomotors. Fluorescence mi-
croscopy images were captured using EVOS FL, fluorescence microscope coupled with
a 20⇥ and 40⇥ microscope objectives and fluorescence filter with red light excitation.
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The fluorescence quenching assay to determine the platelet membrane coverage of
the PL-motors was performed by incubating the PL-motors with a thiolated fluo-
rescent ligand made of a synthesized FITC-thiol conjugate probe, and measuring
the fluorescence spectra of the FITC-thiol, FITC-thiol, and PL-motor mixture, and
FITC-thiol and bare motor mixture, at 520 nm by a Tecan Infinite M200 microplate
reader. The thiolated fluorescent probe was prepared by first conjugating FITC to
cysteamine 4-methoxytrityl resin (EMD Millipore) through N-hydroxysuccinimide
(Thermo Scientific)-mediated amine coupling, followed by trifluoroacetic acid treat-
ment to cleave the conjugate from the resin. To determine the protein content of the
PL-motors, 10 mg mL 1 of both bare motors and PL-motors were centrifuged and
resuspended with 1X PBS for three times, and a BCA colorimetric assay (Thermo
Scientific) was used to determine the protein content. Briefly, the purple-colored
reaction product of this assay is formed by the chelation of two molecules of BCA with
one cuprous ion, and this water-soluble complex exhibits a strong absorbance at 562
nm that is nearly linear with increasing protein concentrations. Gel electrophoresis
followed by protein staining with Coomassie Blue was also performed. The PL-vesicle
and PL-motor samples containing equivalent total proteins were prepared in lithium
dodecyl sulfate sample loading buﬀer (Invitrogen). The samples were then sepa-
rated on a 4-12% Bis-Tris 17-well minigel in 3-(N-Morpholino)propanesulfonic acid
(MOPS) running buﬀer using a Novex Xcell SureLock Electrophoresis System (Life
Technologies). Finally, the protein columns were stained according to manufacturer’s
protocol.
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Propulsion of PL-Motors
A Helmholtz coil pair was used to generate the magnetic rotation field for
remote actuation. The frequency of the rotating magnetic field (15 mT) can be
changed from 1 to 1000 Hz by a sinusoidal wave generator. The above magnetic
nanohelices were dispersed in water droplets for rotation and translation motion tests.
An inverted optical microscope (Nikon Instrument Inc. Ti-S/L100), coupled 20⇥
and 40⇥ objectives, a Hamamatsu digital camera C11440 and NIS Elements AR 3.2
software, were used for capturing movies of the swimming motion. The speed of the
nanoswimmers was tracked using an NIS Elements tracking module (n = 20).
Shiga Toxin (Stx) Binding and Neutralization
To examine the adhesion of PL-motors with Shiga toxin (Stx), Stx (Toxin
Technology, INC, lot# 62411V1) was labeled with fluorescein dye (FITC) following
the specifications of a commercial FITC Labeling kit (MarkerGene, M0955). To
evaluate the adhesion of Stx-FITC to PL-motors, 1 mg of PL-motors were immersed
in the FITC-labeled Stx solution or in FITC dye solution (used as negative control)
for 20 min under magnetic actuation (55 Hz, 15 mT). The fluorescence intensity
corresponding to the Stx-FITC or FITC solutions was then measured (at 495 nm),
before and after the PL-motors binding process, in order to calculate the amount of
bound toxin. After the 20 min magnetic actuation, fluorescence microscopy images
of the Stx-FITC@PL-motors and FITC dye solutions were taken, using EVOS FL
microscope coupled with a 20⇥ and 40⇥ microscope objectives and a fluorescence
filter with green light excitation. Furthermore, cellular toxicity was studied using a
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Vero cell assay. To perform this experiment, fixed amounts of Stx (150 µL of 100
µg mL 1 dissolved in PBS buﬀer were mixed with equal amounts of PBS buﬀer
containing 1 mg PL-motors, 1 mg bare motors (without platelet coating), or 0.07 mg
PL-vesicles (containing equivalent proteins to 1 mg PL-motors). The positive and
negative controls were PBS buﬀer with and without Stx, respectively. All the added
toxin formulations have a final Stx concentration of 100 µg mL 1 along with a final
volume of 150 µL. All samples were treated for 20 min under magnetic field (55 Hz,
15 mT), after which each formulation was added to Vero cell cultured wells (1.2 ⇥
105 cells per well, n = 3 for each formulation) and incubated for 48 h. After the 48 h
incubation, the cell viability was assessed using the CellTiter 96 Cell Proliferation
Assay (Promega Corporation), based on an MTS tetrazolium compound. In brief,
10 µL of the MTS reagent were added into each well, mixed gently, and incubated
at 37  C for 4 h in a humidified CO2 incubator. This was followed by reading the
absorbance of the 96 well- plate at 490 nm using a plate reader. The quantity of
formazan product as measured by Abs at 490 nm was directly proportional to the
number of living cells. Microscopy images of Vero cells after the corresponding 48 h
incubations were captured using an EVOS FL microscope coupled with a 20⇥ and
40⇥ microscope objectives.
Staphylococcus Aureus (MRSA252) Bacteria Adherence and Isolation
MRSA252 obtained from the American Type Culture Collection was cultured
on tryptic soy broth (TSB) agar (Becton, Dickinson and Company) overnight at 37  C .
A single colony was inoculated in TSB medium at 37  C in a rotary shaker. Overnight
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culture was refreshed in TSB medium at a 1:100 dilution at 37  C under shaking for
another 3 h until the OD600 of the culture medium reached ⇡ 1.0 (logarithmic growth
phase). The bacteria were washed and suspended in sterile PBS to a concentration
of 1 ⇥ 108 CFU mL 1. For the nanomotor adhesion study, aliquots of 0.8 mL of
1 ⇥ 108 CFU mL 1 MRSA252 were mixed with 1 mL of 100 mg mL 1 PL-motor,
1 mL of 100 mg mL 1 bare motors, 1 mL of 7.5 mg mL 1 PL-vesicle, or 1 mL of
PBS for 20 min magnetic actuation at room temperature. The suspensions were then
left 30 min at room temperature to have the precipitate settle down with a magnet
placed below the suspension. After removal of the supernatant, the collected pellets
were resuspended in PBS buﬀer and then fixed with formalin and stained with DAPI
subsequently for fluorescence analysis, fluorescence microscopy imaging, and SEM
imaging.
3.3.3 Results and Discussion
To obtain the nanostructures with desired geometric configuration and material
components, we combine template-assisted electrodeposition and cell membrane cloak-
ing techniques to prepare the PL-motors (Figure 3.11B). First of all, Pd nanohelices,
with a diameter of 400 nm and length of 3-5 µm, were synthesized by a template-
assisted electrochemical deposition method, followed by segment-selective chemical
etching. [433,434] The Pd nanohelices were then coated with a 5 nm thick nickel layer
and a 5 nm gold layer by electron beam evaporation and sputter, respectively. The
resulting bare magnetic nanomotors undergo an ex situ stabilization by overnight
incubation with 3-mercaptopropionic acid (MPA) to introduce negative charges onto
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the gold surface, thus allowing the platelet membranes to coat on the negatively
charged gold surface of the nanomotor. [435] The resulting nanomotors were sub-
sequently incubated with platelet-membrane-derived vesicles (diameter 50-100 nm)
under ultrasonication. The small nanoscale platelet vesicles, with high surface energy,
tend to bind and fuse onto the negatively charged gold surface to minimize the free en-
ergy of the system. The ultrasonic mixing further enhanced the adsorption of platelet
vesicles onto the gold surface of the nanomotors. This fusion process allowed for the
retention of the bilayer structure of the platelet membrane and for the preservation
of its protein function. In addition, due to the large asymmetric negative charge
between the ectoplasmic and cytoplasmic surfaces of the platelet membranes, the
outer surface of the platelet membrane is much more negatively charged than the inner
surface. Therefore, electrostatic repulsion allowed the platelet vesicles to fuse onto the
negatively charged motors at the right-side-out orientation of the membranes, which
was similar to what has been observed using platelet-membrane-coated polymeric
nanoparticle system. [432]
Figure 3.11C shows the scanning electron microscopy (SEM) images of bare
helical nanomotors and PL-motors. The characteristic shape of the PL-motors, with
their periodic helical structure, is not aﬀected by the platelet coating, which is expected
from the negligible thickness of the lipid bilayer on 400 nm diameter gold nanomotors.
To further confirm the presence and cloaking of platelet membrane onto the surface
of the motor, platelet-membrane-derived vesicles were labeled with 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine-N-lissamine rhodamine B sulfonyl (DMPE-RhB)
prior to being coated on the nanomotors. Full coverage of the helical motors is
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illustrated in the fluorescence microscopy images in Figure 3.11D, indicating the
successful incorporation of DMPE-RhB-labeled platelet vesicles onto the PL-motors.
To further evaluate the completeness of membrane coverage on the motor surface, we
studied the interactions between the PL-motors and a thiolated fluorescent ligand
using a synthesized fluorescein isothiocyanate (FITC)-thiol conjugate probe. [436] As
shown in Figure 3.11E, at the emission peak of 520 nm of the FITC-thiol, the bare
motors incubated with the fluorescent probe exhibited a greatly reduced fluorescence
intensity in comparison with free FITC-thiol, indicating the presence of fluorescence
quenching resulted from the bare gold surface of the motors. Such a noticeable
quenching eﬀect is absent in the PL-motors incubated with the FITC-thiol. These
results clearly indicate high coverage of platelet membrane on the surface of the
nanomotors, which eﬀectively shields the FITC-thiol probe from being quenched by
the gold layer on the bare motors.
Next, the platelet membrane coating on the nanomotors was investigated
in terms of its protein content. PL-motors were centrifuged and resuspended with
1X phosphate buﬀer saline (PBS) for three times to remove uncoated vesicles and
obtain purified PL-motors. A bicinchoninic acid (BCA) protein assay was used to
quantitatively measure the level of the membrane protein on the nanomotor surface.
As shown in Figure 3.11F, PL-motors exhibited an increase in absorbance at 562
nm indicating the presence of protein content, which was further quantified to be
0.72 ± 0.10 mg mL 1 using a protein standard curve. In contrast, no detectable
absorbance was observed for the bare nanomotors at the same motor concentration
(10 mg mL 1), suggesting no protein was found. Furthermore, gel electrophoresis
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followed by protein staining showed the protein profile of the purified platelet vesicles
and PL-motors (Figure 3.11G). The protein profile of PL-motors matched closely to
the platelet membrane vesicles which evidently demonstrated that platelet membrane
can translocate to the nanomotors and that the preparation of PL-motors did not
alter the profile of platelet membrane proteins.
An important feature of the platelet-mimicking nanomotors is their ability
to resist biofouling, thus ensuring lasting and eﬃcient propulsion of the motor in
biological fluids. After having evaluated the preparation and characteristics of PL-
motors, it is important to test their propulsion performance and antifouling property
in various complex biological environments. The 5 s tracking of PL-motor movement in
Figure 3.12A showcases the motor’s propulsion performance in water, plasma, serum,
and whole blood, respectively. Although the viscosity of each environment aﬀects
the propulsion, the resulting movement remains eﬀective for PL-motor operation
in biological environments, including whole blood. Figure 3.12B compares the
propulsion performance of the PL-motors and of bare nanomotors in diﬀerent media.
It is observed that although their speeds are almost equal in water, the speeds
of PL-motors in plasma, serum, and whole blood are significantly faster than the
speeds of the bare nanomotors in the same solutions. The layer of natural platelet
membrane covering the nanomotors enables their biocompatible and stable operation
in whole blood with no apparent biofouling eﬀects over prolonged periods of time.
The 10 s tracking trajectory, shown in Figure 3.12C, illustrates the movement of a
bare nanomotor in whole blood, which displays slow propulsion at a speed of ⇡ 6
µs 1. The propulsion is further hindered after incubation of the bare nanomotors in
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whole blood for 1 h. Apparently the bare nanomotors undergo severe protein fouling,
which dramatically hinders their propulsion eﬃency. In contrast, the PL-motors
display long-term eﬃcient magnetic propulsion in whole blood. The 10 s tracking
trajectories in Figure 3.12D (demonstrate the magnetic propulsion of PL-motors
in whole blood at 0 and 60 min, respectively. These images illustrate no apparent
diminution of the propulsion eﬃciency over the prolonged actuation in whole blood.
Such eﬀective resistance to biofouling and propulsion behavior of the PL-motors were
further evaluated by incubating them in undiluted whole blood for 48 h. The 10 s
tracking trajectories in Figure 3.12E illustrate the movement of the PL-motors before
and after such 48 h incubation. These data indicate that the PL-motors maintain
eﬃcient propulsion at similar speeds after such prolonged incubation, indicating that
biofouling eﬀects are negligible. Apparently, the platelet membrane coating shields
the nanomotor from biofouling eﬀects in untreated biological fluids.
The therapeutic potential of PL-motors was first evaluated by assessing their
selective binding and rapid isolation of Shiga toxin (Stx), a toxin produced by Es-
cherichia coli that can induce hemolytic uremic syndrome. [437, 438] Shiga and
Shiga-like toxins can bind platelets via specific glycosphingolipid receptors, while
such binding further contributes to the thrombocytopenia, platelet activation, and
microthrombus formation observed in hemolytic-uremic syndrome. [439] To charac-
terize the binding of the Stx with the PL-motors, Stx is labeled with fluorescein
(FITC) and then incubated with PL-motors for a 20 min magnetic actuation. Equal
amount of FITC dye (without Stx conjugation) for nonspecific staining was used as
a negative control. The amount of Stx absorbed on the PL-motors was calculated
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at similar speeds after such prolonged incubation, indicating 
that biofouling effects are negligible. Apparently, the platelet 
membrane coating shields the nanomotor from biofouling 
effects in untreated biological fluids.
The therapeutic potential of PL-motors was first evaluated 
by assessing their selective binding and rapid isolation of Shiga 
toxin (Stx), a toxin produced by Escherichia coli that can induce 
hemolytic uremic syndrome.[42,43] Shiga and Shiga-like toxins 
can bind platelets via specific glycosphingolipid receptors, while 
such binding further contributes to the thrombocytopenia, 
platelet activation, and microthrombus formation observed in 
hemolytic-uremic syndrome.[44] To characterize the binding of 
the Stx with the PL-motors, Stx is labeled with fluorescein (FITC) 
and then incubated with PL-motors for a 20 min magnetic actu-
ation. Equal amount of FITC dye (without Stx conjugation) for 
nonspecific staining was used as a negative control. The amount 
of Stx absorbed on the PL-motors was calculated by measuring 
the Stx-FITC fluorescence intensity before and after incubation 
with PL-motors. As displayed in Figure 3A, a 51% of fluores-
cence intensity decrease in the Stx-FITC conjugate solution was 
measured, compared to only 15% decrease in the FITC dye with 
same amount of PL-motors. Figure 3B displays fluorescence 
microscopy images of the PL-motors after 20 min propulsion 
in the Stx-FITC and FITC solution, respectively. A significantly 
stronger fluorescence binding was observed for the PL-motors 
in the Stx-FITC solution. These results confirm the effective and 
selective binding of the PL-motors to the Shiga toxin.
To further examine the binding of Stx to PL-motors and the suc-
cessful toxin neutralization, cellular cytotoxicity was studied using 
a Vero cell assay, as Stx is cytotoxic in the VCA from 10 pg mL−1 
and above.[45] Experiments were performed by mixing the Stx 
toxin solution with equal amounts of PBS buffer containing 
1 mg PL-motors, 1 mg bare motors (without platelet coating), or 
0.07 mg platelet vesicles. Based on the protein weight measure-
ment displayed in Figure 1F, 0.07 mg platelet vesicles—which 
contain equivalent proteins to those in 1 mg PL-motors—are 
used as static control (without magnetic actuation) of PL-motors. 
The resulting Stx toxin concentration in the above three solu-
tions was 100 µg mL−1. PBS buffer with and without toxin was 
also added as positive and negative control, respectively. After 
20 min of magnetic operation, all of the five formulations were 
added to Vero cell cultured wells for 48 h incubation. Cell via-
bility was then accessed by an (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) 
assay following the manufacturer’s protocol. As illustrated in 
Figure 3C, the PL-motors treated formulation displayed a cell 
viability of 92%, which is comparable with the PBS buffer control 
without toxin. In contrast, the viability of bare nanomotors and 
static platelet vesicles (containing equivalent proteins to those 
in the PL-motors, but without active motion) was only 21% and 
31%, respectively. Figure 3D displays the microscopy images 
showing the morphology of the Vero cells after 48 h incubation 
with the four formulations. It is clearly observed that the Vero 
cells are healthy for the formulation treated by the PL-motors, 
while all other three formulations induce severe damage and 
lysis to the cells. By cloaking platelet vesicles on the magnetic 
nanomotors, the PL-motors can serve as moving decoys that 
attract toxins for cell protection by diverting the toxins away from 
the cell target and rendering the environment nontoxic to cells. 
It is estimated that each PL-motor could adsorb ≈1.9 × 103 units 
of Stx. In addition, under magnetic actuation, the large-scale col-
lective location of the PL-motors can dramatically accelerate their 
binding with Stx, thus enhancing the adsorption process.
We further examined the therapeutic potential of PL-motors 
for binding and isolation of platelet-adhering pathogens. Oppor-
tunistic bacteria, including several strains of staphylococci and 
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Figure 2. Propulsion performance and anti-biofouling capability of PL-motors. A) Tracking trajectories showing the propulsion of PL-motors in various 
media over a timeframe of 5 s. B) Speed comparison of PL-motors with bare helical nanomotors (without platelet membrane coating) in various media. 
C) 10 s tracking showing the propulsion of a bare motor in whole blood at the beginning and after 60 min. D) 10 s tracking showing the propulsion 
of a PL-motor in whole blood at the beginning and after 60 min. E) 10 s tracking showing the propulsion of a PL-motor in whole blood without being 
incubated in the blood and with a 48 h incubation in the blood. Scale bars, 10 µm. The nanomotors were propelled using a frequency of 55 Hz and a 
magnetic field strength of 15 mT. Speed data are averaged for 20 nanomotors under the same conditions.
Figure 3.12: Propulsion performance and anti-biofouling capability of PL-
motors. (A) Tracking trajectories sh wing th propulsion of PL-motors in various
media over a timeframe of 5 s. (B) Speed comparison of PL-motors with bare
helical nanomotors (without platelet embrane coating) in various media. (C) 10
s tracking showing the propulsion of a bare motor in whole blood at the beginning
and after 60 min. (D) 10 s tracking showing the propulsion of a PL-motor in
whole blood at the beginning and after 60 min. (E) 10 s tracking showing the
propulsion of a PL-motor in whole blood without bei g incubated in the blood
and with a 48 h incubation in the blood. Scale bars, 10 µm. The na omotors
were propelled using a frequency of 55 Hz and a magnetic field strength of 15
mT. Speed data are averaged for 20 nanomotors under the same conditions.
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by measuring the Stx-FITC fluorescence intensity before and after incubation with
PL-motors. As displayed in Figure 3.13A, a 51% of fluorescence intensity decrease in
the Stx-FITC conjugate solution was measured, compared to only 15% decrease in
the FITC dye with same amount of PL-motors. Figure 3.13B displays fluorescence
microscopy images of the PL-motors after 20 min propulsion in the Stx-FITC and
FITC solution, respectively. A significantly stronger fluorescence binding was observed
for the PL-motors in the Stx-FITC solution. These results confirm the eﬀective and
selective binding of the PL-motors to the Shiga toxin.
To further examine the binding of Stx to PL-motors and the successful toxin
neutralization, cellular cytotoxicity was studied using a Vero cell assay, as Stx is
cytotoxic in the VCA from 10 pg mL 1 and above. [440] Experiments were performed
by mixing the Stx toxin solution with equal amounts of PBS buﬀer containing 1 mg
PL-motors, 1 mg bare motors (without platelet coating), or 0.07 mg platelet vesicles.
Based on the protein weight measurement displayed in Figure 3.11F, 0.07 mg platelet
vesicles, which contain equivalent proteins to those in 1 mg PL-motors are used as
static control (without magnetic actuation) of PL-motors. The resulting Stx toxin
concentration in the above three solutions was 100 µg mL 1. PBS buﬀer with and
without toxin was also added as positive and negative control, respectively. After 20
min of magnetic operation, all of the five formulations were added to Vero cell cultured
wells for 48 h incubation. Cell viability was then accessed by an (3-(4,5-dimethylthiazol-
2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay
following the manufacturer’s protocol. As illustrated in Figure 3.13C, the PL-motors
treated formulation displayed a cell viability of 92%, which is comparable with the
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streptococci, are able to bind to platelets either directly through 
a bacterial surface protein or indirectly by a plasma bridging 
molecule that links bacterial and platelet surface receptors.[46,47] 
Such bacteria–platelet interactions further lead to immune 
evasion and bacteremia.[35] MRSA252, a strain of methicillin-
resistant Staphylococcus aureus (MRSA) expressing a serine-rich 
adhesin for platelets (SraP) which can bind to platelets,[48] was 
used as a model pathogen for PL-motor adhesion study. After 
20 min of incubation and magnetic actuation of the PL-motors 
(1 mg) in MRSA252 suspension (1 × 108 colony-forming units 
(CFU) mL−1), the PL-motors were recollected through precipita-
tion with a magnet. Bare motors and PL-vesicles were used as 
negative and static (without magnetic actuation) controls. The 
retained bacteria on the collected pellets were fixed with for-
malin and stained with 4′,6-diamidino-2-phenylindole (DAPI) 
subsequently. Figure 4A displays microscopy images, showing 
the binding of the DAPI-stained bacteria on a DMPE-RhB-
labeled PL-motor. Bare motors and PL-vesicles showed negli-
gible increase of the DAPI signal compared to the PBS control 
of Figure 4B. On the other hand, PL-motors exhibit a tenfold 
increase in DAPI fluorescence intensity compared to all other 
groups, which manifests a significant adhesion of the bacteria 
to PL-motors. It is estimated that each PL-motor can capture 
≈ 15 bacteria. The SEM images in Figure 4C also clearly show 
the preferential binding of the bacteria to the PL-motors, while 
the microscopy image in Figure 4D displays “on-the-fly” isola-
tion of a bacterium by a PL-motor. This new nanorobot plat-
form thus presents a unique approach for achieving rapid, 
direct, and real-time isolation of pathogens.
In summary, we have developed a unique PL-motor system, 
based on a magnetically actuated helical nanomotor cloaked 
with a natural platelet membrane, as a new type of biomimetic 
nanorobot possessing efficient locomotion and distinct biological 
functions. The intrinsic antifouling properties of the platelet 
membrane coating shield the synthetic nanomotor from bio-
logical environments. A study of the propulsion of PL-motors in 
whole blood clearly demonstrated their distinct antifouling prop-
erties due to platelet membrane coating, which led to efficient 
propulsion in real complex biological environment, as compared 
to the uncoated nanomotor counterpart. The platelet membrane 
coating of these biomimetic nanomotors imparts also strong 
affinity to platelet-adhering toxins and pathogens, which along 
with the efficient motor movement leads to efficient detoxifica-
tion capacity, as illustrated by the rapid binding and isolation of 
Shiga toxin and MRSA252 bacteria. This study demonstrates that 
biomembrane coating can significantly enhance the binding of 
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Figure 3. Shiga toxin (Stx) binding and neutralization study. A) Fluorescence binding percentage (measured at 495 nm) of the FITC-Stx conjugate 
and FITC dye only with PL-motors (red and gray bars, respectively). B) Fluorescence images of PL-motors after 20 min incubation in whole blood 
and propulsion in FITC-Stx and FITC dye solution only. C) Vero cell viability (1.2 × 105 cells per well, n = 3) after 48 h of incubation with Stx solution, 
PL-motors + Stx, bare motors + Stx, and PL-vesicles + Stx. In all experiments the toxin concentration used was 100 µg mL−1 along with a final volume 
of 150 µL. PBS without Stx was used as a control. One mg of PL-motors (≈ 1.3 × 108 motors) was used for the detoxification process along with 20 min 
of propulsion time. Vero cell viability was measured by using an MTS assay. D) Microscopy images showing the morphologies of the corresponding 
Vero cells treated with different formulations. Each image is representative of five examined sections. Scale bars, 50 µm.
Figure 3.13: Shiga toxin (Stx) binding and neutralization study. (A) Fluores-
cence bi ding p rcentage (measured t 495 nm) of th FITC-Stx conjugate and
FITC dye only with PL-motors (red and gray bars, respectively). (B) Fluores-
cence images of PL-motors after 20 min incubati n in whole blood and propulsion
in FITC-Stx and FITC dye solution only. (C) Vero cell viability (1.2 ⇥ 105
cells per well, n = 3) after 48 h of incubation with Stx solution, PL-motors +
Stx, bare motors + S x, and PL-vesicles + Stx. In all experim nts the toxin
concentration used was 100 µg mL  1 along with a final volume of 150 µL. PBS
without Stx was used as a control. One mg of PL-motors (âĽĹ1.3 ⇥ 108 motors)
was used for the detoxification process along with 20 min of propulsion time.
Vero cell viability was measured by using an MTS assay. (D) Micr scopy images
showing the morphologies of the corresponding Vero cells treated with diﬀerent
formulations. Each image is representative of five examined sections. Scale bars,
50 µm.
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PBS buﬀer control without toxin. In contrast, the viability of bare nanomotors and
static platelet vesicles (containing equivalent proteins to those in the PL-motors, but
without active motion) was only 21% and 31%, respectively. Figure 3.13D displays
the microscopy images showing the morphology of the Vero cells after 48 h incubation
with the four formulations. It is clearly observed that the Vero cells are healthy
for the formulation treated by the PL-motors, while all other three formulations
induce severe damage and lysis to the cells. By cloaking platelet vesicles on the
magnetic nanomotors, the PL-motors can serve as moving decoys that attract toxins
for cell protection by diverting the toxins away from the cell target and rendering the
environment nontoxic to cells. It is estimated that each PL-motor could adsorb ⇡ 1.9
⇥ 10 3 units of Stx. In addition, under magnetic actuation, the large-scale collective
location of the PL-motors can dramatically accelerate their binding with Stx, thus
enhancing the adsorption process.
We further examined the therapeutic potential of PL-motors for binding and
isolation of platelet-adhering pathogens. Oppounistic bacteria, including several
strains of staphylococci and streptococci, are able to bind to platelets either directly
through a bacterial surface protein or indirectly by a plasma bridging molecule
that links bacterial and platelet surface receptors. [441,442] Such bacteria-platelet
interactions further lead to immune evasion and bacteremia. [430] MRSA252, a strain
of methicillin-resistant Staphylococcus aureus (MRSA) expressing a serine-rich adhesin
for platelets (SraP) which can bind to platelets, [443] was used as a model pathogen
for PL-motor adhesion study. After 20 min of incubation and magnetic actuation of
the PL-motors (1 mg) in MRSA252 suspension (1 ⇥ 105 colony-forming units (CFU)
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nanorobots to bacterial toxins and pathogens, which may provide 
a new means of using nanorobots for biodetoxification and for 
targeted treatment of infectious diseases. Magnetic actuation of 
a large amount of PL-motors can further enhance the binding 
and isolation process of these biothreats. Overall, the PL-motors 
represent a powerful biomimetic platform based on the fusion of 
biological materials and synthetic nanorobots. Such bioinspired 
nano robots are expected to open a variety of new attractive oppor-
tunities for both nanomedicine and nanomotor communities.
Experimental Section
Preparation and Characterization of PL-Motors: The PL-motors were 
prepared by enclosing magnetic helical nanomotors with the plasma 
membrane of human platelets. Platelet membrane derivation was 
performed as previously described.[37] Briefly, platelets were isolated 
from whole blood and then resuspended in PBS mixed with protease 
inhibitor tablets. The whole blood we used was human type O-blood 
with 1.5 mg mL−1 EDTA purchased from BioreclamationIVT. The platelet 
membrane was derived by a repeated freeze–thaw process and washed 
by centrifugation in PBS solution mixed with protease inhibitor tablets. 
Aliquots of platelet suspensions were first frozen at −80 °C, thawed at 
room temperature, and pelleted by centrifugation at 4000 × g for 3 min. 
Following three repeated washes, the pelleted platelet membranes were 
suspended in water and stored at −80 °C until use.
Helical nanomotors were synthesized using a template-assisted 
electrochemical deposition method. Before electrochemical deposition, 
a 75 nm gold film was sputtered on one side of a 400 nm pore size 
polycarbonate (Millipore, HTTP02500) membrane to serve as a working 
electrode using the Denton Discovery 18 (Moorestown, NJ, USA). A Pt 
wire and an Ag/AgCl (with 1 M KCl) were used as counter and reference 
electrodes, respectively. The sputtered membrane was then assembled in a 
plating cell with an aluminum foil serving as a contact. All electrochemical 
deposition steps were carried out at room temperature (22 °C). Pd/Cu 
nanorods were deposited at −0.1 V from the PdCl2/CuCl2 plating solution 
mixture containing 20 × 10−3 M CuCl2, 30 × 10−3 M PdCl2, and 0.1 M HCl 
with a total charge of 3C. After electrochemical deposition, the sputtered 
gold layer was completely removed by hand polishing with 3–4 µm 
alumina slurry. The templates were dissolved in methylene chloride for 
10 min to completely release the nanostructures. The latter were collected 
by centrifugation at 9000 rpm for 3 min and washed three times with 
methylene chloride, ethanol, and deionized water each, with a 3 min 
centrifugation after each wash. Then the Cu (of the Pd/Cu nanorods) 
was dissolved using an 8 M HNO3 solution for 10 min, resulting in the 
formation of Pd nanohelices with 400 nm diameter and 3–5 µm length. 
The Pd nanostructures were then dispersed on glass slides, and coated 
with a 5 nm thick Ni layer by electron beam evaporation (using a 
deposition speed of 0.05 nm s−1), and sputtered with a 5 nm Au layer. 
Afterward, the resulting magnetic nanomotors were incubated overnight 
with MPA (Sigma-Aldrich). Then, the MPA-modified helical nanomotors 
were incubated with platelet-membrane-derived vesicles (diameter 
50–100 nm) under ultrasonication for 20 min. Scanning electron 
microscopy (SEM) images of bare helical nanomotors and PL-motors 
were obtained with a Phillips XL30 environmental scanning electron 
microscope (ESEM) instrument, using an acceleration voltage of 10 kV.
To further confirm the presence and cloaking of platelet membrane 
onto the surface of the motors, Platelet vesicles were labeled with 
DMPE-RhB (Avanti Polar Lipids, Inc.) and then incubated with the 
helical nanomotors. Fluorescence microscopy images were captured 
using EVOS FL, fluorescence microscope coupled with a 20× and 
40× microscope objectives and fluorescence filter with red light 
excitation. The fluorescence quenching assay to determine the platelet 
membrane coverage of the PL-motors was performed by incubating the 
PL-motors with a thiolated fluorescent ligand made of a synthesized 
FITC–thiol conjugate probe, and measuring the fluorescence spectra 
of the FITC-thiol, FITC-thiol, and PL-motor mixture, and FITC-thiol and 
bare motor mixture, at 520 nm by a Tecan Infinite M200 microplate 
reader. The thiolated fluorescent probe was prepared by first conjugating 
FITC to cysteamine 4-methoxytrityl resin (EMD Millipore) through 
N-hydroxysuccinimide (Thermo Scientific)-mediated amine coupling, 
followed by trifluoroacetic acid treatment to cleave the conjugate from 
the resin. To determine the protein content of the PL-motors, 10 mg mL−1 
of both bare motors and PL-motors were centrifuged and resuspended 
with 1X PBS for three times, and a BCA colorimetric assay (Thermo 
Scientific) was used to determine the protein content. Briefly, the 
purple-colored reaction product of this assay is formed by the chelation 
of two molecules of BCA with one cuprous ion, and this water-soluble 
complex exhibits a strong absorbance at 562 nm that is nearly linear 
with increasing protein concentrations. Gel electrophoresis followed by 
protein staining with Coomassie Blue was also performed. The PL-vesicle 
and PL-motor samples containing equivalent total proteins were 
prepared in lithium dodecyl sulfate sample loading buffer (Invitrogen). 
The samples were then separated on a 4–12% Bis-Tris 17-well minigel 
in 3-(N-Morpholino)propanesulfonic acid (MOPS) running buffer using a 
Novex Xcell SureLock Electrophoresis System (Life Technologies). Finally, 
the protein columns were stained according to manufacturer’s protocol.
Propulsion of PL-Motors: A Helmholtz coil pair was used to generate 
the magnetic rotation field for remote actuation. The frequency of the 
rotating magnetic field (15 mT) can be changed from 1 to 1000 Hz by 
a sinusoidal wave generator. The above magnetic nanohelices were 
dispersed in water droplets for rotation and translation motion tests. An 
inverted optical microscope (Nikon Instrument Inc. Ti-S/L100), coupled 
20× and 40× objectives, a Hamamatsu digital camera C11440 and 
NIS Elements AR 3.2 software, were used for capturing movies of the 
swimming motion. The speed of the nanoswimmers was tracked using 
an NIS Elements tracking module (n = 20).
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Figure 4. Binding and isolation of platelet-adhering pathogens. A) Micro-
scopic images showing the binding of MRSA252 bacteria with PL-motors: 
i) bright field, ii) blue fluorescence channel showing the DAPI stained 
bacteria, iii) red fluorescence channel showing the DMPE-RhB-labeled 
platelet membrane, and iv) the overlay. B) Normalized fluorescence inten-
sity of DAPI stained MRSA252 bacteria retained on the PL-motors (n = 3). 
Bare nanomotors, PL-vesicles, and PBS were used as controls. Scale bars, 
500 nm. C) SEM images of MRSA252 bacteria attached to PL-motors. 
Scale bars, 500 nm. D) Microscopy image showing one-the-fly isolation 
of a bacterium (labeled with blue circle) with a PL-motor. Scale bar, 2 µm.
Figure 3.14: Binding and isolation of platelet-adhering pathogen .
(A)Microscopic images showing the binding of MRSA252 bacteria with PL-
motors: i) bright field, ii) blue fluorescence cha nel showing the DAPI stained
bacteria, iii) r d fluorescence channel showing the DMPE-RhB-labeled platelet
membrane, and iv) the overlay. (B) Normalized fluorescence intensity of DAPI
stained MRSA252 bacteria retained on the PL-motors (n = 3). Bare nanomotors,
PL-vesicles, and PBS were used as controls. Scale bars, 500 nm. (C) SEM
images of MRSA252 bacteria attached to PL-motors. Scale bars, 500 nm. (D)
Microscopy image showing one-the-fly isolation of a bacterium (labeled with blue
circle) with a PL-motor. Scale bar, 2 µm.
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mL 1), the PL-motors were recollected through precipitation with a magnet. Bare
motors and PL-vesicles were used as negative and static (without magnetic actuation)
controls. The retained bacteria on the collected pellets were fixed with formalin
and stained with 4’,6-diamidino-2-phenylindole (DAPI) subsequently. Figure 3.14A
displays microscopy images, showing the binding of the DAPI-stained bacteria on
a DMPE-RhB- labeled PL-motor. Bare motors and PL-vesicles showed negligible
increase of the DAPI signal compared to the PBS control of Figure 3.14B. On the
other hand, PL-motors exhibit a tenfold increase in DAPI fluorescence intensity
compared to all other groups, which manifests a significant adhesion of the bacteria
to PL-motors. It is estimated that each PL-motor can capture ⇡ 15 bacteria. The
SEM images in Figure 3.14C also clearly show the preferential binding of the bacteria
to the PL-motors, while the microscopy image in Figure 3.14D displays “on-the-fly”
isolation of a bacterium by a PL-motor. This new nanorobot platform thus presents
a unique approach for achieving rapid, direct, and real-time isolation of pathogens.
3.3.4 Conclusions
In summary, we have developed a unique PL-motor system, based on a
magnetically actuated helical nanomotor cloaked with a natural platelet membrane,
as a new type of biomimetic nanorobot possessing eﬃcient locomotion and distinct
biological functions. The intrinsic antifouling properties of the platelet membrane
coating shield the synthetic nanomotor from biological environments. A study of the
propulsion of PL-motors in whole blood clearly demonstrated their distinct antifouling
properties due to platelet membrane coating, which led to eﬃcient propulsion in real
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complex biological environment, as compared to the uncoated nanomotor counterpart.
The platelet membrane coating of these biomimetic nanomotors imparts also strong
aﬃnity to platelet-adhering toxins and pathogens, which along with the eﬃcient
motor movement leads to eﬃcient detoxification capacity, as illustrated by the rapid
binding and isolation of Shiga toxin and MRSA252 bacteria. This study demonstrates
that biomembrane coating can significantly enhance the binding of nanorobots to
bacterial toxins and pathogens, which may provide a new means of using nanorobots for
biodetoxification and for targeted treatment of infectious diseases. Magnetic actuation
of a large amount of PL-motors can further enhance the binding and isolation process
of these biothreats. Overall, the PL-motors represent a powerful biomimetic platform
based on the fusion of biological materials and synthetic nanorobots. Such bioinspired
nanorobots are expected to open a variety of new attractive opportunities for both
nanomedicine and nanomotor communities.
Chapter 3.1, in full, is a reprint of the material as it appears in PLOS Neglected
Tropical Diseases, 2018, Soumita Das, Pavimol Angsantikul, Christine Le, Denny
Bao, Yukiko Miyamoto, Weiwei Gao, Liangfang Zhang, and Lars Eckmann. Chapter
3.2, in full, is a reprint of the material as it appears in Proceedings of the National
Academy of Sciences, 2017, Soracha Thamphiwatana, Pavimol Angsantikul, Tamara
Escajadillo, Qiangzhe Zhang, Joshua Olson, Brian T. Luk, Sophia Zhang, Ronnie
H. Fang, Weiwei Gao, Victor Nizet, and Liangfang Zhang. Chapter 3.3, in full, is a
reformatted of the material as it appears in Advanced Materials, 2018, Jinxing Li,
Pavimol Angsantikul, Wenjuan Liu, Berta Esteban-Fernández de Ávila, Xiaocong
Chang, Elodie Sandraz, Yuyan Liang, Siyu Zhu, Yue Zhang, Chuanrui Chen, Weiwei
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Gao, Liangfang Zhang, and Joseph Wang. The dissertation author was the co-primary
investigator and co-author of these papers.
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Chapter 4
Conclusions
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4.1 Coating nanoparticles with gastric epithelial cell
membrane for targeted antibiotic delivery against
Helicobacter pylori infection
Helicobacter pylori (H. pylori) infection with its vast prevalence is responsible
for various gastric diseases including gastritis, peptic ulcers, and gastric malignancy.
While eﬀective, current treatment regimens are challenged by a fast-declining eradica-
tion rate due to the increasing emergence of H. pylori strains resistant to existing
antibiotics. Therefore, there is an urgent need to develop novel antibacterial strategies
against H. pylori. Inspired by the natural pathogen-host interactions and adhesion,
we report the development of a novel targeted nanocarrier for H. pylori infection
treatment. The plasma membranes of AGS cells (a gastric epithelial cell line) are
coated onto antibiotic-loaded polymeric cores, the resulting biomimetic nanoparticles
(AGS-NPs) carries the same surface antigens as the source AGS cells and thus have
inherent adhesion to H. pylori bacteria. The AGS-NPs demonstrated preferential
binding and retention with H. pylori when compared to control nanoparticles coated
with synthetic PEG. Furthermore, the AGS-NPs loaded with model drug, showed
superior bactericidal eﬀect in vitro and were able to eﬀectively reduce bacterial burden
in a mouse model of H. pylori infection. In addition, mouse body weight and stomach
histology in a toxicity test showed no adverse eﬀects from the AGS-NPs. Overall, the
results demonstrate that AGS-NPs are an eﬀective and safe approach for targeted
antibiotic delivery to treat H. pylori infection.
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4.2 Micromotors spontaneously neutralize gastric
acid for pH-responsive payload release
Magnesium(Mg)-based micromotors are of considerable interest for biomedical
applications, as they can utilize both the Mg-acid or Mg-water reactions for their
propulsion and can potentially operate in diﬀerent biological environments (e.g.
serum, whole blood or gastric acid). We have demonstrated that acid-powered Mg-
based micromotors can eﬃciently induce a transient change in local physiological
pH. Specifically, the reaction of the micromotor with gastric fluid leads to rapid
proton depletion and micromotor propulsion which concurrently generate localized
fluid convection and prompt eﬃcient acid neutralization without aﬀecting the normal
stomach function or causing adverse eﬀects. When coupled to a pH-sensitive payload-
containing polymer coating, this pH change can lead to autonomous release of the
encapsulated cargo. This approach represents a distinct advantage over conventional
stimuli-responsive drug release systems, as the micromotors themselves actively create
the desired local pH essential to trigger the release. The “built-in” micromotor
strategy could potentially be used to adjust physiological environment in vivo to
achieve desired conditions for triggered payload release.
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4.3 Micromotor-enabled active drug delivery for in
vivo treatment of stomach infection
While synthetic micromotors have been extensively investigated under in vitro
conditions for over a decade, their in vivo function has rarely been explored. Recent
research eﬀort has resulted in micromotors that display fast movement in complex
biological media, and possess eﬃcient cargo loading, transport, and release, along
with good biocompatibility. These new capabilities have made synthetic micromo-
tors promising active delivery tools for in vivo applications including treatment of
gastrointestinal diseases. In this work we conducted the first, to the best of our
knowledge, study to evaluate the therapeutic eﬃcacy of a drug-loaded Mg-based
micromotor for in vivo treatment of H. pylori infection in a mouse model. This
pioneering study demonstrated that Mg micromotors, loaded with clinical doses of
drugs, can be retained eﬃciently in the mouse stomach wall, and hence significantly
reduced bacteria burden compared to passive drug carriers. The enhanced drug
delivery capability is coupled with a built-in neutralization of the gastric fluid, hence
eliminating the needs for PPIs. Additionally, no acute adverse consequences were
detected from the micromotor treatment in the mouse models. Consequently, this
early work of micromotor for in vivo infection treatment opens the door to a new
line of micromotor-based therapeutic platforms for in vivo treatment of GI diseases.
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4.4 Neutralization of cholera toxin with
nanoparticle decoys for treatment of cholera
Despite the advancement in medicine, cholera remains a major public health
challenge in many regions of the world. Current medical strategies to combat
this infection can be divided into preventive and therapeutic measures. Although
immunization could oﬀer individuals the protection from infection, but the only
current FDA-approved cholera vaccine comprises live bacterial agent which has the
potential for reversion and cause disease itself. On the other hand, the conventional
treatment, which involves supportive rehydration, could improve survival but severe
disease symptoms can still persist for days during the treatment course. As an
alternative therapeutic strategy, we developed a nanoparticulate intervention to
serve as a decoy to neutralize cholera toxin, which is the primary cause of diarrheal
symptoms in cholera. The nanoparticles surface-functionalized with GM1 ganglioside,
cholera toxin-binding lipid, were fabricated by a robust single-step synthesis. The
GM1-coated nanoparticles (GM1-NPs) demonstrated the capability to bind and
divert cholera toxin from interacting to their target host cells, thereby preventing
its eﬀects on epithelial electrolyte and fluid secretion in vitro and in vivo. This
detoxification strategy represents a novel interventional approach whose mechanisms of
action are physiologically distinct from vaccination, rehydration, or antibiotics, hence
significantly broadening the medical treatment options against cholera. Furthermore,
a similar nanoparticle platform coated with an appropriate toxin-binding receptor
may also oﬀer a promising therapeutic opportunity for other toxin-mediated diseases.
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4.5 Macrophage-like nanoparticles concurrently
absorbing endotoxins and proinflammatory
cytokines for sepsis management
Clinical evidence has indicated that the systemic spread of endotoxins from
septic infection plays a crucial role in the pathogenesis of Gram-negative bacterial
sepsis. However, currently there are no eﬀective ways to manage the diverse endotoxins
released by diﬀerent bacteria. The emerging cell-membrane coated nanoparticle
technology allows the inclusion of natural cell membrane on the surface nanoparticles
and opens up a new range of biomedical applications that would otherwise be
extremely diﬃcult for synthetic platforms to achieve. One such use is to serve as a
decoy for harmful molecules within the body. For instance, endotoxins exploit the
receptors on macrophage membranes to induce responses on the host cells, and by
directly using a toxin’s natural substrate as a coating material, it is possible to target
the working mechanism of the toxin in a manner that doesn’t require specifically
tailoring the nanoparticle to the toxin. This work demonstrates the therapeutic
potential of a macrophage-like nanoparticle for sepsis control through a powerful
two-step neutralization process: endotoxin neutralization in the first step followed
by cytokine sequestration in the second step. The biomimetic nanoparticles possess
an antigenic exterior identical to macrophage cells. The inherited capability to bind
to endotoxins and proinflammatory cytokines has been demonstrated in vitro and
conferred a significant survival advantage in a mouse E. coli bacteremia model. Unlike
conventional endotoxin neutralization agents that compete with endotoxin binding
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pathways and may be associated with significant clinical toxicity, M -NPs take
advantage of the common functionality of endotoxin binding to macrophages, allowing
for a “universal” neutralization approach across diﬀerent Gram-negative bacterial
genus, species, and strains. This detoxification strategy may provide a first-in-class
treatment option for sepsis and ultimately improve the clinical outcome of patients.
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4.6 Biomimetic Platelet-Camouflaged Nanorobots
for Binding and Isolation of Biological Threats
Manmade nanorobots based on a variety of materials and nanostructures
have demonstrated eﬃcient locomotion capacity by harvesting propulsion from either
localized chemical reactions or from external stimuli. These nanorobots possess
advanced locomotive capabilities, including precise speed regulation and spatial
motion control, which has significant implication for a variety of biomedical use. By
taking inspiration from nature, especially the circulating cells such as erythrocytes,
leukocytes, and platelets, essential biological functions of these natural cells can
be potentially imparted into synthetic systems. One exciting research area is to
mimic cellular membranes, which play very important roles in cells’ biointerfacing
with the incredibly complex biological environment. Particularly, human platelets
have inspired the design of functional nanocarriers owing to their many biological
functions including complex interactions with bacteria and bacterial toxins. We
report a biologically interfaced nanorobot made of magnetic helical nanomotors
cloaked with the plasma membrane of human platelets. The resulting biomimetic
nanorobots possess a biological membrane coating consisting of diverse functional
proteins associated with human platelets. The biointerfaced nanorobots display
platelet-mimicking properties, including adhesion and binding to toxins and platelet-
adhering pathogens, such as Shiga toxin and Staphylococcus aureus bacteria. The
locomotion capacity and platelet-mimicking biological function of the biomimetic
nanomotors oﬀer eﬃcient binding and isolation of these biological threats. The
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PL-motors represent a powerful biomimetic platform that merges the biointerfacing
advantages from the biological membrane and the advanced locomotion control from
the magnetic nanomotors. Such bioinspired nanorobots thus holds considerable
promise for diverse biomedical and biodefense applications.
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